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The generation of chemical diversity by the parallel synthesis of potential drug 
candidates has been demonstrated by Parke-Davis' DI\TERSOMER Technology. 
This technology combines solid phase organic synthesis, (SPOS), miniaturization, 
automation, integration and custom equipment to generate "libraries" of discrete 
compounds. 
The research programme involved a detailed analysis of the synthesis of the 
quinolones, a well-known class of antibacterial agents of which over 6000 compounds 
are known to date. A solution phase synthesis was developed which was compatible 
with solid phase reaction conditions and also amenable to parallel SPOS protocols. 
Results of these studies and the parallel synthesis, isolation, purification and analysis 
of a quinolone library will be discussed. 
Additionally, an alternative "solid support" for the SPOS of quinolones will be 
discussed. Construction of the quinolones with a tetrabenzo[a,c,g,i]fluorene, (Tbf) 
handle enables controlled adsorption onto and off porous graphitised carbon (PGC). 
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CHAPTER 1: INTRODUCTION 
1.1. Molecular Diversity and Combinatorial Chemistry 
A key step in any drug development program is the identification of a lead 
compound suitable for clinical trials. Increasing competitiveness in the pharmaceutical 
market and escalating costs for discovery efforts have placed extreme demands on the 
pharmaceutical industry. The search for new drugs has generally relied on traditional 
medicinal chemistry approaches which are both time consuming and costly. The 
discovery and development of a new drug takes on average 12 years, at an estimated 
cost of $357 million.' Recently, advances in high throughput screening and laboratory 
automation have resulted in the synthesis of medicinal compounds becoming a rate 
limiting step in the drug discovery process, (see fig 1. 1).2 
Fig. 1.1. Molecular Diversity: The Need 
Traditional methods for the generation and evaluation of large numbers of 
compounds have relied heavily on natural products, fermentation broths, marine 
organisms,3  and recombinant4  and chemically synthesised' peptides. The advent of 
combinatorial chemistry has provided a means for the preparation of hundreds, or 
even thousands, of diverse chemical libraries at a fraction of the normal cost and time. 
I 
10 
A recent phenomenon, combinatorial chemistry has resulted in the successful 
preparation of peptide  and oligonucleotide7  based libraries. This new field of 
chemistry has also been expanded to small organic molecules such as the 
benzodiazepines8'9 and hydantoins.8  Consistent with this trend, most of the top selling 
drugs on the market are low molecular weight, heterocyclic compounds. 
As an illustration of the power of combinatorial chemistry, the synthesis of a 
penicillin antibiotic containing five sites of diversity could provide over 3.2 million 
compounds,2  (fig 1.2). This apnlication of cnnihinifnrii1 rhpmictr, c1,r1rl 
considerably shorten the drug discovery process, provided that methods are available 
for deconvolution of such large numbers of compounds. 
Fig. 1.2. Synthesis & Optimisation Example: Penicillin Analogues 
It has been said that, "the power to synthetically create and evaluate huge 
numbers of known and future pharmacophores is unprecedented and suggests that 
combinatorial technologies may rapidly intersect and ultimately shortcut the 
traditional path of medicinal chemistry".1°  The promise of combinatorial chemistry has 
yet to be realised. However, the potential is evident and worthy of pursuit. 
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1.2. Solid Phase Synthesis, (SPS) 
Historically solid phase chemistry has focused on the preparation of 
biopolymers such as peptides by the use of a few well characterised chemical 
transformations to generate repetitive structural backbones. In comparison, small 
organic molecules are generated from a large repertoire of diverse chemical reactions. 
For example, a J3-lactam antibiotic may be synthesised via eight different reactions, 
while a pentapeptide is generated in eight steps but using only two different reactions. 
The limited number of chemical transformations developed on solid supports has 
therefore restricted the number of non-oligomeric compounds synthesised, despite the 
inherent advantages of this method. 
The concept of performing reactions on an insoluble polymeric support or 
"immobilised media" was enunciated by R.B Merrifield" in 1963 and later by 
Letsinger and Kornet in 1964.12 Today Solid Phase Peptide Synthesis (SPPS) is a 
straightforward yet elegant contribution to the art of chemical synthesis. The actual 
chemistry used is based on synthesising a peptide in a repetitive, sequential manner on 
a solid support (resin), from attachment of the first amino acid to the addition of the 
final residue. During the synthesis, the peptide-resin heterogeneous mixture remains in 
the same reaction vessel until the final product is cleaved and released into solution. 
The simplicity of the methodology has led to semi-automated systems. 13 
Since Merrifleld's pioneering work, solid phase chemistry has progressed 
significantly and now dominates peptide chemistry. Oligonucleotide'4 and 
oligosaccharide'5  chemistry have similarly adopted solid phase approaches, and most 
present day combinatorial chemistry approaches have also embraced this 
methodology. 
The multiple, simultaneous synthesis of peptide libraries was pioneered by 
Mario Geysen el al. in 1984.16 Based on Merrifield's SPPS methods, the group at 
Australian Coselco Mimotopes Pty. successfully synthesised over 200 peptides a day. 
The initial utility of the peptide libraries was epitope mapping. To enable this, the 
peptides were left attached to the polystyrene rods and exposed to soluble antibodies. 
However, "the rate limiting factor for their work was the testing and evaluation" of 
3 
the library mixture. '7  Ironically, the rate limiting step in the drug discovery process 
today is the synthesis of compounds for both lead generation and lead optimisation.2 
Today, advances in molecular biology and automation have driven combinatorial 
chemistry as an efficient method for the synthesis and the supply of compounds for 
testing. In turn, this has renewed the interest of the chemical community in organic 
synthesis on solid supports.'8'19 
The advantages of solid phase synthesis over traditional solution based 
methods were clearly demonstrated with the synthesis of a tetrapeptide by 
Merrifleld.1' Excess reagents are readily tolerated by the solid support, reactions 
generally show favorable kinetics and can be driven to completion, product isolation is 
improved by washing away excess reagents from the solid support, and no purification 
of reaction intermediates is required. Thus, SPPS has now developed into a multi- 
million dollar business. In general, these advances have resulted in the current day 
methodology for combinatorial chemistry heavily relying on solid phase techniques. 
Furthermore, the utility of solid supports as a tool for the chemists and 
biologists is evident by the interdisciplinary nature and possible applications in the 
fields of biochemistry, organic synthesis, catalysis and organometallic chemistry.20 
1.3. Solid Supports 
1.3.1. Polystyrene Supports 
A variety of polymers have been described for solid phase synthesis, yet the 
literature related to polymeric supports is dominated by functionalised cross-linked 
polystyrene .2' The most probable reasons for this are :22 
Widely available and easily functionalised. 
The chemistry has been extensively studied. 
The notable success of early workers using this resin in the field of SPPS. 
Polystyrene, (2) has generally been prepared by copolymerisation of styrene, 
(1). In order to create a cross-linked structure, styrene is polymerised in the presence 
4 
of a small amount of a divinyl compound such as p-divinylbenzene (D\TB), (3) to 





(1) + (3) SnCI4 
C) = Polystyrene 
_/J\CH2Cl 
(4) 
Fig. 1.3. Preparation of Merrifield Resin 
Copoly(styrene- 1 %-divinylbenzene)chioromethylated resin, (4) was the solid support 
chosen by Merrifield. More commonly referred to as Merrifield resin, the polymer 
served as the prototype for the standard approach associated with his name.23  
The structure and morphology of polystyrene generally depends on the degree 
of cross-linking incorporated into the polymeric network.24 The resin originally used 
by Merrifield contained 2% DVB,25  but most commercial resins typically contain 1% 
D\TB cross-linking.26  This has arisen directly as a consequence of the swelling 
properties of the resin. Once suspended in a compatible solvent such as 
5 
dichioromethane (DCM) the polymeric chain forms a gel. With 1% DVB present, 
such gels have a greater degree of swelling, are generally porous and allow good 
molecular mobility. Crosslinking greater than 1% DVB limits porosity which in turn 
limits resin swelling, while resins with crosslinking lower than 1% are soft and cannot 
be filtered.28  Within this there are macroscopic (particle size/shape, chemical/thermal 
stability) and microenvironmental (degree of functionality, loading) considerations.27 
Solvent selection is a critical component in both solution phase and solid phase 
chemistry. Polystyrene derivatised resins are largely hydrophobic in nature and good 
swelling is obtained in nonpolar, aprotic solvents. On swelling the resin, the compact 
network of the support opens Out and exposes functional groups for enhanced 
reaction kinetics. However, polar solvents such as water and methanol are to be• 
avoided for the opposite reasons, (see Table 1. 
Table' 1.1. Solvent Swelling Capacity29 
th')I/t•fl ke....ifl iffligi 	•.. .. ••U(1/ufl /.//J (flf 	) 
MeOH 1.5 	.... 
.EtOH 
 
••. • •Tw•• 5.1 
1.8 .. 5.1 
PbCHOH 2.ii 5.2 




. 	. 5.3 
Eth 	• 2.4 •• 5.5 
DMF 3.5 Hexar 1.8 
£tQA 3.7 	 • • 
The influence of solvents was clearly recognised in the early development of 
SPPS. Apart from swelling properties, the solid support must be inert to all the 
solvents and reagents used during the multi-step synthesis, apart from the required 
appropriate functionality. The uniformity of the resin beads is also critical to the 
quality of solid phase reactions. Inhomogeneity in the density of crosslinking is a 
6 
major problem in the polymerisation of styrene,3°  resulting in subsequent variable 
degrees of functionality. 
The degree of loading (substitution) measured in (mmollg) must also be 
considered. A general problem in SPPS is poor or incomplete amino acid coupling. 
This can vary with distance from the resin and the sequence of the growing peptide 
chain; however high resin substitution can lead to incomplete couplings .3' For SPOS, 
high substitution (0.7-1.0 mmollg) is more favoured since it involves the generation of 
low molecular weight compounds; however, it can lead to intermolecular aggregation 
within the polymeric network.32 
The chemical modification of cross-linked polystyrene has provided an 
attractive route to functionalisation. Chioromethylation and lithiation have been the 
most frequently used methods of introducing ftinctionalisation into the polymeric 
backbone, (fig. 1.4) 33  While chioromethylation provides an electrophilic centre within 





Fig. 1.4. Functionalisation of Polystyrene 
The traditional route pursued by Merrifield was chioromethylation; however, 
over the years chemical modification of Merrifield resin has greatly increased the 
number of polymeric supports on the market.27  The introduction of Wang (p-
benzyloxybenzyl alcohol) resin 34  in 1973 by Wang replaced Merrifield resin as the 
resin of choice for Fmoc based SPPS.35  The synthesis and cleavage of Wang resin, (5) 
is illustrated in (fig. 1.5). 
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Fig. 1.5. a. Preparation of Wang Resin 
b. Cleavage of Wang Resin 
In principle, a wide variety of synthetic methods exist for the modification of 
polystyrene resin. For SPOS, polystyrene supports have proved the most successful 
both as a solid support and analytical tool. Aside from Merrifield resin, other supports 
include aminomethylated resin,36  (6), 10,1 l-dihydro-5H_dibenzo[a,d]cyclohepten5. 




(6) 	 (7) 
0 	 (8) 
[ R = —CH 2—NHCH2— ] 
Fig. 1.6. Representative Polystyrene Supports 
1.3.2 Tentagel® Supports. 
Polystyrene-polyethylene glycol (PS-PEG) graft copolymers, (9), more 
commonly referred to as Tentagel®, are a family of polystyrene derivatised solid 
supports.39  Compared to traditional polystyrene, Tentagel® resins are advantageous 
for SPS, particularly for peptide and oligonucleotide chemistries.40'4' 
For the preparation of Tentagel®,  polystyrene is derivatised with a 
polyethylene glycol (PEG) spacer between the polystyrene backbone and the 
attachment point of the synthetic peptide 42  (fig. 1.7). The PEG spacer is believed to 
match the hydrophilic nature of the growing peptide chain enabling more efficient 
syntheses of long and complex peptides. As with traditional polystyrene resins, the 
terminus of the resin can be flinctionalised with various R groups. 
CH2 H  	
H2CH2)—OC H2C H2R 





Polystyrene 	Poly ethyleneglycol 
	(9) 
Matrix 	 Linker 
Fig. 1.7. General Structure of Tentagelo Supports 
While the swelling properties of polystyrene supports play a key role in 
reaction conditions, Tentagel® resins are easily solvated in both polar and aprotic 
solvents with the swelling ratio in water and DCM nearly equal,43 (Table 1.2). 
Subsequently, Tentagel® beads are more suitable for continuous flow synthesis. 





With the advent of combinatorial chemistry there has been renewed interest in 
Tentagel® resin as an alternative solid support to polystyrene. Chapman and Rano 
report the use of Tentagel® in the solid phase synthesis of aryl ethers44 while Dorif 
and Hauske use it as a new matrix specific linker .4' The key attraction of Tentagel® 
supports is that they provide an environment that closely resembles solution phase 
chemistry conditions. Recently, Tentagel® supports have been particularly useful as an 
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analytical tool. Bayer el al.  4' and Gallop et al.  4' both report that PEG grafted resins 
exhibit unique physical and nuclear magnetic resonance (NMR) properties. 
The use of '3C NMIR to visualise compounds bound to a solid support has 
been well documented.485°  However, typical '3C NIvIR experiments involving 
polystyrene resins require good swelling and thousands of transients. Often, 
differential relaxation rates in the resin-bound products gives poorly resolved spectra. 
The incorporation of large amounts of PEG in Tentagel® results in highly swollen 
states. This in turn generally reduces the extensive changes in size and solvation 
properties which are normally encountered with standard polystyrene supports. 
Additionally, '3C NIVIR spectra of polystyrene supports are complicated by broad 
aromatic and aliphatic resonances. The spectra obtained from Tentagel® supports 
provide enhanced spectral resolution because the polystyrene matrix is not visible in 
the '3C NIMIR. Functional groups such as carbonyls are easily recognised and - the PEG 
spacer appears as a single resonance peak at 70 ppm.47  
NIvIIR studies of Tentagel® supports have also been extended to 'H spectra. 
Fitch et al. 5' demonstrated the use of magic-angle spinning (MAS) for line narrowing 
in the 'H NTvIIR of Tentagel®bound substrates. The detection of two diasteroisomers 
of Tentagel®bound norborane-2-carboxylic acid has also been successfully 
demonstrated using MAS 13C_ 1H correlated NMR 52 
The utility of Tentagel® resins as alternatives to polystyrene resins is 
attractive; however, Tentagel® resins offer low loading, typically 0.15-0.30 mmol/g.53  
While this may be of use in oligomer synthesis, higher loading is desired in the solid 
phase synthesis of small organic compounds. Furthermore, Tentagel® supports are 
mechanically unstable to magnetic stirring and sonication.54  This subsequently limits 
the utility of the resin to certain reactions and automation techniques exemplified by 
the DIVERSOMER technology. 
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1.3.3 Controlled Pore Glass Supports. 
Controlled Pore Glass (CPG), unlike polystyrene derivatised supports, does 
not have a microporous structure and morphology, but instead consists of an 
inorganic, rigid silicate matrix uniformly milled with screened particles of almost pure 
silica that are honeycombed with pores of controlled size.55  CPG is currently the 
accepted solid support for automated deoxyribonucleic acid (DNA) synthesis. 16  CPG 
has also been applied to the synthesis of small peptides. 17 
For use in solid phase DNA synthesis, the beads of CPG are derivatised with a 
long chain alkylamine (LCAA) resulting in a primary amine loading of about 100 
tmolIg, (fig. 	This can then be reacted directly with 5'-O-dimethyloxytrityl 
deoxyribonucleoside-3 '-O-succinates to give the general structure, (10). 
CH2ODMTr 
OMe 	 OAc 	H 	 o 
I H 	JH p_ 	O oyN ) o 
OMe 
(10) 
Fig. 1.8. Linkage of DNA to LCAA/CPG 
In contrast to polystyrene derivatised solid supports, the inorganic nature of 
CPG makes it a non-swelling support. Thus, while peptide synthesis is frequently 
impacted by differential amino acid coupling efficiencies, the 4 bases adenine, guanine, 
thymine and cytosine (A, G, C, T) in DNA synthesis give almost equivalent rates of 
coupling.58  The excellent mechanical properties of CPG also makes it a good 
candidate for continuous flow systems, with oligonucleotides greater than 180 bases 
in length being capable of synthesis.59  Problems associated with CPG are generally 
leaching or decomposition of silicates. Fitzpatrick et al.6°  attempted to eliminate this 
problem by synthesising DNA sequences on a hydrophilic membrane support. 
Despite its success in DNA synthesis, and to a limited extent in SPPS, the use 
of CPG as a solid support has not been generally applied to SPOS. As with Tentagel 
12 
supports, CPG provides low loading. On average, nucleoside loadings are 25-40 
tmol/g. 55 
1.3.4 Polydimethylacrylamide-Kieselguhr Supports. 
In the early 1970s, R.C. Sheppard and co-workers" prepared an alternative 
support to the original Merrifield resin, based on the argument that the polymeric 
support would be more desirable if it was chemically analogous to the attached 
peptide chain. This led to the introduction of polyamide supports and "Fmoc 
TM polyamide synthesis".62  More commonly known as PepSyn,63 the polyamide 
support, (14) is derived from the copolymerisation of bis(acrylamido)ethane, (11), 
dimethylacrylamide, (12), and acryloyl sarco sine methyl ester, (13), (fig. 1.9), with 
properties the reverse of polystyrene based resins.6' 




(12) 	 (13) (11)  
ç0NMe2 C0NMe2 
DCM/DMFIH2Q 	 CONHCH2
go 	 I 
	= (3—CO2Me 
50°C 	 CONHCH2 	 (14) 
Me2NC0 Me2NCO CONCH2CO2Me 
Me 
Fig. 1.9. Preparation of PepSynTM 
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Although, generally used for the solid phase synthesis of small peptides, 
PepSyntm' supports are not applicable to continuous flow synthesis. However, 
polyacrylamides are more hydrophilic than polystyrene, therefore reactions can be 
carried out in polar media, making PepSyn m an ideal support for SPOS. PepSynTM  
also gives moderate loading, typically 0.3 nimollg.64 
In order to create a more free-flowing support, Sheppard and co-workers,65 in 
1986 introduced polydimethylacrylamide-Kieselguhr (PepSynK) supports. The 
structure of PepSynKTm  is a composite of cross-linked polydimethylacrylamide gel 
which is polymerised within the pores of inert, fabricated macroporous Kieselguhr 
beads. Kieselguhr is a low density, highly permeable inorganic matrix and is more 
polar than standard polystyrene supports. The resulting polymer mixture has pores 
several thousand Angstroms in diameter, creating an organic gel of high porosity 
allowing rapid permeation of solvents and reagents. However, loading is low, typically 
0.1 mmollg, therefore limiting its use in SPOS.27 
1.3.5 Alternative Polymeric Supports 
Polystyrene denvatised solid supports have largely dominated peptide 
chemistry and SPOS, while CPG has been the accepted support for DNA synthesis. 
Over the years several groups have studied alternative polymeric supports in order to 
increase the diversity of reactions carried out on a solid support. 
In 1972, Koster and Heyns published two papers reporting the use of silica66 
and Sephadex LH 2067 as alternative polymeric supports in DNA synthesis. These 
supports are highly hydrophilic in nature, and at the time, were a suitable alternative 
to polystyrene in order to avoid the problems encountered with the high polarity of 
the phosphodiester bond. Reactions involving Sephadex LH 20 could also be followed 
by infrared, (IR) spectroscopy, making it a useful support in organic synthesis. 
In the late 1980's, simultaneous multiple peptide synthesis was reported by 
several groups. Geysen's PEPSCAN method  ("pin-method") synthesised peptides on 
the tip of polyacrylate grafted polyethylene rods. Later Koster et al.68 and Frank el 
14 
al.69'70  report the use of membranes and cellulose paper discs respectively. Unlike the 
covalent attachment to polystyrene beads, synthesis on membrane and cellulose sheets 
is based on absorption onto the solid support. Both supports can be functionalised and 
the absorbed peptides can be used immobilised on the support in a solid phase binding 
assay, or can be desorbed for use in solution .7' The supports are mechanically stable 
and amenable to miniaturisation, and automated operation. Despite the non-swelling 
nature of these supports, their application to SPOS is limited by their low loading, 10-
20 llmoL'g and the use of solvents of high volatility which are not acceptable. 
Furthermore, cellulose rapidly disintegrates in strong acid .72  Table 1.3. summarises 
some properties of the different solid supports discussed in this chapter. 
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Table 1. 3. Summary of Comparative Solid Supports 
Xm <Ummot > Immoi 'B !MR CNMR Chmkat Mthwska 
Polystyrene ++  
Tentagel® ++  
CPG ++  
PepSyn ++ + + + + + 
PepSynK ++ - + 





++ Excellent, + Good, +1- Moderate, - Poor. 
1.4. Representative Solid Phase Reactions 
While peptide chemistry has branched into its own field of science, the general 
application of insoluble polymer supports to organic synthesis has received scattered 
attention.73'74  As early as 1969, Merrifield, recognised the potential of polymeric 
supports in organic synthesis, "a gold mine awaits the discovery by organic 
chemists" .7' Despite this, the subsequent 20 years saw limited research into this area, 
either as a result of limited resources, or due to no interest in SPS. After all, solution 
phase chemistry was well established therefore there was a lack of impetus for change. 
1.4.1. Polymer Supports in Organic Synthesis 
Most of the reactions to generate non-oligomeric compounds on polymeric 
supports have used polystyrene derivatised resins largely due to their advantages as 
discussed in the previous section .22,2' One of the earliest to report the use of insoluble 
polymers as polymeric reagents in organic synthesis was Takagi in 1967.76  The 
reaction involved the formation of an insoluble peracid reagent for use in epoxidation 
of olefins. Thus, the product of the reaction can be obtained by evaporation of the 
solvent, while the acid by-product remains attached to the solid support. 
Following this, Shambhu and Digenis77 reported the use of polymeric 
acetylating reagents. Using Letsinger's "popcorn" polymer, 12  insoluble anhydrides 
were prepared which on subsequent. treatment with aniline or ethanol gave resin-
bound benzanilide and ethyl benzoate, respectively. 
The use of polymer-bound ylides has been well documented.7880 Ylides are 
generally highly reactive; however, once attached to a solid support they are easier to 
handle compared to the analogous, classical solution reagents. Furthermore, by 
attaching the Wittig reagent to an insoluble support, residual triphenylphosphine oxide 
remaining in the reaction mixture can simply be filtered off from the product. 
For the solid phase Wittig reaction, (fig. 1.10), the resin-bound Wittig reagent, 
(16) is prepared by copolymerisation of styrene, (1), DVB, (3) and p- 
17 
styryldiphenyphosphine, (15). Addition of an alkyl halide followed by base treatment 
provides the resin-bound ylide reagent, (17). Subsequent treatment with an 
appropriate aldehyde or ketone releases the desired olefin (19) into solution and the 
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Fig. 1.10. Polymeric Wittig Reagent 
The solution phase synthesis of cyclic compounds has long been a synthetic 
problem in organic chemistry with yields often low and, in many cases, the products 
isolated as mixtures.8' One example of this is the Dieckmann cyclisation of di-esters, 
(fig. 1. 11).  82  In solution phase, the cyclisation of a ben.zyl triethylmethyl diester yields 
a mixture of keto-esters, which are inseparable by chromatographic methods. Crowley 
and Rapoport 12 showed that by executing the reaction on a solid support not only did 
they obtain higher yields, but that during cyclisation of the resin-bound ester, (20), the 
mixture of products, (21) and, (22) could be easily separated by filtration of the resin 












Fig. 1.11. Solid Phase Dieckmann Cyclisation 
In many synthetic schemes, it is often desired that only one functional group 
reacts. However, the direct reaction of one equivalent of a bifunctional compound and 
one equivalent of reagent often gives a mixture of unreacted starting materials, over-
reacted products and the desired monoreacted product. Protecting groups can be 
used, but selective protection of one functional group of a symmetrical bifunctional 
compound can be difficult. Leznoff and Wong 83,84  were the first to demonstrate that 
an insoluble polymer support can be used as a selective blocking group for completely 
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Fig. 1.12. Solid Phase Monoprotection 
Initially, Merrifield resin, (4) was reacted with the sodium salt of 2,2-dimethyl-
1,3 -dioxolane-4-methanol in excess 2,2-dimethyl- 1,3 -dioxolane-4-methanol as the 
solvent.85  Acid hydrolysis gave the resin-bound diol, (23) containing a vicinal diol 
functional group which was subsequently treated with terephthaldehyde, (24), or 
isophthalaldehyde, (25) to generate the resin-bound acetals, (26) and (27), 
respectively containing a free aldehyde group. The resulting products were then used 
to prepare oximes, (28), alkenes, (29) and (30) via a solid phase Wittig reaction, and 
for the preparation of the Gngnard products, (31). In each case the resin-bound diol, 
(23) is regenerated for subsequent use. While classical solution phase preparations of 
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these products can lead to mixtures which are often difficult to purify, the primary 
advantage of using resin (23) is shown in the high yields. and selectivity of the solid 
phase reactions. However, resin-bound acetals are limited to use in reactions that only 
employ basic conditions. 
Similar selective functionalisation of polyhydroxy alcohols was reported by 
Frecht and Nuyens in 1975.86 Later that year Leznoff and Fyles87 report the use of 
solid supports for the protection of symmetrical diols in the synthesis of insect 
pheromones. 
It is clear from this early work that Leznoff, like Merrifield, was well aware of 
the key advantages of SPS versus traditional solution phase chemistry. However, in 
contrast to Merrifield, Leznoff also demonstrated the problems, and to a certain 
extent the limitations, of SPOS. 
Incomplete coupling or reaction completion was a problem. While this issue 
has largely been eliminated in peptide synthesis, our work has shown this to be a 
problem in the present SPOS methodology. The stability of the polymer supports was 
a common problem, however this point has been confronted over the years, with new, 
more stable, non-degradable polymers prepared offering wider general use.88 The 
limitations of compatible solvents similarly restricted the chemistry attempted on solid 
supports. A long term problem has been the difficulty of determining the course and 
extent of a chemical reaction on a polymer support.899' 
IR spectroscopy of insoluble resin-bound products and / or cleavage of the 
resin-bound products from the insoluble polymer after each reaction have been the 
main methods of following reactions on insoluble supports. More recently '3C gel 
phase N1vIR485° and 'H NMR5' have further aided the identification of resin-bound 
intermediates and products. However, IR and NN'IIR spectroscopy are not quantitative 
and in many cases the complex spectrum of the resin tends to obscure the spectral 
features of the attached moiety. Quantitative results can be obtained from cleavage of 
the resin-bound intermediates, but this can be time consuming and in many cases the 
intermediates are not stable to the cleavage conditions. 
In 	1976, Crowley and Rapoport 14  published a paper, where they further 
review the problems discussed by Leznoff regarding "non-peptide solid phase 
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chemistry whose resolution is required if the process is to mature from publishable 
novelty to fundamental methodology". Hyperentropic Efficacy 12  was the main topic of 
discussion. This is predominantly concerned with studying possible conditions of high 
dilution on an insoluble support and intra-resin reactions.9' To a certain extent the 
paper is obscure and in conclusion the authors presumed that SPOS would remain a 
"laboratory curiosity" in the years to come. 
This did not deter Leznoff and co-workers who yet again published a series of 
papers reporting new solid phase organic chemistry. 92-94  As with previous work, the 
key attraction of solid supported reactions versus solution phase chemistry was the 
ease of product workup and isolation by simple filtration. Leznoff called this the 
"Fish-hook" principle, 93  whereby the fish is the desired product which has been 
"fished" Out of the reaction mixture, while the hook is analogous to the insoluble 
polymeric support. 
Four main areas of multistep organic synthesis were studied on a solid 
support, with the chemistry largely concentrated on the selective monoprotection of 
difunctional compounds. 
The insect sex attractants of Lepidoptera, (36) have the general formula 
shown below, (fig. 1.13)91 and are particularly useful candidates to prepare on a solid 
support since the initial reaction requires monoprotection of the symmetrical diol. The 
use of trityl chloride resin, (32), which reacted selectively with primary hydroxyl 
groups versus secondary and tertiary groups, 95  was attractive due to the ease of 
cleavage of the trityl ether in mildly acidic medium. Three independent routes were 
successfully attempted using (32) and a series of three long-chain diols. The first route 
pursued was an alkyne approach, 92  (fig. 1.13). Following monoprotection of the diols 
and monomesylation of the free hydroxyl, the resin-bound monomesylates (33) were 
stirred in the desired alkyne mixture overnight to generate the resin-bound alkyne 
derivatives, (34). Acidic cleavage gave the recovered trityl resin, (32) and the 
acetylemc alcohols, (35) which were reduced and acetylated to yield a mixture of cis 
and trans isomers of the Lepidoptera family, (36). 
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Fig. 1.13. Alkyne Route 
In order to achieve higher stereoselectivity of the final products, (36), a solid 
phase "normal" Wittig reaction 92  (fig. 1.14) was attempted by condensation of Wittig 
reagents, (38) with the resin-bound aldehydes, (37) to yield the resin-bound olefins, 
(39). They also attempted a "reverse" Wittig reaction 92  (fig. 1.14) of a resin-bound 
Wittig reagent, (41) with a range of aliphatic aldehydes, (42). In this case, the resin-
bound monomesylate, (40) was treated with molten triphenylphosphine at 100°C to 
give the corresponding resin-bound phosphonium salt; (41). As before, acid hydrolysis 
of the product from the Wittig reaction gave the recovered polymer, (32) and alcohol 
which on acetylation yielded the product, (36). Again comparable yields with solution 
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Fig. 1.14. "Normal" Wittig and "Reverse" Wittig Reaction 
The monoprotection reaction was also used in the synthesis of helicenes via 
resin-bound terephthaldehyde, however overall yields were very low. Macrocyclic 
formation of the lycoramine-like alkaloid skeleton has also been attempted by solid 
phase approaches. The solid phase synthesis of the 1,4-ben.zodiazepinone 
tranquillisers, (44) date back to 1974. The synthesis critically depends on site isolation 
of the resin-bound imine, (43) for a cyclisation step analogous to Patchomik's 
synthesis of cyclic peptides96  and is particularly aided by the unlikely probability of 
intermolecular dimerisations, (fig. 1.15). More recent methods have reported the solid 

















Fig. 1.15. SPOS of 1, 4-Benzodiazepinone Tranquillisers 
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1.4.2. Combinatorial Chemistry 
While real practical advances have been made in SPOS, it has essentially lain 
dormant since Leznoff's work in the late 1970s. More recently it has generally been 
accepted that SPS facilitates the assembly of combinatorial libraries. 
Combinatorial chemistry is a synthetic strategy by which large, diverse 
libraries of compounds can theoretically be created.98 Combinatorial chemistry has 
added to the pool of compound sources available at present in the pharmaceutical 
industry, (fig. 1.16). Many believe that combinatorial chemistry will revolutionise the 
drug discovery process by cutting the time and cost of finding suitable drug 
candidates.2 
LCombinatorial  Chemistryj 
Compounds 	
I 	
L Medicinal Chemistr] 
L Natural Product Librariei] 
LExternal Acquisitions j 
Biological Sourcesj 
[Virtual Databases 1 
Fig. 1.16. Compound Sources 
To date, combinatorial strategies have primarily concentrated on libraries of 
peptides, and this area has been extensively reviewed.6"0"8 Other methods for the 
synthesis of oligomeric libraries include, peptoids, carbamates, vinylogous amides, 
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Fig 1.17. Current Oligomeric Libraries 
For a long time peptides have served as models for the more traditional, small 
molecule drugs. However, due to poor bio-availability and pharmokinetic parameters, 
peptides have limited use as suitable drug candidates. Alternatively, small molecule 
libraries, with molecular weight < 500 amu, such as the benzodiazepines, 13-lactams 
and imidazoles are typically heterocyclic in nature, and are ideal drug candidates. Fig. 
1.18 generalises the pros and cons of both oligomeric and non-ologimeric libraries, 
while (fig. 1.19) demonstrates the current molecular diversity approaches and the 
number of compounds which can be generated. 19 
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Fig. 1.18. Oligomeric vs Non- Oligomeric Libraries 
At present, combinatorial chemistry, in conjunction with SPOS, is at a critical 
and delicate stage in the drug discovery process. Without doubt, combinatorial 
chemistry offers medicinal chemistry the possibility to expand the scope of structures 
that may be screened for biological activity. The main objectives of combinatorial 
chemistry are two-fold; 
0. Lead Generation 
or random screening. A lead compound is identified in the absence of any 
structural information. 
. Lead Optimisation 
or direct screening. The objective in this case is to evaluate and establish SAR 
around a known biologically active pharmacophore. 
Both paradigms are aimed at preparing large, structurally diverse libraries of low 
molecular weight compounds. A common feature with each case has been the 
renaissance of SPOS. 
28 
Chemical 	Fine 
Lead Identification 	Analogi ng Tuning 
Number of Molecules 
1012 1010 108 106 104 102 100  
I. 	I 	I 	I 	I 	I 
r Recombinant 
Peptide Diversit 
[Noncoded / Encodedi 
Synthetic Libraries J 







Medicinal 	[ Diver-) 
Chemistry Lmers J 
Fig. 1.19. Molecular Diversity Approaches 
In comparison with SPPS, the chemistry of small molecules on a solid support 
is not fully understood, yet a number of non-peptide libraries have been prepared, 
most notably the 1,4-benzodiazepines which is a common pharmacophore found in 
many drugs, such as Valium®. Eliman and Bunin9 laid the groundwork for the 
construction of a small molecule library of 1 ,4-benzodiazepines utilising solid phase 
methodology, (fig. 1.20). 
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Fig. 1.20. Eliman et at SPOS of Benzodiazepines 
A library of 8 ben.zodiazepines were synthesised from three major 
components: aminobenzophenones, amino acids and alkylating agents. Initially the 2-
aminobenzophenone hydroxy or carboxy derivatives were attached to the polystyrene 
solid support via an acid-cleavable linker (4-hydroxymethylphenoxyacetjc acid) to 
yield the resin-bound starting material, (45). Deprotection of the Fmoc group, was 
followed by coupling (45) to an a-N-Fmoc amino acid fluoride. A second Fmoc 
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deprotection of the intermediate, (46) and treatment with 5% acetic acid in DMIF 
provided the resin-bound cyclised lactam, (47). Subsequent alkylation introduced the 
final site of diversity and acid cleavage of the resin-bound benzodiazepines, (48) 
generated 8 pure compounds, (49) in high overall yield based on HPLC data. No 
structure activity relationships (SARs) of the products was carried out. More recently, 
Eliman and co-workers have reported the synthesis and biological testing of a library 
of 192 1,4-benzodiazepines. 97 
Independently, DeWitt et al. ,8  at Parke Davis reported the preparation of an 
array of 40 benzodiazepines, (53), (fig. 1.21) simultaneously but separately by 
reacting each of five amino acid resins, (50), with eight 2-amino benzophenone 
imines, (51). 
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Fig. 1.2.1. DeWitt et al SPOS of Benzodiazepines 
Unlike Eliman's approach, 97  the Parke-Davis route required no prior introduction of 
functionality for resin attachment. Additionally, the process was fully automated with 
an apparatus unique to the solid phase synthesis of small molecules which they term 
DIVERSOMERSTh1. A further advantage of the DeWitt route is that the 
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benzodiazepines are directly released into solution by acid cyclisation of the resin- 
bound products, (52). This should result in unreacted products or side-reagents 
remaining attached to the solid support with the final products cleaved in greater 
purity. 
DeWitt et al.' have also described the solid phase synthesis of an array of 40 
hydantoins, (57), (fig. 1.22), utilising the DIVERSOMERTm technology. The 
hydantoins form a primary nucleus in the anti-epileptic drugs Phenytoin® and 
Dilantoin®, and the aldose reductase inhibitor Sorbinil®.'°° The solid phase synthesis 
involved treatment of five groups of resin-bound amino acids, (54) with a series of 
isocyanates, (55), after Fmoc or Boc deprotection. The resulting resin-bound ureas, 
(56) were subsequently cleaved by acid induced cyclisation to provide 40 separate 
hydantoins, (57) in solution. 
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Fig. 1.22. SPOS of Hydantoins 
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(57) 
Both sets of 40 benzodiazepine and hydantoin libraries were characterised by 
'H NIvIR and MS, and analysed for biological activity. Another unique feature of the 
DeWitt approach has been the use of 13C gel-phase NIVIIR to monitor reaction 
progress of the resin-bound intermediates. 
Not surprisingly, polymer-supported synthesis has not been restricted to the 
benzodiazepines and hydantoins. Other areas of research by the Parke-Davis group 
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have involved the generation of benzoisothiazolone10 ' and substituted amide 
libraries. 102 Eliman and co-workers have covered a wider range of compounds 
including the solid phase synthesis of prostaglandins,103  1,4-benzodiazepine-2,5-
diones,104  aspartic acid protease inhibitors105  and [3—turn mimetics.'°6 
Kurth and co-workers 107 have reported the multi-step solid phase synthesis of 
2,5 -di substituted tetrahydrofurans, (61) which are important structural moieties in 
many polyether antibiotics.108 The reaction involved a tandem 13-dinolar 
cycloaddition/electrophilic cyclisation sequence. In solution phase, the complex nature 
of the reaction frequently results in the undesired bis-1,3-dipolar cycloaddition 
product. 
Cl 
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Fig. 1.23. SPOS of 2,5-Disubstituted Tetrahydrofurans 
As an approach to solving this, they attached a nitromethane group to the 
resin-bound aldehyde, (58) via the Henry reaction. After protection of the hydroxyl 
group as the TMS ether, phenylisocyanate mediated dehydration of, (59) and 1,3- 
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dipolar cycloaddition with 1,5-hexadiene provided resin-bound isoxazoline, (60). As 
with the benzodiazepine library generated by the group at Parke-Davis, the final stage 
in the synthesis involved direct release of the target cyclic ethers, (61) in solution 
following iodocyclisation. The resin-bound aldehyde, (58) was also regenerated in the 
same step. The authors do not report the preparation of a library of compounds, 
however the diversity of reactions and conditions involved in the synthesis 
demonstrates the versatility of SPOS. 
In a later paper Kurth and co-workers'09 report the preparation of a library of 
27 water soluble antioxidants, (64), (fig. 1.24). Surprisingly, and in comparison with 
the Ellman and DeWitt approaches they adopted a "split and mix synthesis" which is 
commonly used for the generation of peptide libraries. 
The first step involved split-vessel esterification of sodium acetate, 
methoxyacetate and hydrocinnamate with Merrifield resin, (4) to introduce the first 
site of diversity, (R1). The resulting resin-bound products, (62) were then mixed and 
partitioned into nine separate flasks. Following enolate formation and aldol 
condensation with seven aryl aldehydes (R2R'2C0), and two aryl ketones (R2R'2C0), 
a library of 27 resin-bound propanediol analogues, (63), were prepared. Subsequent 
reduction with diisobutylaluminum hydride liberated the 27 antioxidants, (64) as a 
mixture. Despite the fact that a mixture was obtained, a deconvolution assay was set 
up in solution. The results indicated that three trimethoxy analogues gave comparable 
antioxidative efficiency, with (64a) identified as the lead compound. 
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Fig. 1.24. SPOS of Antioxidants 
More recent work, by Gallop et al. at Affymax have reported the SPOS of a 
library of the potent ACE inhibitor, Captopril."°  All these examples have successfully 
demonstrated the renewed interest in solid phase chemistry. However, construction of 
a combinatorial library of a class of therapeutic agents critically depends on the 
availability of general and high-yielding strategies for synthesising these compounds 
on a solid support. 
Many groups have adopted this approach in their research either in the 
development of new solid 	 or new resin-bound reactions. The formation 
of solid phase carbon-carbon bonds has received considerable attention; after all such 
bonds are of great importance in the construction of small organic compounds. 
Typical reactions have included enolate alkylation,"5 palladium-mediated Suzuki 
cross-coupling, 111,116 Heck 	 the Stille reaction 120  and the Mitsunobu 
reaction. 121 
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1.4.3. Concluding Remarks 
The concept of combinatorial chemistry is at an early stage, and represents a 
major advance in medicinal chemistry/drug discovery and development. Judging by 
the number of review articles, papers, scientific meetings and new companies dealing 
with combinatorial chemistry, this has resulted in one of the fastest growing research 
areas in chemistry today. Combinatorial technologies are also important in food and 
agricultural chemistry, immunology, molecular biology, polymer science and inorganic 
synthesis. 
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1.5. DWERSOMERTM Technology. 
The production of large populations of molecules or libraries involves a 
complex interplay between classical organic synthesis techniques, rational drug design 
strategies, and, robotic and scientific information management. An on-going priority 
in the field of combinatorial chemistry is the possibility of, and need for, automation of 
library generation, data handling and combinatorial screening of final products. 
While large numbers of oligomeric compounds such as peptides and 
oligonucleotides can be rapidly synthesised, few methods have been developed for the 
preparation of small organic compounds. The potential for small molecule diversity is 
vast and a key element in this equation is automation and technology for both lead 
optimisation and lead generation. 
By combining solid phase chemistry, organic synthesis and automation, Parke 
Davis Pharmaceuticals (Ann Arbor, MT)2'8  have created a unique apparatus capable of 
generating "libraries" of non-oligomenc compounds which they term 
DIVERS O]VffiR5 
o Multiple, Simultaneous Synthesis 
O 40 Potential Drug Candidates 
O Multiple Components 




Electronic data handling 
Unique Apparatus 
The DIVERSOIVifiRThI technology was conceptualised as a method for the 
multiple, simultaneous synthesis of organic compounds. The library, or array, of 
compounds is synthesised in a parallel array (8 or 40) on a solid support (resin). The 
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whole process is fully automated, from initial addition of the resin to the final 
submission of the soluble products for biological testing. 
Using the DIVERSOMERTm technology, DeWitt et al. 8 have simultaneously 
synthesised and characterised several unique arrays of compounds, including 40 
benzodiazepines and 40 hydantoins, (fig. 1.21 and fig. 1.22), respectively. The 
libraries generated incorporated 3 sites and 4 sites of diversity respectively, yielding 2-
14 mg (9-63% yield) of the desired benzodiazepines and 0.3-11.5 mg (4-81% yield) 
of the desired hydantoins. 
Planning. 
The generation of 40 discrete compounds involves a complex system of data 
collection, manipulation, analysis and calculations. The DIVERSONERTm technology 
has implemented several Microsoft® Excel spreadsheets as a method for library design 
and data control. 
Apparatus. 
A diagrammatic representation of the DIVERSOMER apparatus is shown 
in (fig. 1.25).8 The apparatus design employs gas dispersion tubes, referred to as 
"PINS", with flitted glass filters which physically contain the resin, allowing efficient 
mixing between reactants in the reservoir wells and resin in the flit. Additionally, it 
aids in the separation of resin-bound intermediates from excess reagents, solvents and 
by-products. The upper portion of the PINS serve as condensers when a chilled 
atmosphere of gas is circulated into the manifold allowing for refluxing conditions. 
Inert atmospheric conditions can also be applied via the manifold. The holder block 
serves to secure the PINS and allows the array to be handled as a single unit. Teflon 
gaskets on either side of the holder block act as sealants. The reaction block (2 x 4, or 
4 x 10) containing disposable glass vials (wells) acts to accommodate the PINS. 
Separate reaction wells are necessary to allow individual reactions to be executed and 
monitored, while at the same time maintaining the integrity of filtrates, intermediates 
and final products at each point in the array. The reservoir block can be successfully 
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heated or cooled as required. Addition of reagents or removal of samples during 
reaction cycles is achieved via the gasket layer at the top of the manifold. 
HOLDER ?L'T': 













Fig. 1.25. DIVERSOMERTAI Apparatus 
Once complete, the DI\ERSOMIER apparatus can be agitated by sonication 
or in some cases rotational platform shaking. Heating and cooling of the apparatus 
can be carried out in either water, a mixture of water/anti-freeze, or silicone oil 
depending on the temperature of reaction. 
Automation. 
A novel method for the rapid generation of non-oligomeric molecules has been 
designed. However the multiple, parallel synthesis of 40 discrete samples over a 
number of steps employing several reagents is both physically and mentally 
challenging. The DI\/ERSOMERThI technology has eliminated this problem by 
utilising a TecanTht 5032 Robotic Sample Processor (RSP). A typical protocol for 
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library generation involves resin loading, reaction cycles, reaction monitoring, wash 
cycles, isolation & purification and final product handling. 
At present Parke Davis' technology is the only method whereby full 
automation for the generation of small molecule libraries has been successfully 
demonstrated. In combinatorial chemistry terms, the actual number of compounds 
produced in a single array (40) utilising the DIVERSONERrm technology is 
significantly smaller than the current methods for generating peptide libraries (1 ø- 107  
peptides). However, the technology offers increased chemical and structural diversity. 
Undoubtedly this unique technology has the leading edge for small molecule 
combinatorial synthesis by automation and integration. 
40 
1.6. QUINOLONE Antibacterials and related Compounds: Mode of Action & 
Biological Activity. 
The synthesis of DNA and ribonucleic acid (RNA) is essential to all living 
cells. The formation of nucleic acids can be blocked by a variety of means. 122-124 The 
quinolone antibiotics inhibit the replication of DNA in bacteria, without immediately 
affecting RNA or protein synthesis in sensitive cells. 12' The mode of action of the 
quinolones is believed to be different from other antibiotics, which generally operate 
at the bacterial cell wall or at the ribosome.126  Studies have shown that the primary 
physiological target of the quinolones within the bacterial cell is DNA gyrase, a 
bacterial type II topoisomerase which is not present in eukaryotic cells. 127,128 
DNA gyrase is an essential enzyme required for DNA replication and 
transcription. 129 The DNA bacterial chromosome is compact, however DNA 
replication and recombination require that the DNA strands separate and unwind the 
double helix. One protein that controls this process is DNA gyrase.'3° This enzyme 
introduces negative supercoils into DNA by binding covalently to specific sequences 
of the DNA, cleaving the two DNA strands, passing one under the other and resealing 
the strands. ATP hydrolysis plays a key part in this supercoiling, knotting-unknotting 
and catenation-decatenation process of the DNA gyrase. '3' 
The quinolones, like other mammalian topoisomerase II inhibitors appear to 
stabilise the transient DNA fragments cleaved by DNA gyrase in the initial gate-
opening step of the DNA supercoiling process, (see fig. 1.26). 132 Consequently, this 
leads to inhibition of bacterial growth with the overall end point of the reaction being 
bacterial cell death, with the DNA gyrase being converted into a cellular poison. 133 
Clearly the selectivity of the quinolones for bacterial DNA gyrase over mammalian 
topoisomerase II is vital to the process since both these enzymes are closely related. 
More recently, the quinolones have been shown to have in vitro activity against M. 
tuberculosis 134 and in vivo antineoplastic activity. 131 
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Fig. 1.26. Cellular Action 
The therapeutic utility of the quinolones as effective antibiotics is well 
demonstrated by their annual world-wide sales; Ciprofloxacin® alone recorded $1.3 
billion sales in 1994.136 In addition to being prescribed for urinary tract infections 
(UTI) such as cystitis, the quinolones have other clinical uses, such as treatment for 
endocarditis, osteomyelitis and chronic prostatis.'37 Compared to the frequent 
development of resistance to earlier quinolones and other classes of antibiotics, the 
fluoroquinolones are active against both Gram negative and Gram positive pathogens. 
However, side effects such as nausea, vomiting and diarrhoea are still common. 
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CHAPTER 2: RESULTS AND DISCUSSION 
2.1. QUINOLONES & 1,8-NAPHTHYRJDINONES; General Synthetic Routes 
Since the early 20th century many antibiotics derived from microorganisms or 
by synthetic means have been discovered as effective drugs in the anti-infective 
chemotherapy field.135  The discovery of penicillin by Fleming led to one of the first 
antibiotic substance to find use in man in the 1940s. 140  Antibiotics such as the 3- 
lactams, macrolides, aminoglycosides and tetracyclines are generally obtained from 
the chemical modification of the naturally isolated substrates 141  whereas the more 
recent quinolone and 1,8-naphthyridinone antibacterial agents are purely of synthetic 
origin. 
The identification of the first lead structure of this family dates back to the late 
1950's where the drug was discovered solely by serendipity. 142 The first member of 
this group to be synthesised was nalidixic acid, (69), [1 ,4-dihydro- 1 -ethyl-7-methyl-4-
oxo-1,8-naphthyridine-3-carboxyljc acid] in 1962, by Lesher et al. 143  The original 
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Fig. 2.1. Synthesis of Nalidixic acid 
In the initial step, 6-methyl-2-aminopyridine, (65) was condensed with diethyl 
ethoxymethylenemalonate (66) to yield the anilinomethylenemalonate derivative, 
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(67). Cyclisation was achieved by heating in Dowtherm A (Gould-Jacobs reaction), or 
by 	Friedel-Crafts catalyst 114  to yield the oxonaphthyndine-3-carboxylate, (68). 
Alkylation followed by hydrolysis give nalidixic acid, (69). 145 
Several variations of the Gould-Jacobs reaction were introduced in 
subsequently. In 1971, Agui et aL' 46 replaced the traditional cyclisation conditions by 
the use of polyphosphoric acid (PPA), while in 1978 Mitscher et al. 147  reported the 
preparation of the naphthyridone ester by reaction of isatoic anhydride with sodio 
ethyl formylacetate. In another approach, the naphthyndones were prepared by a 
Dieckmann cyclisation step 141  followed by oxidation and hydrolysis, (fig. 2.2). 
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Fig. 2.2. Dieckmann Cyclisation 
Since the clinical introduction of nalidixic acid, numerous other derivatives 
have been prepared in the search for improved antibacterial activity. The early 1980s 
saw major developments in this field, most notably with the introduction of 
Norfioxacin, (70), [1 ,4-dihydro- 1 -ethyl-6-fluoro-4-oxo-7-( 1 -piperazinyl)-quinoline-3 - 








Fig. 2.3. Structure of Norfioxacin 
Norfioxacin was the first of many quinolones with a fluorine atom substituted 
at the C-6 position and a piperazine moiety at C-7. Additional variations at N-i were 
also introduced. It also represented the first significant increase in antibacterial activity 
covering both Gram-positive and Gram-negative micro-organisms.'5° However, the 
synthetic methodology, the Gould-Jacobs reaction and related methods normally used 
for preparing the quinolones proved to be unsuccessful for the synthesis of the new 
quinolones, generally referred to as the fluoroquinolones.15 ' 
An efficient and regiospecific general synthetic method was quickly reported 
by Grohe et al., 112  and by Chu et al.153 Called the cycloaracylation process, the 
reaction involved an intramolecular nucleophilic displacement cyclisation step as 
shown in (fig. 2.4). 
0 0 	 0 0 
OEt HC(OEt3, (X(0Et NH2R1 
R 
x Cl 	 Ac20 	
R 	
Cl OEt 
0 0 	 0 
OEt 	base 
hydrolysis 	R ) 
R1 	 R1  
Fig. 2.4. Cycloaracylation Process 
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The synthesis of the quinolones has accelerated at an unprecedented rate in 
recent years. To date, the cycloaracylation process has remained the method of choice 
for the synthesis of the quinolones. More recent studies have introduced a Vilsmeier 
type approach, 154,115  (fig. 2.5). 
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Fig. 2.5. Vilsmeier Approach to the Quinolones 
In 1984, Smith"' devised a general nomenclature and numbering system for 
the arylated fused 4-pyridine anti-bacterials. The general body consists of a 1-
substituted- 1,4-dihydro-4-oxopyrdine3...carbo,cyljc acid moiety (A) combined with an 
aromatic or heteroaromatic ring (B), nalidixic acid being the prototype of the 
naphthyridine class, while Norfioxacin represents the quinolone family. Fig. 2.6 shows 
a diagranmiatical representation of the most favourable structural variations around 
the molecule. It is obvious that the antibacterial activity, in addition to the bicyclic 
heteroaromatic system also depends on the nature of the peripheral substituents and 
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Fig. 2.6. Structural Variations of the Quinolones 
Extensive research into both the chemistry and biology of the quinolones has 
been carried out by Schentag et al., 117 Chu & Fernandes"' and Mitscher et al.' 59 It 
has generally been accepted that the preferred substitutions involve the utilization of 
fluorine at C-6, the piperazinyl group at C-7 and the ethyl, cyclopropyl, or 
fluorophenyl groups at N-i. Several tricyclic analogues which contain a three atom 
bridge connecting the vicinal positions of the quinolones have also been reported. 160-
163 
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2.2. SPOS of the Quinolones 
2.2.1. Project Aims 
The quinolones represent a class of highly potent, broad-spectrum antibacterial 
agents (see section 1.5). Over 6000 novel quinolone compounds have been 
synthesised worldwide to date. 164  However, this represents only a fraction of the total 
potential diversity for this class of compounds. For example, (fig. 2.7) showing three 
sites of diversity can lead to the generation of over 9000 quinolones. 
R3)çxf 
10 Keto-esters (RI) 
30 Amines (R2) 
30 Amines (R3) 
9,000 Quinolones 
Fig. 2.7. Quinolones: Potential Diversity 
The synthesis of the quinolones involves a complex series of reactions, and our 
initial objective was validation and optimisation of a solution phase route which would 
also be amenable to SPOS. Typically, reaction conditions were designed to exploit the 
advantages of SPOS while circumventing the disadvantages of the polystyrene solid 
support. For the development of the solution phase chemistry, and its compatibility to 
a solid phase route, several criteria are vital to any synthetic pathway, as highlighted 
below; 
o Identify Compound Targets. 
Design and Validate Solution Phase Chemistry Amenable to Solid Phase 
Chemistry. 
Validate and Optimize Solid Phase Chemistry. 
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ID Select Diversity for Building Blocks. 
@ Design Reaction Format. 
O Develop Automated Methods for Synthesis. 
O Develop Automated Methods for Purification. 
O Execute Synthetic Process. 
This section will discuss the aspects involved in this work; from resin 
functionalisation for the attachment of the quinolones to a solid support, through the 
development of the solution phase chemistry, to the SPOS of the quinolones and, 
finally the generation of a library of 40 quinolones utilising the DIVERSOMER Tm 
technology. 
2.2.2. Resin Functionalisation of Ring (B) 
With few exceptions, the quinolone antibacterials of this type are generally 
prepared by the cycloaracylation process '52'153 discussed in the previous section. In 
order to generate a library of the quinolones using the DIVERSOMERTM technology, 
we implemented several studies of the possibilities for attachment of the quinolone 
moiety to a solid support, preferably polystyrene derivatised resins. 
Our initial studies investigated resin attachment via ring (B) of the quinolones. 
Ring (B) is usually aromatic or heteroaromatic in nature, with a range of subtituents 
introduced at various sites, (fig. 2.6). Particulary notable in this regard are a fluorine 
atom at C-6, and a five or six membered nitrogen-linked heterocycle at C-7. Among 
the many modifications investigated at the C-7 position, the 1-pipera.zinyl group and 
related derivatives have long been the group of choice, offering excellent antibacterial 
activity. 165,166 
In 1992, Segawa et al., 16' and later in 1993, Laborde et al., 167  separately 
reported the preparation of the quinolones starting from a range of piperazinyl 
derivatives. Both routes were viable possibilities for our studies of SPOS with 
attachment at ring (B). 
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An aminomethyl derivatised polystyrene resin168 developed in our laboritories 
was used in an attempt to prepare resin-bound piperazine, (fig. 2.8). The resin, 2-
copoly(styrene- 1 %-divinylbenzene)methylaminocarboxy-methoxydibenzocyclohepta-
dien-5-one, (7) was initially suspended in a solution of DCM containing excess 
piperazine. Following the addition of a Lewis acid, titanium(IV) chloride, it was 
hoped that the resin-bound imine salt, (71) would be formed and subsequently 
reduced with lithium borohydride. 
0 
Pi 	e, DCM, 
TiCI4 





R= —CH2—C—NHCH2---j 	 )( 
H 
(72) 
Fig. 2.8. Attempted Synthesis of Resin-bound Piperazine 
However, analysis of the resin-bound piperazine product, 2-copoly(styrene-
1 %-divinylbenzene)methylaminocarboxymethoxy-5-(9-pjperazinyl)dibenzocyclohepta 
dien-5-one, (72) by an isatin test give a negative result, indicating that no reaction had 
occurred. An analogous reaction with resin-bound heptylamine give a positive isatin 
test. 169  Additionally, both JR and 13C gel phase NMR of the resin-bound piperazine 
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products confirmed the failure of the reaction, with only the starting material, (7) 
identified. 
Following these results, we continued the solid phase studies of alternative 
resins and routes for the generation of resin-bound ring (B) derivatives. Again we 
concentrated on the piperazine moiety as a viable attachment point. In order to 
prepare the resin-bound piperazine, 170,171  (73), chioromethylated resin, (4) was 
suspended in a solution of toluene containing piperazine, and heated to 70°C for 18 
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Fig. 2.9. Synthesis of Resin-bound Piperazine 
Analysis of the resin-bound piperazine intermediate, copoly(styrene- 1%-
divinylberizene)piperazinyl, (73) by 13C gel phase NMR confirmed formation of the 
desired product. However, subsequent to the nucleophilic aromatic substitution 
reaction with 2,4,5-trifiuorobenzoic acid in pyridine, no carbonyl stretching band was 
seen in the IR spectrum. The arylation reaction was later repeated in DMF to give a 
strong band at 1683 cm', corresponding to the resin-bound product, (74) but the 13C 
NMIR spectrum obtained was very weak. 
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These results offered a potential solid phase route for the generation of the 
quinolones via an attachment point on ring (B). Additionally, an analogous reaction to 
that reported by Laborde et al. 167  for the quinolones could be attempted, as shown in 
(fig. 2.10). 
F 	CO2H 








Fig. 2.10. Synthesis of Quinolones via Ring (B) 
However, the attachment of a solid support to the piperazine moiety at C-7 
limits the overall diversity generated at this active site of the quinolone ring. This in 
turn would restrict the number of quinolones generated using the DIVERSOMER Tm  
technology. An additional problem could be the final cleavage of the resin-bound 
quinolone from the solid support. 
Recently, Dankwardt et al. 172  have reported the SPOS of aryl and ben.zyl 
piperazines. Many active therapuetics contain the piperazinyl moeity, and this work 
introduces a possible method for the generation of piperazinyl based libraries. Their 
work also illustrates some new solid phase chemistry, increasing the number and type 
of reactions now possible on polystyrene based solid supports. 
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2.2.3. Resin Functionalisation of Ring (A) 
The synthetic methodology for the generation of the quinolones has been 
extensively discussed in section 2.1. Following the limited utility of the resin-bound 
ring (B) derivatives as potential linkers in the SPOS of the quinolones, we 
concentrated our studies on the more traditional Gould-Jacobs reaction and 
cycloaracylation process. With both cases, we studied a possible resin attachment 
point to the quinolone structure via ring (A). 
For the synthesis of Norfioxacin, we employed the Gould-Jacobs reaction 
sequence (fig. 2.11). A key attraction of this route for the solid phase synthesis of the 
quinolones via ring (A) was the possibility of selective attachment of diethyl 












Fig. 2.11. Gould Jacobs Reaction 
The reaction is also of interest in terms of library generation, whereby a 
variety of substituted anilines, (75), can be employed; however, introduction of the 
first site of diversity (R1) at position one is limited to groups that undergo SN2 
alkylation or amination. Consequently, this would limit the overall diversity of groups 
introduced at R1  and therefore does not meet with the requirements of the 
DIVERSOMER technology. 
Another limitation and concern with the Gould-Jacobs reaction was the high 
temperature cyclisation step. While this is easily achieved in solution, our work has 
shown that high temperature reactions are generally not favoured by polystyrene solid 
supports, with resin bead breakdown or polymerisation a frequent problem. 
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Thus, as an alternative approach to the SPOS of the quinolones and 
considering the disadvantages of the above route, the cycloaracylation process was 
attractive since it provided a direct pathway for attachment of the f3-keto ester, (77) 
to a functionalised polystyrene solid support. In order to provide the corresponding 13-
keto enamide intermediates, (79), two separate routes are possible, (fig. 2.12). 152,173 
As with the Gould-Jacobs route, several problems were of concern with the 
























Fig. 2.12. Cycloaracylation Process 
Pursuing the reaction via route (a) would allow the direct attachment of the 
enamine starting material, (78), to a solid support, however for each R1  group 
introduced, the starting materials would require prior preparation in solution phase. 
Again this would not meet with the requirements of the DIVERSOMERTM  
technology. Both routes, (a) and (b) have the advantage of providing an array of R1  
substituents at position one which would be otherwise unattainable using the SN2 
methodology described above. This in turn will increase the total number of molecules 
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generated in any library. However, a potential drawback of the cycloaracylation 
process is the availability of the starting benzoic acid derivatives, (76), relative to the 
anilines, (75), in the Gould Jacobs reaction. 
For the SPOS of the quinolones, we ultimately pursued route (b) of the 
cycloaracylation process. Our main concern at this stage was the preparation of the 
resin-bound 13-keto ester intermediate. In the original synthetic plan for a 
DIVERSOMIER' approach to the quinolones the reaction involved the generation of 
the resin-bound 13-keto ester via the 13-keto acid. 174  Subsequently, we set out to 


















Fig. 2.13. Preparation of/3-Keto Acids 
The acid chlorides, (81, and 82), (R, = H, F) were suspended in a reaction 
mixture containing the mono anion of bis[trimethylsilyl] malonate. Subsequent 
treatment with water led to hydrolysis and decarboxylation of the intermediate triacyl 
compounds, (83, and 84), to yield the desired 13-keto acids, (85, and 86), as white 
crystalline powders. On repeating the reaction, yields of greater than 90% were 
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obtained when an excess of bis[trimethylsilyl] malonate was employed. The acids 
were found to exist in keto-enol tautomerism (3:1). 
In order to prepare the corresponding resin-bound 13-keto esters we 
concentrated our efforts on a number of methods for activating the carboxylic acid 
functional groups. SPPS has for a long time used acid chlorides 176  and acid azides'77 
as methods of coupling the first amino acid residue to the polystyrene resin. 
Preliminary work had shown that the acid chloride of monoethyl malonate had 
successfully coupled to hydroxybenzyl resin; however such results were not 
reproducible with the activated 3-keto acids, (fig. 2.14). 
F 	 OH a; (C OC 1)2 
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R1 = H, F 
Fig. 2.14. Acid Chloride Activation 
Two separate routes were employed for the preparation of the acid chlorides; 
(a); oxalyl chloride and (b); thionyl chloride, with the corresponding products, (85a) 
and (86a), confirmed by TLC and JR spectroscopy. On coupling the acid chlorides to 
Wang resin, the product from the oxalyl chloride reaction gave a black resin, while the 
thionyl chloride product give a pale orange coloured resin identified as unreacted 
Wang resin. 
Following this and analogous to SPPS, we attempted activation of the 
carboxylic acids by the more favoured methods of mixed anhydrides 17' and active 
esters. '79  A pre-formed symmetrical anhydride, (87), was prepared of each of the 13-
keto acids, (85, and 86) by activation of the carboxyl group using three equivalents of 








solutions were added to Wang resin pre-swollen in DMF. As an alternative to the 
mixed 	anhydride 	approach, 	ethyl-i -hydroxy- 1 H- 1,2,3 -triazole-4-carboxylate, 
(HOCt)181"82  was added to a solution of DIC containing the 0-keto acids. The 
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Fig. 2.15. Mixed Anhydride and Active Ester Activation 
IR studies suggested the addition of the activated acids to Wang resin; 
however, as with the products from the acid chloride routes, '3C gel phase NMIR 
confirmed no reaction to have taken place with all the products identified as unreacted 
Wang resin. The sensitivity of 0-keto acids to hydrolysis and decarboxylation'83 is the 
most likely cause of failure of all four reactions. 
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The solution phase synthesis of the quinolones via the cycloaracylation 
process involves the preparation of the 0-keto ester, (77), as shown in (fig. 2.12): 
Following the unsuccessful solid phase activation of the 3-keto acids, we 
subsequently prepared the 13-keto esters 2,4,5-trifiuorobenzoylacetic acid ethyl ester, 
(97), and 2,3,4,5-tetrafluorobenzoylacetjc acid ethyl ester, (98), (fig.2. 19)184 and 
studied methods for the generation of the corresponding resin-bound 13-keto esters. 185-
188 
We initially used diethyl malonate and di-t-butyl malonate, as the prototype in our 
studies. After an extensive study of various reagents and reaction conditions, 
transesterification of the 13-keto esters to Wang resin, (5), was achieved by heating in 
toluene with a catalytic amount of DMAP, at 110°C, for 72 hours, 188  to generate the 
resin-bound 0-keto esters. On repeating the reaction with 2,4,5-trifluorobenzoylacetjc 
acid ethyl ester, and 2,3,4,5-tetrafiuorobenzoylacetic acid ethyl ester, the 
corresponding resin-bound 13-keto esters, (89, and 90), were successfully identified by 
13C gel phase NMR, (fig 2.16). 
o 0 	 o o 
OH + EtO 	 DMAP, Toluene, 
(5) 
	 110°C, 72h 
R1 	 R1 
( 
R1  = H, F 	
97), (98) (89), (90) 
Fig. 2.16. Transester,fication Reaction 
58 
2.3. Development of Solution Phase Chemistry 
For the solution phase synthesis of the quinolones, Ciprofloxacin® (91), [1-
cyclopropyl-6-fluoro- 1 ,4-dihydro-4-oxo-7-( 1 -piperazinyl)-quinoline-3 -carboxylic 
acid], and the related compound, 1-cycloproryl-6,8-difluoro-1,4-dihydro-4-oxo-7-(1-
piperazinyl)-quinoline-3-carboxylic acid were used as the prototypes for our research. 
The traditional synthesis of Ciprofloxacin®, as carried out by the group at Parke-




























Fig. 2.17. Parke-Davis Solution Phase Synthesis of Ciprofloxacin® 
With a point of resin attachment via the ester functionality at the C-3 position 
of the quinolone structure now established, we attempted the Parke-Davis synthetic 
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route for the solid phase synthesis of Ciprofloxacin®, (fig. 2.18). Transesterification 
of the J3-keto ester, (97), to Wang resin, (5), generated the corresponding resin-bound 
13-keto 	ester, 	copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl2,4, 5- 
trifiuorobenzoylacetate,188 (89), starting material. Treatment of (89), with triethyl 
orthoformate in acetic anhydride at 130°C for 2 hours followed by 16 hours at 75°C 
gave the one carbon homologue enol ether intermediate, copoly(styrene-1%-
divinylbenzene)p-benzyloxybenzyl-(2-ethoxymethylene)-2,4, 5 -trifiuorobenzoylacetate, 
(92). 
cOH + EtO)LJ F 


























= Wang resin 
Fig. 2.18. Preliminary SPOS Studies 
Subsequent displacement of ethyl ether in the resin-bound enol ether was 
attempted by the addition of cyclopropylamine in a solution of t-butanol. Following 
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18 hours at room temperature, the resin mixture was then heated to 50°C for a period 
of 4 hours. As an attempt to induce cyclisation, the predicted resin-bound J3-keto 
enamide, copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl 2-(2,4, 5-trifluoro 
benzoyl)-3-cyclopropylaminoacrylate, (93) was resuspended in a slurry of potassium 
(-butoxide and t-butanol and stirred for 18 hours at room temperature followed by a 
further 2 hours at 55°C. However, attempted acid cleavage of the expected resin-
bound product, copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzy! 6, 7-difiuoro-4-
oxo-1-cyclo-propylamino-quinoline-3-carboxylate, (94) confirmed no cyclisation to 
have taken place. 
In a second attempt to prepare resin-bound Ciprofloxacin®, the resin-bound 
enol ether, (92) and enamide, (93) intermediates were each isolated and analysed by 
13C gel phase NIMR. While the enol ether product was successfully identified, the 
"enamide intermediate" was clearly not the desired product, with the '3C NIvliR being 
identical to that of the enol ether, (92) starting material. 
This attempt was instructive in two major issues. Firstly, it highlighted the 
problems of using high temperatures and poor resin swelling solvents in SPOS. 
Secondly, it showed the importance of solution phase development of the synthetic 
scheme for compatibility with solid phase methodology. In light of these results, we 
subsequently carried out an extensive re-evaluation and optimisation study for the 
solution phase chemistry for the quinolones. Particular interest was focused on the use 
of low to ambient temperatures and non-polar aprotic solvents which swell the resin 
well. Such conditions are important for the development of solid phase methodology, 
yet both limit the reaction conditions and reagents which can be used in the solid 
phase synthesis of the quinolones. 
2.3.1. Optimisation of Enol Ether and Enamide Chemistry 
Again our studies concentrated on the cycloaracylation process using the two 
3-keto ester starting materials 2,4,5-trifiuorobenzoylacetic acid ethyl ester, (97) and 
2,3,4,5-tetrafluorobenzoylacetjc acid ethyl ester, (98). For the preparation of the 13- 
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keto esters, 2,4,5-trifluorobenzoic acid, (95), and the related compound, 2,3,4,5-
tetrafluorobenzoic acid, (96) were treated with thionyl chloride to give the 
corresponding acid chlorides, which were directly treated with potassium ethyl 
malonate, anhydrous magnesium chloride and triethylamine in acetonitrile to afford, 
(97), and (98), respectively, (fig. 2.19)184 On treatment of the 13-keto esters with 
triethyl orthoformate and acetic anhydride at 130'C for 3 hours, followed by a further 
10 hours at 80°C the enol ether intermediates, ethyl (2-ethoxymethylene)-2,4,5- 
tnfiuoroben.zoylacetate, 	(99), 	and 	ethyl 	(2-ethoxymethylene)-2, 3,4,5 - 
tetrafiuorobenzoylacetate, (100) were isolated. While this reaction gives good results 
in solution phase, the poor resin swelling nature of acetic anhydride was of obvious 
concern to us, as was the high temperature of reaction. However, the reaction was 
repeated and analysis of the products after only 3 hours at 130°C gave the enol ether 
intermediates, (99, and 100) in 95 and 96% yields respectively. Both products were 
present as a mixture of E and Z isomers (3:1). 
Ri = H; 79% (97) 
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Ri = H; 95% (99) 
	
R1 = H; 89% (101) 
R1 = F; 96% (100) Ri = F; 86% (102) 
Fig. 2.19. Solution Phase Optimisation of Enol Ether and Enamide Intermediates 
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Preparation of the corresponding 13-keto enamides, however, proved more 
problematic. Solid phase studies had shown the failure of the reaction was probably 
due to the poor resin swelling properties of t-butanol. Subsequently we attempted the 
displacement reaction with a suspension of cyclopropylamine in DM After only 3 
hours, at 25°C, the reaction had gone to completion, and the resulting products; ethyl 
3 -cyclopropylamino-2-(2,4, 5 -tnfiuorobenzoyl)acrylate, 	(101), 	and 	ethyl 	3- 
cyclopropylamino-2-(2, 3,4, 5-tetrafluorobenzoyl)acrylate, (102) were isolated in 89 
and 86% yields, respectively. Again the products were present as a mixture of E and Z 
isomers (3:1). For an analogous reaction in the solid phase, the replacement of I-
butanol with DCM should give improved resin swelling; hence a larger surface area of 
reactive beads is exposed which can undergo reaction. Also, the reaction is carried 
out at ambient temperatures rather than at 50°C, which would further aid the solid 
phase reaction. 
However, despite the successful solid phase synthesis of the enol ether 
intermediates and the re-evaluated solution phase reaction, there was still concern 
with the poor resin swelling nature of acetic anhydride and the elevated temperature 
used in the reaction. This led us to find an alternative route which would be more 
favoured when applied to SPOS. 
In the synthesis of the quinolones, the t3-keto esters, have an active methylene 
bridge situated between the dicarbonyl moiety. Such methylene units are known to 
react with formamide acetals under mild conditions.'9' They are also known to be 
useful in the synthesis of enamines.'92'193 Recently, Wentland et al. 194  have reported 
the preparation of f3-keto enamide intermediates, via an analogous reaction to that 
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Fig. 2.20. Alternative Enamide Synthesis 
Initially, the 3-keto ester, (97) was dissolved in a solution of anhydrous THF 
and dimethylformamide dimethyl acetal added. Following agitation for 18 hours at 
room temperature, 2 equivalents of cyclopropylamine was added and the reaction 
mixture was stirred for a further 72 hours, at 25°C, with the resulting enamine 
identified as the desired product, (103), which was present as a mixture of E and Z 
isomers in 85 % yield. 
Compared to the traditional synthetic route shown in (fig. 2.19), the 
alternative enamide method, introduces more compatible conditions for the analogous 
solid phase methodology. The reaction is carried Out at ambient temperatures, thus 
avoiding problems inherent in the use of elevated temperatures with a solid support. 
Furthermore, the use of THF instead of acetic anhydride gives improved swelling of 
the polystyrene solid support and therefore enhances the reaction kinetics. This has 
subsequently been confirmed by an analogous reaction with the resin-bound 13-keto 
ester, (see section 2.4). 
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2.3.2. Optimisation of Base Cyclisation 
Re-evaluation of the solution phase synthesis has successfully optimised the 
first three steps in the synthesis of the quinolones using reaction conditions which are 
compatible with SPOS. It was also necessary to re-evaluate the solution phase 
chemistry of the base cyclisation step, which to date has proved the most problematic. 
Generally, the most favourable conditions for ring closure are the use of potassium 1-
butoxide in a solution of either t-butanol or DMSO.'95 Early solid phase studies 
confirmed the failure of both these reaction conditions when the reaction was 
attempted using the traditional synthetic methodology. On replacement of (-butanol 
with DMSO, it was hoped that the good swelling properties of DMSO would improve 
the solid phase reaction. Also, the use of a slurry of potassium t-butoxide in DMSO 
yields a more basic system than in t-butanol;'96 however, both t-butanol and DMSO 
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Fig. 2.21. Base Cyclisation 
A systematic study of various bases and reaction conditions, seventeen in 
total, was executed whilst focusing on conditions compatible with SPOS, (see table 
2.1). Cyclisation of, (101), and concomitant elimination of hydrogen fluoride (HF) 




intermediates, (fig. 2.21). Incomplete cyclisation was monitored by NMR studies, 
which indicated a mixture of two products; namely, the desired quinolone, ethyl 1-
cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylate, (104) and the Z 
isomer, (B), obtained in a (3:11) ratio respectively. In an analogous reaction, 
cyclisation of ethyl 3 -cyclopropylamino-2-(2, 3,4, 5-tetrafluorobenzoyl)acrylate, (102) 
gave similar results. For solution phase chemistry, a mixture of products can easily be 
separated by chromatographic methods, but incomplete cyclisation of the resin-bound 
enamine is not satisfactory as this would lead to the build-up of resin-bound 
impurities. 
Table 2.1. Optimisation of Base Cyclisation Studies 
(See Fig. 2.21) 
Entry Conditions A B C 
1 KOtBu / tBuOH, 25°C, 16h + 55°C, 2h . 
2 KOtBu / THF, 25°C, 16h + 55°C, 2h / 
3 KOtBu / THF, 50°C, 16h  
4 KOtBu / DMSO, 25°C, 16h+550C,2h / 
5 Et3N./DMSO, 25°C, 16h 1/ 
6 Et3N / DCM, reflux, 16h 
7 DBU / DCM, reflux, 16h / 
8 DBU / DCM, reflux, 24h 
9 DBU / CHC13, reflux, 16h 
10 DBU /THY, 25°C,16h / / 
11 DIMSYL Na / DMSO, 70°C, 16h / 
12 DIMSYL Na / DMSO, 25°C, 16h 
13 TMG /DCM, 25°C,16h / 
14 TMG / DCM, 55°C, 16h 
15 TMG / THF, 25°C, 16h  
16 NaH / THF, 66°C, 4h 
17 LDA / THF, -780 to 25°C, 16h / / 
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Ultimately, two of the seventeen reactions studied in solution phase were 
suitable for later evaluation on a solid phase support. The organic base, 1,1,3,3-
tetramethylguanidine (TMG) in DCM at reflux for 16 hours, (entry 14), gave the pure 
cyclised quinolones in 80% and 76% yields respectively. Several studies have also 
been carried out using TMG at reduced temperatures and timescales, with a mixture 
of products, both cyclised quinolone and Z isomer observed. Although complete 
formation of the quinolone ring system proceeded with sodium hydride in THF at 
refiux for 4 hours, (entry 16), the physical manipulation of reactions in parallel using 
sodium hydride would prove unmanageable. 
In a similar reaction, the solution phase synthesis of ethyl 1-[4-fluorophenyl]-
6,7, 8-trifluoro- 1 ,4-dihydro-4-oxo-quinoline-3 -carboxylate, (107) was successfully 
carried Out, which further confirmed the efficiency of the cyclisation step, (fig. 2.22). 
Due to the strong electron withdrawing power of the 4-fluorophenyl group in the 
enamide, ethyl 3 -[4-fiuoroanilino]-2-(2,3  ,4, 5-tetrafluorobenzoyl)acrylate, (106) there 
was concern that such an electronegative effect would reduce the basicity of the 
nitrogen and hence that the TMG / DCM reaction mixture would not induce 
cyclisation. Nonetheless, the desired product was isolated in 85% yield as a bright 
orange powder. 
(106) 	F  
0 0 
TMG / DCM 
55°C, 18h 	F): 	N 
F 
(107) 	F 
Fig. 2.22. Synthesis of Ethyl 1-(4-Fluorophenyl)-6, 7, 8-trifluoro-1 , 4-dihydro-4- 
oxo-quinoline-3-carboxylate 
67 
2.3.3. X-ray analysis of the Quinolones 
The quinolones, (104) and (105) were analysed by the standard techniques. 
Furthermore, confirmatory X-ray studies were also performed following 
crystallisation of the products from chloroform. These crystal structures have not 
been previously reported either in Chemical Abstracts or in the Crystallographic 
database 197  and analysis of the esters shows that the molecules are planar with the 
cyclopropyl ring at approximately 45° to the plane of the molecule. An interesting 
feature is the complexation of ethyl l-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-
quinoline-3-carboxylate, (104), with chloroform, at a distance of 3 .oA between 
fluorine at position seven of the quinolone ring, and chlorine at position two in 
chloroform, (table 2.2 and fig. 2.23a). This is clearly not present in the related 
molecule, 	ethyl 	I -cyclopropyl-6, 7, 8-trifluoro- 1 ,4-dihydro-4-oxo-quinoline-3 - 
carboxylate, (105), (table 2.3 and fig. 2.24a). On the other hand, the stacking 
arrangement of both crystals, reveals that the molecules form an antiparallel alignment 
with adjacent molecules, (fig. 2.23b, and fig 2.24b). It is widely held that this is 
analogous to the conformation adopted by the corresponding acids in the bacterial 
cell, as shown in (fig. 1.26)132 
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Table 2.2. Crystallographic Information of the Ethyl 1-Cyclopropyl-6, 7-dfluoro- 
1, 4-dihydro-4-oxo-quinoline-3-carboxylate / Chloroform Complex, (104) 
(See Figs. 2.23a & b) 
Empirical formula C16H14C13F2NO3  
Formula weight 412.63 
Crystal system Orthorhombic 
Crystal size 0.82 x 0.31 x 0.23 [mm] 
Cell dimensions a [A] 6.7432(8) 
Cell dimensions b [A] 14.760(3) 
Cell dimensions c [A] 17.595 (3) 
Cell dimensions a [O]  90.00 
Cell dimensions 13 [O]  90.00 
Cell dimensions y [O]  90.00 
Density 1.565 [glcm3] 
Z 4 
Table 2.3. Crystallographic Information of Ethyl 1-Cyclopropyl-6, 7, 8-trifluoro- 
1, 4-dihydro-4-oxo-quinoline-3-carboxylate, (105) 
(See Figs. 2.24a & b) 
Empirical formula C15H12F3NO3  
Formula weight 311.26 
Crystal system triclinic 
Crystal size 0.45 x 0.15 x 0.10 [mm] 
Cell dimensions a [A] 7.830(3) 
Cell dimensions b [A] 9.601(5) 
Cell dimensions c [A] 10.169(5) 
Cell dimensions a [O]  62.92(3) 
Cell dimensions 13 [0]  82.17(3) 
Cell dimensions y [0]  89.23 (3) 







Fig. 2.23a. X-ray Structure of the Ethyl 1-cvclopropyl-6, 7-dzfluoro-1,4-dihydro-4-
oxo-quinoline-3-carboxylare / Chloroform Complex 
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Fig. 2.23b. X-ray Stacking Arrangement of the Ethyl 1-C'yclopropyl-6, 7-dfluoro- 
1, 4-dihydro-4-oxo-quinoline-3-carhoxylate / Chloroform complex 
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U— 
Fig. 2.24a. X-ray Structure of Ethyl 1-Cyclopropyl-6, 7,8-trjfluoro-1,4-dihydro-4-
oxo-quinoline-3-carboxylate 
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Fig. 2.24b. X-ray Stacking Arrangement of Ethyl 1-Cvclopropyl-6, 7,8-trifluoro-
1, 4-dihvdro-4-o.o-quinoline-3-carbotylate 
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2.3.4. Optimisation of Arylation 
In the traditional solution phase cycloaracylation route, the final step in the 
preparation of the quinolones involves nucleophilic aromatic substitution in the 
presence of the carboxylic acid moiety at C-3. However, in our SPOS route, this 
reaction must occur in the presence of the, resin-bound ester, (fig. 2.25). 
OEt 
F)
)L 	pipe razine DO ' 
(104) (108) 
Fig. 2.25. Optimisation of Aromatic Nucleophilic Substitution 
Therefore an extensive study of the solution phase chemistry was undertaken 
to elucidate reaction conditions compatible to SPOS, (table 2.4). In total, 7 reactions 
were attempted. The desired product, ethyl 1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxo-7-( I -piperazinyl)-quinoline-3 -carboxylate, (108), was obtained by refluxing the 
ester, (104) with piperazine in pyridine for 48 hours (entry 6). However, the long 
reaction time was of concern, and it was found that heating the quinolone in 1-methyl-
2-pyrrolidinone (NW) for only 4 hours, (entry 7), gave the product in 89 % yield. 
Later work confirmed the reaction to have gone to completion after only 2 hours. 
Additionally, no amide product in either case was observed. Base hydrolysis of (108) 
in aqueous sodium hydroxide afforded the required product, Ciprofloxacin®. 
11 
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Table 2.4. Aromatic Nucleophilic Substitution Studies 
(See Fig. 2.25) 
Entry Conditions Results 
1 ME, 110°C, 3h NR 
2 DMF, 25°C, 16h NR 
3 Dioxane, 100°C, 24h NP. 
4 DCM/TMG,55°C,60h NP. 
5 DMSO, 150°C, 20h NR 
6 Pyridine, 115°C, 48h 108 
7 NMP, 110°C, 4h 108 
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2.4. SPOS of Ciprofloxacin® 
The previous sections have discussed the development of the solution phase 
chemistry for the preparation of the quinolones, and its compatibility to solid phase 
chemistry. Polystyrene denvatised Wang resin has been successfully used as the solid 
support for the SPOS of the quinolones, however Tentagel® resins were also 
investigated as possible solid supports. Tentagel® resins are generally known to 
exhibit good swelling properties in both aqueous and organic solvents,43 and thus can 
be useful for carrying out reactions which are limited to aqueous conditions. 
However, our work has shown that Tentagel® resins are mechanically unstable to both 
sonication and magnetic agitation. This was confirmed by transesterification of 2,4,5-
trifluorobenzoylacetic acid ethyl ester, (97), onto Tentagel® resin, whereby analysis of 
the resin-bound product by '3C NMR revealed breakdown of the Tentagel® solid 
support. 
The development of a new route to the quinolones has not been a trivial task. 
Our early work proved unsatisfactory for the solid phase preparation of the 
quinolones and illustrated the need for re-evaluation of the traditional synthetic 
methodology in order to attempt such reactions on a polystyrene solid support. With a 
possible resin linkage obtained via ring (A), and the solution phase methodology fully 
optimised for the synthesis of the quinolones, we attempted the solid phase synthesis 
of Ciprofioxacin®, (fig. 2.26) and some related quinolones, (fig. 2.27). 
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Fig. 2.26. Solid Phase Synthesis of Ciprofloxacin 
Transesterification was carried out as discussed in section 1. The reaction 
required refiuxing at 110°C, for 72 hours, however this caused some concern 
regarding the possibility of resin bead breakdown. Subsequently, we studied different 
solvents and reaction conditions, (Table 2.5), but on analysis of the resin-bound 
products, only unreacted Wang resin, (5) was identified. This led us to return to the 
77 
original toluene solution and study the reaction over the given timescale by 13C gel 
phase NMR. To our surprise the product, copoly(styrene-1%-divinylbenzene)p-benzyl 
2,4,5-trifluorobenzoylacetate, (89), had formed after only 16 hours, and thus 
eliminated any fears we had with regard to resin bead breakdown at the elevated 
temperature of 110°C. Using the DIVERSOIv1ER apparatus, a (4 x 1) array-
transesterification'reaction was set up using Wang resin and each of the following 3-
keto esters: diethyl malonate,di-t-butyl malonate, 2,4,5-trifiuorobenzoylacetic acid 
ethyl ester, and 2,3,4,5-tetrafiuorobenzoylacetic acid ethyl ester. 
Table 2.5. Optimisation of Transestenfication Conditions 
Entry Transesterification Conditions Results 
1 DMF/DMAP, 154°C, 72h NR 
2 Pyridine, 110°C, 72h NR 
3 Dioxane, 100°C, 72h NB. 
4 Toluene / DMAP, 110°C, 72h Product 
5 Benzene / DMAP, 80°C, 72h NR 
6 Pentan-3 -one / DMAP, 110°C, 72h NR 
7 Toluene / DMAP, 110°C, 16h Product 
The resin-bound enamide, copoly(styrene-1%-divinylbenzene)p-benzyl 2-
(2,4,5-trifluorobenzoyl)-3-cyclopropylamjnoacrylate (109), was prepared by two 
alternative routes. Route (B) involved activation of the resin-bound 13-keto ester, (89), 
with dimethylformamide dimethyl acetal in situ, followed by the addition of an excess 
of cyclopropylamine.'94  The good swelling properties of THF, and the ambient 
temperatures used, both proved successful in the reaction in comparison to the 
conditions used in route (A), (fig. 2.26). 
Cyclisation of, (109), in TMG / DCM at reflux, for 18 hours provided the 
resin-bound quinolone, copoly(styrene- I %-divinylbenzene)p-benzyl 6, 7-difluoro- 1-












confirmation of the reaction was achieved by treatment of (110) with 40% TFA in 
DCM and analysis of the filtrates by both 1H NIEVIR and MS. Post-cleavage 
purification was carried out by silica gel chromatography to liberate the product, 1-
cyclopropyl-6, 7-difluoro- 1 ,4-dihydro-4-oxo-quinoline-3 -carboxylic acid, (111), in 
approximately 56% yield. 
The remaining resin-bound cyclised quinolone, (110) was subsequently 
arylated with a solution of piperazine in NMP. After 4 hours at 110°C, the presence 
of resin-bound Ciprofloxacin®, (112) was confirmed by '3C NMR. Treatment of (112) 
under resin cleavage conditions confirmed the isolated product as Ciprofioxacin®, 
(113). Following purification by chromatography, Ciprofioxacin® was isolated in 61% 
yield. The purity was quantitatively determined to be >95 % by 'H NIvIIR in 
combination with acetonitrile as an internal standard (ISTD). 
Additionally, the following quinolones were prepared using the methodology 
outlined in (fig.2.26). The resulting resin-bound quinolones were characterised by gel 
phase '3C N]VIIR. Analysis of the cleaved products are pending, (fig. 2.27). 
Fig. 2.27. SPOS of Quinolones and Related Compounds 
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2.4.1. Cleavage Studies 
The powerful electron donating p-alkoxy substituent of Wang resin 14  enhances 
the acid senstivity of the ester linkage in the resin-bound synthesis of the quinolones. 
Early workers in the field of SPS used a combination of IR spectroscopy and cleavage 
of the resin-bound products for characterisation of the solid phase products. Both 
these methods are still in use and proved highly efficient for the SPOS of the 
quinolones. However, during the synthesis of the quinolones, acid cleavage of the 
resin-bound 13-keto ester, enol ether and enamide intermediates proved to be 
unsuccessful due to the acid sensitivity of the products. Subsequently, '3C gel phase 
NMIR played a key role in the analysis of all resin-bound products in the quinolone 
synthesis. In addition to '3C NIvIIR analysis of the resin-bound quinolones, both these 
products were successfully cleaved by acid and characterised. In fact, the quinolones 
are soluble only in TFA. 
Table 2.6. Acid Cleavage Studies to Produce Ciprofloxacin 
Entry Cleavage Conditions Results 
1 TFA H20, (95%), 25°C, 18h Product 
2 TFA / H20, (70%), 25°C, 2h Product 
3 TFA / H20, (50%), 25°C, 2h Product 
4 TFA / DCM, (50%), 25°C, 16h Product 
5 TFA / DCM, (40%),250C, lh Product 
6 IM TMSBr / TFA, 0°C, 0.25h NR 
Table 2.6 illustrates a range of acid cleavage conditions investigated in order 
to optimise the product yield of the cleaved Ciprofloxacin®. Our early work used 
concentrations of 95% TFA, however, analysis obtained after cleavage of the solution 
revealed a large percentage of impurities present, as well as the desired product. Later 
we reduced the actual concentration of the acid, whilst at the same time replacing 
water with DCM, to improve resin swelling during the cleavage stage. The optimium 
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conditions were finally obtained with 40% TFA in DCM for only one hour, at room 
temperature, (entry 5). Further attempts utilized 1M TMSBr in TFA at 0°C, for 15 
minutes, (entry 6). However this route did not afford any of the desired quinolone. 
While the TFA cleavage conditions gave promising results, there were still 
residual impurities present in the 'H NMR spectrum of the cleaved quinolones, even 
with concentrations as low as 40% TFA. Initially, we concluded these had arisen from 
the cleavage of some resin-bound intermediates formed during the synthesis of the 
quinolones. However, none of the impurities could be identified by TLC and UV 
studies, thus suggesting that they were not derived from resin-bound intermediates. 
Subsequently, we investigated the possibility that the impurities arose from the 
Wang resin. In an attempt to eliminate these possible resin impurities, Wang resin was 
pre-treated with the cleavage conditions (40% TFA in DCM) prior to synthetic use, 
(fig. 2.28). Analysis of the treated Wang resin by IR confirmed that esterification in 
the presence of TFA had occurred. When we subsequently attempted to use the pre-








Fig. 2.28. Pre-treatment of Wang Resin with the Cleavage Conditions 
The acidic filtrate from the pre-treated Wang resin was also examined. 
Following concentration of the sample, the resulting oil was submitted for 'H NMR 
analysis, which confirmed that the impurities in the cleaved Ciprofloxacin® sample 
came solely from the Wang resin. In another study, three commercial samples of 
Wang resin, (0.6 - 0.9 mmollg, BaChem, Fluka, and NovaBioChem), were treated 
with the above acidic medium for one hour, at room temperature. As with the 
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previous example, the BaChem sample gave the same impurities. However, the 
samples from both Fluka and NovaBioChem revealed DMF as the impurity. As a 
further possible method of eliminating resin impurities, Wang resin was sonicated in a 
solution of dioxane for one hour at 25°C. Again, several common impurities were 
observed on analysis of the filtrate. 
The problem of resin impurities is undoubtedly fundamental in the 
development of any SPOS reaction. While our work has only touched on this issue, 
future work for the development of SPOS protocols should include controlled 
experiments designed to isolate and quantify resin degradation products and 
impurities. 
2.4.2. Biological Results 
No medicinal chemistry project is complete without the testing of potential 
drug candidates for biological activity. This is also true for any set of compounds 
synthesised using the DIVERSOMERTm technology. For our studies, which involved 
the SPOS of four separate samples of Ciprofloxacin®, the resin cleaved samples were 
assayed and the results compared with an authentic sample of Ciprofloxacin®, (Lot 5), 
(Table 2.7). 
Table 2.7. Biological Results of Ciprofloxacin ® 
1 Solid Phase '.'. 	- L6 
2 Solid Phase 0.I 0.2 
3: Solid Phase 3 1.1 
4 Solid Phase 0.2 3.1 
5 Solution Phase 0.025 0. 1 
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All four samples were prepared in individual round-bottomed flasks and 
confirmed as crude products by 'H NltvlIR and / or MS, with the major impurities 
related to resin by-products and not intermediates in the quinolone synthesis, as 
discussed above. 
The results for all four samples prepared using SPOS methodology clearly do 
not give the same biological activity as the solution phase sample, although Lot 2 is 
consistent with known results. It must also be noted that from the literature 
Ciprofloxacin® gives widely varying results, ranging from 0.2 to 0.8 xg/ml for PA-7. 
While these results were initially disappointing, they demonstrated four mains 
considerations for the SPOS of the quinolone: 
the need for purification; 
the need for quantification of contained product; 
the confirmation of product identity in combination with NIVIIR / MS; 
the need to correlate light and temperature sensitivity with product purities. 
The results obtained from our research have resulted in a new synthetic route 
to the quinolone antibacterial agents. The successful re-evaluation of the solution 
phase chemistry has demonstrated the need for reagents and reaction conditions which 
are compatibile with SPOS. Resin impurities have been and continue to be a major 
problem in the purification of the final products. 
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2.5. Synthesis of Quinolone Antibiotics by D1VERSOMERTM technology 
Following the successful SPOS of Ciprofioxacin® and some related 
quinolones, the DI\TERSOIv1iER technology employing robotic automation and 
proprietary equipment was implemented with the SPOS route in (fig. 2.26) for the 
preparation of a library of 40 quinolones. The generation of a DI\TERSOMER Tm 
library involves a complex set of methodologies that range from planning the synthetic 
reaction scheme, to building compound libraries and finally interpreting the results. All 
of these methods require the use of Microsoft®  Excel Spreadsheets which help in data 
handling and tracking for the generation and storage of large volumes of information. 
One such system has been developed by MDL Information Systems Inc, which has 
helped in this crucial planning stage of the library design, by providing a series of 
databases for new structure creation, storage, and the ability to manage large volumes 
of data associated with the library generation. 
For the parallel synthesis of 40 quinolones incorporating three sites of 
diversity, (R1, R2 and R3) over a six step synthesis, the information generated and 
required can be both immense, and mentally draining, in terms of the amount of 
paperwork produced. However, with the use of Project Library, a "master" 
spreadsheet to designate and organise the final compounds which are generated in the 
DIVERSOMERTm array was set up as shown in (fig. 2.29). Initially, a single generic 
structure for the quinolone library was built up, followed by the thirteen building 
blocks associated with the library generation. In addition, to the building blocks, other 
reagents in the synthetic scheme are fed into the programme for later use in the 
reaction sequence handling. Following this, the library of 40 quinolones was 
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Fig. 2.29. Quinolone Generic Structure and Library 
Subsequently, for each discrete structure generated in the library, (1-40), the 
molecular formula and weight are automatically calculated, with only the notebook 
number, type and product identifier being fed into the programme manually, (fig. 
2.30). Additional spreadsheets are set up for calculating reaction yields, reaction 
conditions and reagent concentrations. Furthermore, the Chemical and Biological 
Information (CBI) file can be accessed easily, and for the 40 quinolones generated in 
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Fig 2.30. Library Information Programme 
The reaction scheme for the synthesis of 40 quinolones, outlined in (fig. 2.31), 
involved the use of a 40 (4 x 10) array format labelled, A144, corresponding to 
quinolones 1 to 40 respectively. The first site of diversity (R1) was introduced during 
the transesterification reaction (R1S1).. In 12 of the 40 reactions, R1  = H, (A1-C4) 
and in the remaining 28, R1  = F, (D144). Activation of all 40 resin bound 13-keto 
esters with dimethylformamide diemethyl acetal, (R2S 1) was followed by the in situ 
addition of four separate amines (R2); (R2S2), cyclopropylamine, 4-fluoroaniline, 
2,4,-difluoroaniline, and t-butylamine, in the arrangement (Al-Ji) to (A444) 
respectively. Following TMG cyclisation (R3 Si), of all 40 resin-bound enamides, the 
final site of diversity (R3), was introduced by arylation (R4S1) with a range of seven 
piperazinyl derivatives; (A1-C4) and (D1-F4) were each suspended in a solution of 
piperazine, 2,6-dimethylpiperazine and 1-ethylpiperazine respectively, while the 
remaining four reagents; 1-methylpiperazine, 2-methylpipera.zine, 1-
isopropylpiperazine and piperidine were added to the reaction wells (G144) 
respectively. Finally all 40 of the resin-bound quinolones were cleaved (R5 Si) in 40% 
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Fig. 2.31. Reaction Scheme Format 
In an attempt to remove resin by-products, automated parallel purification, by 
gradient elution of pre-packed chromatography cartridges, and solid phase extraction 
(SPE) methods were developed and implemented. In total 10 sets of fractions (400 
samples) were analysed by automated TLC methods, combined robotically and 
concentrated to afford an average of 26% yield (9.2 mg), based upon loading of 
commercial polystyrene Wang resin. Two of the samples, B 1 and J3 were 
contaminated with residual t-butylamine from the eluting solvent mixture. 
Table 2.8. Quinolone Product Yields 
Well R1  K3 Yield mg Yield % 
Al H cyclopropyl piperazine 17.0 61 
A2 H 4-fluorophenyl piperazine 5.0 15 
A3 H 2,4-difluorophenyl piperazine 6.1 18 
A4 H t-butyl piperazine 7.2 25 
B! H cyclopropyl 2,6-dimethylpiperazine 27.1 90* 
B2 H 4-fluorophenyl 2,6-dimethylpiperazine 8.2 24 
B3 H 2,4-difluorophenyl 2,6-dimethylpiperazine 2.7 7 
B4 H t-butyl 2,6-dimethylpiperazine 3.0 10 
Cl H cyclopropyl 1-ethylpiperazine 18.7 62 
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#C2 H 4-fluorophenyl 1-ethylpiperazine 4.3 12 
C3 H 2,4-difluorophenyl 1-ethylpiperazine 6.1 17 
C4 H t-butyl 1-ethylpipera.zine 4.9 16 
Dl F cyclopropyl piperazine 7.5 23 
D2 F 4-fluorophenyl piperazine 12.5 33 
D3 F 2,4-difluorophenyl piperazine 7.2 18 
#D4 F t-butyl piperazine 6.5 19 
El F cyclopropyl 2,6-dimethylpiperazine 9.6 27 
#E2 F 4-fluorophenyl 2,6-dimethylpiperazine 8.1 20 
E3 F 2,4-difluorophenyl 2,6-dimethylpiperazine 9.7 23 
#E4 F t-butyl 2,6-dimethylpiperazine 8.4 23 
Fl F cyclopropyl 1-ethylpiperazine 14.3 41 
#F2 F 4-fluorophenyl 1-ethylpipera.zine 8.4 21 
F3 F 2,4-difluorophenyl 1 -ethylpiperazine 8.6 21 
#F4 F t-butyl 1-ethylpiperazine 6.4 17 
Gl F cyclopropyl 1-methylpiperazine 8.1 24 
#G2 F 4-fluorophenyl 1-methylpiperazine 7.6 20 
G3 F 2,4-difluorophenyl 1-methylpiperazine 8.4 21 
#G4 F t-butyl 1-methylpiperazine 8.5 24 
111 F cyclopropyl 2-methylpiperazine 6.9 20 
#H2 F 4-fluorophenyl 2-methylpipera.zine 4.2 11 
113 F 2,4-difluorophenyl 2-methylpiperazine 7.8 19 
#114 F t-butyl 2-methylpiperazine 8.8 25 
Ii F cyclopropyl isopropylpiperazine 6.8 19 
#12 F 4-fluorophenyl 1-isopropylpiperazine 10.1 24 
#13 F 2,4-difluorophenyl 1-isopropylpiperazine 3.6 8 
#14 F t-butyl 1-isopropylpiperazine 8.7 23 
#Jl F cyclopropyl piperidine 10.0 31 
#J2 F 4-fluorophenyl piperidine 11.3 30 
#J3 F 2,4-difluorophenyl piperidine 30.4 78* 
#J4 F t-butyl piperidine 6.4 19 
Average 9.2 26 
* residual t-BuNH2 
# new quinolones. 
Several random samples from the library of 40 were analysed by 1H NMR, 
however additional impurities were shown to be present, which were later identified 
as polypropylene by-products from the SPE cartridges. A second attempt to 
purification of the quinolones was attempted, using 5 ml pipette columns, 
automatically loaded with silica. However additional problems were encountered, 
such as disintegration of the viton o-rings, resulting in contamination of the fractions, 
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(fig. 2.32). Analysis of the products by both 'H NTvIIR and MS spectroscopy 
confirmed decomposition of the products. 
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Fig. 2.32. Qunilone Product Yields 
These results were discouraging, however, our work in comparison to our 
competitors has been unique in stressing the utility of parallel purification and 
quantitative purity assessment. Indeed we are the only ones employing any 
purification techniques. 
2.6. Conclusion and Future work 
The chemistry of the quinolones involves a complex set of reactions. Our 
work has been the first to successfully demonstrate the SPOS of the quinolone 
antibiotics. Additionally, we have illustrated the utility of the DIVERSOMERTm  
technology to carry out 240 reactions in the parallel synthesis of 40 quinolones. The 
problem of final product purification has clearly been of great importance in our work. 
Subsequently, the 40 quinolones will be resynthesised. 
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CHAPTER 3: RESULTS AND DISCUSSION cont. 
3.1. Alternative Support: Tbf Derivatives and PGC 
3.1.1. Introduction 
Merrifield's pioneering SPPS methodology, which was based on the sequential 
addition of N'-protected amino acid residues to an insoluble polymeric support, 
revolutionised peptide synthesis. This greatly simplified the task of peptide synthesis 
and, in particular, eliminated conventional methods for purification of intermediates. 
However, one of the main obstacles in SPPS is the difficulty of purification of the final 
product due to the accumulation of truncated peptides on the resin.198 Several 
methods of separation have utilised antibody affinity based interactions; 19920' however 
these methods can prove costly. Instead most research groups have predominantly 
concentrated on chromatographic separations using ion-exchange columns and 
reverse phase-high performance liquid chromatography (RP-HPLC).'68 
In 1986, Knox et aL 202 published a paper reporting the use of porous 
graphitised carbon (PGC) as a stationary phase for use in HPLC, giving results 
comparable to those using traditional bonded silica gels. More importantly, PGC was 
shown to have strong hydrophobic adsorption with unique selectivity, particularly to 
aromatic systems.203  
PGC has a porous two-dimensional graphite structure, and has a large surface 
area (ca. 150 m2/g) available for affinity binding.202 Preparation of the material 
involves polymerising a phenol-hexamine mixture within the pores of silica gel, 
followed by pyrolysing the resin in an atmosphere of nitrogen and then heating to an 
excess of 2000°C. The resulting amorphous glassy carbon is black in colour, and is 
chemically and physically stable. 
In order to exploit the hydrophobic interaction which PGC exhibited for large, 
flat molecules, Ramage & Raphy 204,205  set out to design a new, planar, aromatic 
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Fig. 3.1. Affinity Purification of Thfmoc Peptide on PGC"" 
Their concept was to tag the N-terminus of a peptide chain with a suitable 
aromatic derivatised protecting group, as shown in (fig. 3. 1), (step A). Subsequently, 
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the tag should be selectively adsorbed on PGC, (step B). Truncated peptides could 
then be easily removed by washing, and the final pure peptide obtained by 
deprotection and elution from PGC, (step C). 
Their general concept centred on the utility of benzo-fused fluorenes, (119), 
(fig. 3.2), as the basis for the required protecting group .201,201  While such polycyclic 
aromatic compounds containing fluorene have been extensively described in the 
literature, derivatives of tetrabenzo[a,c,g,i]fluorene, (Tbf), (123) have received little 
attention. In 1960, Martin et al. 209'21° reported the first synthesis of 
tetrabenzo[a,c,g,i]fluorene. During the next 30 years, the chemistry of Tbf remained 
untouched until 1988 when Ramage & Raphy205 synthesised three derivatives of Tbf 
as potential intermediates in the synthesis of N-(17-tetrabenzo[a,c,g,i]fluorenyl)-17-
methyoxycarbonyl, (Tbftnoc) amino acids and peptides. 
Ar ...o o _- Ar 
(119) 
(123) 
Fig. 3.2. Benzofluorenes and Tetrabenzofa,c,g,iJfluorene 
In addition to the strong fluorescent properties of tetrabenzo[a,c,g,i]fiuorene, 
it also exhibited strong hydrophobic binding to PGC. Both of these properties could 
be exploited in peptide and oligonucleotide synthesis. Indeed Ramage, Irving & 
Brown 21' 	and Ramage & 	Wah1212 	have 	successfully investigated 
tetrabenzo[a,c,g,i]fiuorene derivatives for the design of a highly hydrophobic N'-
amino protecting group and a 5'-hydroxyl protecting group for DNA synthesis 
respectively. It was found to be useful in the final purification step either by selective 
affinity binding to PGC, or as a hydrophobic chromatographic label to allow ITPLC- 
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based purification. More recently, work in our laboratories has used Tbfmoc and its 
affinity binding to PGC for the purification of a library of 27 endothelin antagonists.21 ' 
A key element in the synthesis of appropriate protecting groups has been the 
reactivity of the methylene bridge at position 17 of the tetraben.zo[a,c,g,i]fluorene 
molecule. The hydrogen atoms are highly acidic and analogous to those of the 
methylene bridge at position 9 of fluorene. The acidity in both systems is attributed to 
the high stability of the resonance stabilised cyclopentadienyl anion generated under 
basic conditions. 
With these unique properties in mind, Ramage214 in 1991 proposed to the 
BioOrganic chemistry group at Parke-Davis the possibility of utilising the PGC I Tbf 
affinity interaction for the generation of a library of DIVERSOMERSTh.t. It was 
predicted that by replacing the standard resin supports with 
tetrabenzo[a,c,g,i]fluorene derivatives, which have strong adsorption onto PGC, it 
should be possible to prepare pure compounds analogous to the methods 
demonstrated by peptide and oligonucleotide chemistry, (fig. 3.3). Thus, solution 
phase chemistry could be adopted but at the same time the advantages of solid phase 
methodology could be fully exploited. 
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Fig. 3.3. Alternative Support: PGC/ TbJ 
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3.1.2. Tbf derivatives / Quinolones. 
For our studies, the preparation of Ciprofloxacin® attached to a Tbf derivative 
was attempted in order to investigate the use of PGC as a method for library 
purification of the final product in the quinolone synthesis. The original synthesis of 
tetrabenzo[a,c,g,i]fluorene described by De Ridder & Martin 209  involved a series of 
reactions requiring harsh conditions, and gave a poor overall yield of less than 12% of 
the final product. In a second synthetic route, Martin et al.210 prepared several 
derivatives via the Wagner-Meerwein rearrangement of the fluorene system. As with 
the first route, poor yields were reported making it somewhat difficult for a large scale 
synthesis. Inspired by Martin's work, Ramage & Raphy204 exploited a procedure 
developed by Hopkinson et al.215  for the synthesis of benzofluorenes via the 
rearrangement of a-alkoxycarbonyldiarylmethyl cations. However, low yields were 
obtained with several chromatographic separations required in the synthesis. 
In light of these results, it was thought that an analogous reaction for the 
synthesis of 9-fluorenylmethanol as described by Carpin0216 could also be applied for 
the preparation of 17-tetrabenzo[a,c,g,i]fluoreneylmethanol via tetrabenzo-
[a, c,g, i]fluorene. 
In the reaction,217  (fig. 3.4), the Grignard reagent derived from 9- 
bromophenanthrene, (120) was generated in anhydrous THF. Following the addition 
of 0.5 equivalents methyl formate, the alcohol, (bis-phenanthren-9-y!)methanol, (121) 
was isolated in 80% yield. A [2+2] cyclisation of the bis alcohol occurred upon 
treatment with TFA in DCM, to give the cyclised fluorescent Tbf compound, (122) in 
90% yield. Previous attempts to generate tetrabenzo[a,c,g,i]fluorene via cyclisation of 
the alcohol in polyphosphoric acid ,205  concentrated sulphuric acid ,218 aluminium 
















Fig. 3.4. Synthesis of Tetrabenzofa, c,g,iJfluorene 
While initial studies predicted the isolated product to be (123), analysis of the 
cyclised material by 'H NIMIR showed subtle differences from the literature compound. 
A more complex aromatic splitting pattern was observed than would normally be 
expected for a symmetrical structure such as, (123). Additionally, only one proton 
signal at 6 5.42 ppm was observed, whereas structure (123) would require two. There 
were also slight differences between the UV spectrum and the published spectra.209 
Based on earlier work, Ramage et al.204'211'212 predicted that the polycyclic 
aromatic tetrabenzo[a,c,g,i]fluorene (123) was formed through a deprotonation and 
reprotonation isomerisation reaction, catalysed by base. The resulting isomeric 
products are generally referred to as 8bH-tetrabenzo[a,c,g,i]fluorene, (122), and 17-
tetrabenzo[a,c,g,i]fluorene, (123), respectively. Further confirmation of the structure 
of 17-tetrabenzo[a,c,g,i]fluorene was obtained by X-ray analysis which revealed a 
molecule, symmetrical about the C2 axis, with a slight twist between the two 
phenanthrene moieties indicating non-planarity in the molecule, in the crystalline 
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state.217  The ring system is mobile in solution as exhibited by NIvIIR which indicates a 
symmetrical molecule. 
Treatment of, (122) with n-butyllithium at -78°C in THF, followed by the 
addition of allyl bromide gave the alkene derivative, 1-(17'-
tetrabenzo[a,c,g,i]fluorenyl)prop-2-ene, (124) in 70% yield. The terminal alkene was 
subsequently hydroborated using 9-BBN in anhydrous THF, followed by the addition 
of sodium hydroxide and hydrogen peroxide to generate the primary alcohol, 3-(17'-











Fig. 3.5. Synthesis of 3-(1 7'- Tetrabenzo[a, c,g,iJfluorenyl)propanol 
In order to synthesise the quinolones, we predicted that the preparation of the 
alcohol, (125), would provide us with a linker for the attachment of the quinolone 
structure to the Tbf moiety via the transesterification reaction discussed in chapter 2. 
Initial studies involved transesterification of 3-(17'-tetrabenzo[a,c,g,i]fluorenyl)-
propanol, (125) and three equivalents of ethyl 1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxo-.7-(l-pipera.zinyl)-quinolone-3-carboxylate, (108) in the presence of a catalytic 
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amount of DMAP, (fig. 3.6). The reaction mixture was heated to reflux in toluene and 
monitored by TLC. After 72 hours, analysis of the reaction mixture confirmed that 
only the starting materials were present, with no product formed. This result 
confirmed previous evidence reported in the literature'88 which concluded that only 












Fig. 3.6. Attempted Transesterijication Synthesis 
Rather than find an alternative transesterification route, we decided to pursue 
the route shown above via the cycloaracylation process for the quinolones, as 
discussed in the previous chapter. Preliminary experiments were carried out on 
transesterification of 3 -(17' -tetrabenzo[a, c,g, i]fluorenyl)propanol, (125) with diethyl 
malonate or di-t-butyl malonate, to confirm the Tbf-bound 3-keto esters. As 
predicted, in an analogous reaction, the transesterification product of 2,4,5-
trifiuorobenzoylacetic acid ethyl ester, (97) with (125) under the same conditions gave 
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the 	Tbf-bound 13-keto ester, 3 -(17' -tetrabenzo [a, c,g, i]fiuorenyl)propyl 2,4,5 - 
trifiuorobenzoylacetate, (126) in 56% yield after purification, (fig. 3.7). The product 









Fig. 3.7. Synthesis of 3-(1 7'-Tetrabenzo[a,c,g,i]fluorenyl)propyl 2,4,5- 
trzfluorobenzoylacetate 
With the primary synthetic intermediate of the quinolones now attached to the 
Tbf moiety, the binding affinity of (126) to PGC was studied prior to any further 
synthetic work in the quinolone synthesis. Some UV studies were carried out, see (fig. 
3.8). Initially, (126) was dissolved in DCM and the UV spectrum measured for the 
presence of the Tbfchromophore in the range 400-350 nu-n. Following the addition of 
PGC (40 mg)220, the Tbf/ PGC mixture was agitated and centrifuged. UV analysis of 
the supernatant confirmed 80% adsorption of (126) onto PGC. This was later 
increased to 90% adsorption by the addition of methanol. 
The 	hydrophobic interaction of 3 -(17 '-tetrabenzo [a, c,g, i]fiuorenyl)propyl 
2,4,5-trifiuorobenzoylacetate with PGC results in a solid phase environment 
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analogous to that of the resin-bound 13-keto ester in (fig. 2.20), (chapter 2). However, 
rather than filtering the resulting Tbf-PGC complex (126), impurities and by-products 
from the reaction mixture were removed in the supernatant following centrifugation. 
A further advantage of this methodology is that the equilibrium can be easily reversed 
by the addition of alternative solvents or by heating of the reaction mixture. In our 
studies, toluene was added to the Tbf-PGC complex and following analysis of the 
supernatant, 72% desorption of (126) from PGC was observed. 
( 	I. 126 (1.6 mg) in DCM (100 ml) 
Solution (I) and PGC (40 mg) 
Solution (ii) and MeOH (1 ml) 
Solution (iii) and MeOH (1 ml) 
Lv. Toluene (10 ml) 
400 nm 
R93-8. UV studies of 3-(1 7'- Tetrabenzo[a,c,g, iJfiuorenyl)propyl 2,4,5- 
trifluorobenzoylacetate 
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3.1.3. Alternative Linker 
As mentioned earlier, a major advantage in the synthesis of 
tetrabenzo[a,c,g,i]fiuorene is the reactivity of the methylene bridge at C-17, which 
can be selectively targetted for the introduction of various functional groups. 
Despite the fact that 3 -(17' -tetrabenzo[a, c,g, i]fiuorenyl)propyl 2,4,5 - 
trifiuorobenzoylacetate was envisaged as a suitable reagent for the synthesis of the 
quinolones, we decided to further increase the distance between the Tbf moiety and 
the quinolone f3-keto ester starting material. The reasons for this were two-fold; 3-
(17'-tetrabenzo[a,c,g,i]fiuorenyl)propanol, (125) only has a three carbon linker 
between the C-17 position of the Tbf moiety and the hydroxyl position of the chain 
terminus, which we predicted might result in some steric interaction between the 
planar Tbf rings and the attached quinolone. Secondly, cleavage of the Tbf-bound 
quinolone product was also of some concern in the synthesis design. The use of 
polystyrene derivatised solid supports has demonstrated the success of substituting 
hydroxymethyl resin with Wang resin, whereby the powerful donating p-alkoxy 
moiety aids in the acid cleavage of the final product, (fig, 1.5). (chapter 1). Thus, by 
the introduction of an analogous ether linkage into the tetrabenzo[a,c,g,i]fluorene 
chain, the acid sensitivity of the ester linkage between the Tbf derivative and the 
quinolone unit could be substantially enhanced. In order to achieve both these 
requirements, it was decided to introduce an acid sensitive linker, via the preparation 
of the ether product, (128), (fig. 3.9). 
CO2Et 	 CO2Et 
I. NaH, DMF, 
ii. Br(CHBr 
100°C, 12h 
OH 	 O(CH2)10Br 
(127) 	 (128) 
Fig. 3.9. Synthesis of Ethyl 4-(1 O-bromodecyloxy)benzoate 
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The linker, ethyl-4-(10-bromodecyloxy)benzoate (128) was prepared by a 
Williamson ether type synthesis. Ethyl 4-hydroxybenzoate, (127) was deprotonated in 
a solution of sodium hydride and DMF, to generate the sodium salt in situ. Following 
the addition of 1,1 0-dibromodecane, the solution was heated to 100°C for 12 hours. 
The product, (128), was isolated in 54% yield after purification. 
In order to attach the ten carbon ether chain of (128) to the C-17 position of 
tetrabenzo[a,c,g,i]fluorene, (122), deprotonation of the latter was carried out by the 
addition of tetrabutylammonium hydroxide in degassed dioxane.22' On heating the 
mixture to reflux, a bright yellow salt was precipitated and isolated under nitrogen by 
filtration. The solid was subsequently resuspended in dioxane, ethyl 4-(10-
bromodecyloxy)benzoate added and the mixture refiuxed for 2.5 hours. Extraction 
and purification of the resulting brown oil gave the alkylated product, ethyl 4-[10-
0 7' 
-[ -
(1 ' -tetrabenzo [a, c,g, i]fiuorenyl)decyloxy]benzoate, (129), in 63% yield, (fig. 3.10). 
Subsequent reduction of the ester, (129) to the corresponding benzyl alcohol 
was carried out at room temperature using DIIBAL in THF with the product, 4-[10-
(17' -tetrabenzo[a, c,g, i]fiuorenyl)decloxy]benzyl alcohol, (130) being isolated in 88% 
yield. Previous work by Ramage & Wahl had demonstrated an analogous reaction for 
the reduction of 4-( 17' tetrabenzo{a, cg, i]fiuorenylmethyl)benzoate. 
In order to generate the Tbf-bound quinolones, transesterification of (130) and 
2,4,5-trifiuorobenzoylacetic acid ethyl ester, (97) was attempted and the resulting 13- 
keto 	ester, 	4-[ 1 0-( 1 7'-tetrabenzo[a, c,g, i]fluorenyl)decloxy]benzyl 	2,4,5- 
trifiuorobenzoylacetate, (131) isolated as a keto-enol (3:1) tautomeric mixture in 38% 
yield. The product, (131) was subsequently studied by UV analysis and its affinity to 























Fig. 3.10. Synthesis of 4-[1 0-(] 7'-Tetrabenzo[a,c,g,ijfluorenyl)decloxyJbenzyl 2,4,5 
trzfluorobenzoylacetate 
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I. 131 (1.6 mg) in DCM (100 ml) 
Solution (I) and PGC (40 mg) 
Solution (ii) and MeOH (1 ml) 
Toluene (10 ml) 




Initially, (131) was dissolved in DCM and the UV spectrum recorded over the 
normal range. Following the addition of PGC (44 mg) and analysis of the supernatant, 
7% of the Tbf derivative remained in solution after the addition of methanol. In 
comparison to the previous example, this represented an increase of 13% adsorption 
to PGC. Desorption studies were carried out to further investigate the properties of 
the new linker. While 3-(17'tetrabenzo[a,c,g,i]fluorenyl)propanol resulted in a 72% 
desorption profile, the new linker "released" only 36% of the product in toluene. This 
caused some concern and consequently we decided to heat the Tbf-PGC toluene 
mixture. After sonication at 40°C for twenty minutes, a total of 72% desorption was 
recorded, analogous to the results obtained for Tbf-propanol. Further heating and 





Fig. 3.11. UV studies of 4-(1 O-(1 7'-Tetrabenzo[a, c,g,iJfluorenyl)decloxy)benzyl 
2,4, 5-trifluoro benzoylacetate 
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3.1.4. Future Work 
The preparation of the Tbf quinolones has been limited to the initial 
transesterification reaction. Preliminary work on the enol ether derivatives of the Tbf-
13-keto esters looks promising. The introduction of an alternative linker, ethyl 4-(10-
bromodecyloxy)benzoate, between the Tbf moiety and the quinolone structure has 
given interesting results. The UV studies of both Tbf derivatised 13-keto esters have 
successfully demonstrated the affinity of the quinolone backbone for PGC. 
Furthermore, this work illustrates the advantages of using an "alternative" solid 
support which would allow standard solution phase chemistry to be used, while at the 
same time being able to exploit the advantages of solid phase chemistry. Future work 
will continue with the preparation of the quinolones, thus demonstrating the utility of 
PGC for the purification of small molecule libraries. 
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CHAPTER 4:EXPERJMENTAL 
4.1. Techniques and Instrumentation 
Functionalised resins for solid phase synthesis were purchased from BACHEM, 
Switzerland, unless otherwise stated. The resins were used as supplied. Other 
chemicals were obtained from commercial sources such as Aldrich and Lancaster and 
used without further purification. Melting points were determined in open capillaries 
using a Buchi 510 melting point apparatus and are uncorrected. Thin layer 
chromatography (TLC) was performed on plastic or aluminium sheets precoated with 
silica gel (K.ieselgel 60 F254) in the following solvent systems; 
A 	chloroform 
B 	9:1 chloroform / methanol 
C 	8:2 hexane / ethyl acetate 
D 	9:1:0.5 chloroform / methanol / acetic acid 
E 	9:1:0.5 acetonitrile / triethylamine / water 
F 	18:2:1 acetonitrile / tributylamine / water 
G 	3:1:1 propanol / ammonia / water 
Flash chromatography was performed using silica gel 60 230-400 mesh (wet flash) or 
silica gel 60 5-40 pm (dry flash). Compounds were visualised using suitable 
combinations of ultra violet absorption at 254 and 365 nm, iodine vapour, methanolic 
sulphuric acid, Mary's reagent, (4,4-bis(dimethylamino)diphenylcarbinol), and 
ninhydrin. Infrared spectra were recorded on a Bio-Rad FTS-7 spectrometer in 
bromoform solution or KBr discs. Ultra violet spectra were recorded on a Varian 
Cary 210 double beam spectrophotometer. Fast atom bombardment mass spectra 
(FAB MS) were recorded on a Kratos MS50TC, and electron impact mass spectra 
(El MS) on a Kratos 902MS. Elemental analyses were carried out on Carlo Erba 
1106 or Perkin Elmer 2400 instruments. Proton NIMIR spectra were recorded on 
either Brucker WP 80 (80 MHz), WP 200 (200 MHz), or AC 250 (250 MHz) 
spectrometers in the solvent indicated relative to tetramethylsilane (TMS) as the 
external standard. Carbon-13 NMIR spectra were recorded on either Brucker WP 200 
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(50 MHz), AC 250 (250 MHz) or WH 360 (90 MHz) machines in the solvents 
indicated relative to TMS as the external standard. Gel phase carbon-13 NIvIIR spectra 
were recorded on either Brucker WP 200 (50 MHz) or AC 250 (250 MHz) machine. 
The resins were swollen in CDC13. Fluorine-19 NIIvR spectra were recorded on a AC 
(235 MHz). Single crystal X-ray structure determination was performed on a Stoe 
Stadi-4, four circle diflIactometer, graphite monochromated (Cu-Ka radiation, 
1=1.54184A). All solvents used were of analytical grade, or were distilled before use. 
The following solvents were dried when required using the reagents indicated: 
benzene (sodium wire), dichioromethane (calcium hydride), diethyl ether (sodium 
wire), THF (sodiumlbenzophenone indicator), toluene (sodium wire). 
Elemental analysis on tetrabenzo [a,c,g,i] fluorene derivatives. 
Microanalysis results on tetrabenzo[a,c,g,i]fluorene derivatives have generally been 
unsatisfactory. This has been attributed to the large number of quaternary carbons 
present in the system. 168  Increased oxygen concentrations and the addition of 
vanadium pentoxide have given improved combustion. 
Automation - DIVERSOMERTM apparatus. 
Information management was accomplished with Microsoft Excel®  spreadsheets, 
Parke-Davis proprietary database and MDL® ISIS / Base, ISIS / Draw and Project 
LibraryTm software packages on Gateway 2000 4DX2-66V and Macintosh lici 
Personal Computers. All liquid sample handling in the DIVERSOMER" approach 
was achieved using a TecanTm 5032 Robotic Sample Processor (RSP). Reaction 
agitation for the arrays was accomplished with Ney 250 ultrasonic baths coupled with 
Brinkmann RM6 Lauda temperature controllers. The heat exchange fluid used in the 
temperature controller was a ratio of 70% ethylene glycol / 30% water (v/v). The 
ultrasound bath fluid was water at ambient temperatures, and Dow Corning 550 
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silicone fluid at high temperatures. Final products were purified using Varian Mega-
Bond Elut pre-packed 12 ml cartridges. Normal phase cartridges were packed with 2 
grams of silica gel. Concentration of the final product solutions was achieved by 
applying vacuum in a centrifuge, SAVANT Instruments SC 110 SpeedVacTM. Drying 
of the final products with vacuum was done in a NAPCO model 5831 vacuum oven. 
Proton NIvIR spectra and carbon NIvIIR spectra were recorded on either Varian Unity 
400 (400 MHz), or Varian UnityPlus 400 (400 MHz) spectrometers, in the solvents 
indicated relative to TMS as an internal standard. Electrosray mass spectra (ES MS) 
were recorded on a Finnigan MAT 900 Q Mass Spectrometer. 
I 
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4.2. Synthetic Procedures 
Copoly(styrene-1 %-divinylbenzene)piperazine, (73). 
Copoly(styrene-1%-divinylbenzene)chloromethyl resin (0.20 g, 0.7 mmol / g), was 
suspended in toluene (100 ml). Pipera.zine (0.47 g, 55 mmol) was added and the resin 
mixture heated to 70°C, under an atmosphere of nitrogen, overnight. After 16 hours, 
the resin was filtered off and washed with copious amounts of dioxane, 
dioxane:water, toluene, methanol, water, THF and DCM. The product was dried in 
vacuo to yield a cream coloured resin identified as the title compound, (0.20 g). öC 
(50 MIFIz, CDC13), 145, 133-125 (polystyrene), 63, (polystyrene), 54 (w, CH2's), 46 
(CH2's), 40 (polystyrene) ppm. 
2,4,5-Trifluorobenzoylacetic acid, (85). 
A 1.6M solution (13 ml) of butyllithium in hexane was added over 10 minutes to a 
stirred solution of bis[trimethylsilyl] malonate (4.96 g, 20 mmol) in dry ether (20 ml), 
under an atmosphere of nitrogen, at -60°C. The mixture was then allowed to warm to 
0°C and a solution of 2,4,5-trifluorobenzoyl chloride (1 g, 5.1 mmol), in dry ether (20 
ml) was added in one portion. The mixture was stirred for another 10 minutes, at 0°C, 
and then shaken thoroughly with cold 5% aq. sodium hydrogen carbonate (100 ml) 
for 10 minutes. The aqueous layer was acidified to pH 1-2 with cold 4N H2SO4  and 
extracted with ether, (3 x 50ml). The extract was dried over MgSO4 and evaporated 
in vacuo to give the 3—keto acid as a white crystalline powder. (1.1 g, 96 %); m.p; 
104-105°C; TLC, Rf(C) 0.26; C,H, found C, 48.10; H, 2.29, C9H5F303 requires C, 
48.16; H, 2.29 %; Vmax (CHBr3 mull) 3500-3000 (b, OH), 1726 (C0), 1712 
(C=O) 1598 (aromatic) cm'; oH (60 MHz, CDCI3), 8.9-8.4 (m, 1H, aromatic), 8.0- 
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7.5 (m, 1H, aromatic), 3.9 (d, CH2) ppm; m/z (FAB) 219 (M+), HIR.MS(FAB) found 
219.02691, C9H5F303 requires 219.02690. 
2,3,4,5-Tetrafluorobenzoylacetic acid, (86). 
A 1.6M solution (6.5 ml) of butyllithium in hexane was added over 10 minutes to a 
stirred solution of bis[trimethylsilyl] malonate (2.48 g, 10 mmol) in dry ether (20 ml), 
under an atmosphere of nitrogen, at -60°C. The mixture was then allowed to warm to 
0°C and a solution of 2,4,5-trifluorobenzoyl chloride (1 g, 5.0 mmol), in dry ether (10 
ml) was added in one portion. The mixture was stirred for another 10 minutes, at 0°C, 
and then shaken thoroughly with cold 5% aq. sodium hydrogen carbonate (50 ml) for 
10 minutes. The aqueous layer was acidified to pH 1-2 with cold 4N H2SO4 and 
extracted with ether (4 x 30m1). The extract was dried over MgSO4 and evaporated 
in vacuo to give the 13—keto acid as a white crystalline powder. (0.90 g, 77%); m.p 
111-113°C; TLC, Rf(C) 0.24; C,H, found: C 45.76; H, 1.96, C9H4F404 requires C, 
45.76; H, 1.69 % Vmax (CHBr3 mull) 3500-3000 (b, OH), 1739 (C=O), 1712 
(CO), 1599 (aromatic) cm-1; 8H (200 MHz, CDCI3 I DMSO), 7.65-7.50 (m, 1H, 
aromatic), [12.3 (s), 5.92 (s), 4.03 (d), 3J = 3.8 Hz] 2H, ppm; mlz (FAB) 237 (M+), 
HRMS(FAB) found 237.0 1749, C9H4F403 requires 237.0 1747. 
Copoly(styrene-1 %-divinylbenzene)p-benzyloxybenzyl-monoethyl malonate. 
Copoly(styrene-1%-divinylbenzene)pbenzyloxybenzyl alcohol, (Wang) resin (0.20 g, 
0.8 mmol) was suspended in toluene (15 ml). A catalytic amount of 4-DMAP and 
diethyl malonate (0.33 g, 2.1 mmol) was added. The reaction mixture was allowed to 
stir, for 3 days, under a nitrogen atmosphere. After 72 hours, the resin was filtered off 
and washed with copious amounts of toluene, DMF, and finally DCM to yield a pale 
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cream coloured resin (0.20 g). Vmax (KBr disc) 1750 (C=O), 1736 (C=O) cm'. öC 
(60 MHz, CDC13), 145, 133-125 (polystyrene), 114 (polystyrene), 69 (p-benzyloxy 
CH2), 65 (benzyl CH2), 61 (COCH2CH3), 41 (COCH2CO), 14 (COCHH3) ppm. 
2,4,5-Trifluorobenzoylacetic acid ethyl ester, (97). 
Potassium ethyl malonate (10.2 g, 60 mmol) was stirred in MeCN (90 ml) under .a 
nitrogen atmosphere at 10-15°C. To this mixture was added Et3N (6.35 g, 62 mmol) 
followed by M902 (6.6 g, 70 mmol) and stirring continued at 20-25°C for 2.5h. The 
resulting slurry was recooled to 0°C and 2,4,5-trifluorobenzoyl chloride (5 g, 26 
mmol) added dropwise over a period of 25 minutes, followed by the addition of more 
Et3N (0.58 g, 5.7 mmol). The mixture was allowed to stir overnight at room 
temperature and the next day concentrated under vacuum to remove MeCN. Toluene 
(50 ml) was added and the resulting mixture reconcentrated under vacuum. More 
toluene (60 ml) was added and the mixture cooled to 10-15°C. Aqueous HCI (13 %, 
50 ml) was added cautiously while keeping the temperature below 25°C. The aqueous 
layer was separated and the organic layer washed with 12% aq. HC1 (2 x 30 ml) 
followed by H20 (2 x 40 ml). After drying over MgSO4 the organic layer was 
concentrated under vacuum to give the title compound as a white coloured product, 
(5.04 g, 79%). m.p. 57-59°C (lit.  114 55-570C); TLC, Rf (A) 0.35, Rf (B) 0.62; Vmax 
(CHBr3 mull) 2986, 2933 (aromatic St.), 1733 (C=O), 1707 (C=O) cm'; A.max 
(DCM) 296 ( = 11885 dm 3rnol4cm'), 280 11270 nm; C,H, found C 53.36; H 3.90; 
C1 1H9F303 requires C 53.60; H 3.66 %; oH (200MHz, CDC13), 7.74 (m, 1H, 
aromatic), 7.04 (m, 1H, aromatic), 4.26 (m, 2H), [13.21 (s), 5.84 (s), 3.93 (d,J4)], 
2H, 4.32-4.16 (m, 2H, 3J = 7.14 Hz, CO2CH2CH3), 1.35-1.15 (m, 3H, 3J = 7.12 Hz, 
CO2CHH3) ppm; OC (50MHz, CDC13), 187 (C=O), 173 (CO2Et), 166 (CO2Et), 
163, 159, 155, 151, 149, 145 (quaternary aromatic C's), 118 (aromatic CH), 107 
110 
(aromatic CH), 61 (COCH2CH3), 49 (COCH2CO), 13.8 (COCH2çH3) ppm; oF 
(235 MHz, CDC13), -110 (m, aromatic F), -111 (m, aromatic F), -123 (m, aromatic 
F), -128 (m, aromatic F), -140 (m, aromatic F), -141 (m, aromatic F) ppm; m/z (El),-
247 
;
(M+), 201, 159; FIRMS (El), found 247.05820, C11H,0F303 requires 247.05820. 
2,3,4,5-Tetrafluorobenzoyf acetic acid ethyl ester, (98). 
Potassium ethyl malonate (3.84 g, 22 mmol) was stirred in MeCN (34 ml) under a 
nitrogen atmosphere at 10-15°C. To this mixture was added Et3N (2.25 g, 21 mmol) 
followed by M902 (2.50 g, 27 mmol) and stirring continued at 20-25°C for 2.5h. The 
resulting slurry was recooled to 0°C and 2,3,4,5-tetrafluorobenzoyl chloride (2.5 g, 
11 mmol) added dropwise over a period of 25 minutes, followed by the addition of 
more Et3N. The mixture was allowed to stir overnight at room temperature and the 
next day concentrated under vacuum to remove MeCN. Toluene (20 ml) was added 
and the resulting mixture reconcentrated under vacuum. More toluene (30 ml) was 
added and the mixture cooled to 10-15°C. Aqueous HC1 (13 %, 25 ml) was added 
cautiously while keeping the temperature below 25°C. The aqueous layer was 
separated and the organic layer washed with 12% aq. HO (2 x 15m1) followed by 
H20 (2 x 20 nil). After drying over MgSO4 the organic layer was evaporated in 
vacuo to give the title compound as a pale orange low melting solid. The product was 
recrystallized from hexane, (2.11 g, 73 %). m.p. 59-61°C, (Lit. 184  63-640C); TLC, Rf  
(A) 0. 24, Rf (B) 0.60; C,H, found: C, 49.89; H, 2.91; C11H8F403 requires C, 50.00; 
H, 3.03 %, Vmax (CHBr3 mull) 2984, 2937 (Ar St.), 1739 (C=O), 1712 (CO) cm1; 
A.max (DCM) 286 ( = 26402 dm 3mol'cm 1), 241 (6270) nm; OH (250MHz, 
CDCI3), 7.67-7.51 (m,1H, aromatic), [12.7 (s), (OH), 5.82 (s), 3.96 (d), 3J3.8Hz,] 
(2H), 4.32-4.16 (m, 2H, 3J = 7.11 Hz, CO2CH2CH3), 1.36-1.22 (m, 3H, 3J = 7.15 
Hz, CO2CHH3) ppm; OC (50 MHz, CDCI3), 186 (C=O), 172 (CO2Et), 166 
111 
(CO2Et), 162, 146, 145, 143, 141, 138 (quaternary aromatic C's), 111 (aromatic CH), 
93 (CCH), 61 (COcH2CH3), 49 (COCHCO), 13 (COCHH3) ppm; m/z (FAB) 
265 (M+), 219, 177; HIRMS (FAB), found 265.04878, C9115F403 requires 
265.04877. 
Copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl 	2,4,5-trifluorobenzoyl- 
acetate, (89). 
Copoly(styrene-1%-divinylbenzene)p-benzyloxyben.zyl alcohol resin (1.0 g, 0.96 
mmol I g) was suspended in toluene (30 ml). A catalytic amount of 4-DM.AP and 
2,4,5-trifluorobenzoylacetic acid ethyl ester (1.24 g, 5.0 mmol) were added and the 
reaction mixture heated to 110°C under an atmosphere of nitrogen, overnight. After 
18 hours, the resin was cooled and filtered off, then washed with copious amounts of 
the following solvents; toluene, DMF (x 2), methanol, water, THF and chloroform. 
The title compound was obtained as an - orange product (1.0 g). Vmax (KBr disc), 1751 
(C=O), 1735 (C=O) cm'; öC (60 MHz, CDC13), 145, 133-125 (polystyrene), 117 
(aromatic CH), 114 (polystyrene), 106 (aromatic CH), 70 (p-benzyloxy CH2), 64 
(benzyl CH2), 49 (COcH2CO) ppm. 
Copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl 2,3,4,5-tetrafluoro-
benzoylacetate, (90). 
Copoly(styrene-1%-divinylbenzene)p-benzyloxybenzyl alcohol resin (1.0 g, 0.96 
mmol I g) was suspended in toluene (30 ml). A catalytic amount of 4-DMAP and 
2,3,4,5-tetrafluoi-obenzoylacetic acid ethyl ester (1.39 g, 5.0 mmol) were added and 
the reaction mixture heated to 110°C under an atmosphere of nitrogen, overnight. 
After 18 hours, the resin was cooled and filtered off, then washed with copious 
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amounts of the following solvents; toluene, DMF (x 2), methanol, water, THF and 
chloroform. The title compound was obtained as an orange product (1.0 g). Vmax (KBr 
disc), 1751 (C=O), 1735 (C=O) cm'; öC (60 MIHz, CDCI3), 145, 133-125 
(polystyrene), 117 (aromatic CH), 114 (polystyrene), 69 (p-benzyloxy CH2), 65 
(benzyl CH2), 48 (COcH2CO) ppm. 
Copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl 	(2-ethoxymethylene)- 
2,4,5-trifluorobenzoylacetate, (92). 
Copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl 2,4,5 -trifluorobenzoylacetate 
(0.20 g, 0.96 mmol / g) was suspended in a solution of acetic anhydride (10 ml) and 
triethyl orthoformate (2.40 ml, 7.25 mmol). The resin mixture was heated to 130°C 
for 4 hours. After cooling, the resin was filtered off and washed with copious amounts 
of DMF (x 2), ethanol, chloroform and DCM. On drying, the title compound was 
isolated as a dark brown product (0.195 g ); öC (60 MHz, CDCI3), 145, 133-125 
(polystyrene), 118 (aromatic CH), 114 (polystyrene), 111 (aromatic CH), 69 (p-
benzyloxy CH2), 66 (benzyl CH2), 58 (OCH2CH3), 18 (OCHH3) ppm. 
Copoly(styrene-1 %-divinylbenzene)p-benzyloxybenzyl 2-(2,4,5-trifluorobenzoyl) 
-3-cyclopropylaminoacrylate, (109), route (A). 
Copoly(styrene- I %-divinylbenzene)p-benzyloxybenzyl 2,4, 5-trifluorobenzoylacetate 
enol ether, (0.17 g, 0.96 mmol / g) was suspended in DCM (20 ml). 
Cyclopropylamine (1.00 ml, 14.7 mmol) was added and the mixture was stirred, under 
an atmosphere of nitrogen, at 25°C. After 3 hours, the resin was filtered and washed 
with copious amounts of the following solvents; DMF (x 2), methanol, water, TI-IF 
and chloroform. The title compound was dried in vacuo to yield an orange coloured 
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product (0.20g). öC (60 MHz, CDC13),  145, 133-125 (polystyrene), 118 (aromatic-
CH), 114 (polystyrene), 105 (aromatic-CH), 69 (p-benzyloxy CH2), 66 (benzyl CH2), 
30 (CH), 6 (CH2CH2) ppm. 
Ethyl (2-ethoxymethylene)-2,4,5-Trifluorobenzoylacetate, (99). 
Triethyl orthoformate (1.21 ml, 7.25 mmol), was added to a solution of 2,4,5-
trifluorobenzoylacetic acid ethyl ester (1 g, 4.0 mmol) in acetic anhydride (2.11 ml, 
22.35 mmol). The solution was heated at 130°C for 3 hours and, on cooling, 
evaporated in vacuo under reduced pressure to yield a pale orange mobile oil, (1.17 g, 
95 %).TLC, Rf (A) 0.24, Rf (B) 0.60; Vmax (CHBr3 mull) 3064, 2986, 2939, 2900 
(aromatic St.), 1713 (C=O), 1668 (C=O), 1626 (aromatic) cm'; 	(DCM) 290 (e = 
8636 dm 3moF'cm 1), 240 (12121) run; oH (250 MHz, CDC13), 7.64 (s, 1H, C=C), 
7.59-7.49 (m, 1H, aromatic), 6.90-6.79 (m, 1H, aromatic), 4.14-4.08 (q, 2H, 3J = 
7.12 Hz, COCH2CH3), 4.07-3.99 (q, 2H, 3J = 7.11 Hz, OCH2CH3), 1.37-1.14 (t, 3H, 
= 7.10 Hz, COCHH3), 1.12-0.98 (t, 3H, 3J = 7.11 Hz, COCHH3) ppm; OC (50 
MHz, CDC13), 186 (CO), 184 (CO2Et), 167, 163 (C=CH), 158, 154, 150, 148, 144 
(quaternary aromatic C's), 124 (C=C), 118 (aromatic CH), 112 (C=C), 105 (aromatic 
CH), 72 (COCH2CH3), 60 (OcH2CH3), 14 (COCHH3), 13 (OCH2çH3) ppm; OF 
(235 MHz, CDC13), -113 (m, aromatic F), -126 (m, aromatic F), -142 (m, aromatic F) 
ppm; m/z (El); 302(M+), 257, 200, 159; HRMS (El), found 302.07625 requires 
C14H13F304 requires 302.07659. 
Ethyl (2-ethoxymethylene)-2,3,4,5-Tetrafluorobenzoylacetate, (100). 
Triethyl orthoformate (1.21 ml, 7.25 mmol), was added to a solution of 2,3,4,5-
tetrafluorobenzoylacetic acid ethyl ester (1.16 g, 4.4 mmol) in acetic anhydride (2.11 
114 
ml, 22.35 mmol). The solution was heated at 130°C for 4 hours and, on cooling, 
evaporated in vacuo to yield a pale orange mobile oil, (1.36 g, 96 %).TLC, Rf (A) 
0.24, Rf (B) 0.60; Vmax (CHBr3 mull) 3064, 2986, 2939, 2900 (aromatic st.), 1713 
(C0), 1668 (C0), 1626 (aromatic) cm'; oH (250 MHz, CDC13), 7.67 (s, 1H, 
C=C), 7.44-7.36 (m, 1H, aromatic), 4.19-4.16 (q, 211, 3J = 7.11 Hz, COcH2CH3), 
4.14-4.06 (q, 2H, 3J = 7.16 Hz, OCH2CH3), 1.38-1.18 (t, 3H, 3J = 7.12 Hz, 
COCHH3), 1.17-1.07 (t, 3H, 3J = 7.16 Hz, OCH2cH3)  ppm; OC (50 MHz, CDC13), 
185 (C=O), 183 (CO2Et), 168 (C=CH) 164 (C=CH), 148, 144, 142, 141, 138 
(quaternary aromatic C's), 123 (C=C), 111 (aromatic CH), 72 (COCH2CH3), 60 
(OcH2CH3), 14 (COCHH3), 13 (OCHH3) ppm; OF (235 MHz, CDC13), -138.0 - 
-138.8 (m, aromatic F x 2), -149 (m, aromatic F), -155 (m, aromatic F) ppm; m/z 
(El); 320(1\4+), 275, 247, 159; HRMS (El), found 320.06701, C14H12F404 requires 
320.06717. 
Ethyl 3-cyclopropylamino-2-(2,4,5-trifluorobenzoyl)acrylate, (101). 
The mobile oil, ethyl (2-ethoxymethylene)-2,4, 5-trifluorobenzoylacetate (1.17 g, 3.9 
mmol), was suspended in DCM (15 ml) and cyclopropylamine (0.413 g, 7.25 mmol) 
added. The solution was stirred at 25°C for 3 hours, under an atmosphere of nitrogen. 
After evaporation in vacuo, the residue was dried to yield a pale green coloured 
solid, (1.09 g, 89%); m.p. 52-54 °C; TLC, Rf (B) 0.59, Rf (D) 0.75; C,H,N, found: 
C, 57.33; H, 4.44; N, 4.27; C15H14F3NO3 requires C, 57.50, H, 4.47; N, 4.47 %, Vmax 
(CHBr3 mull), 3280 (NH), 3232 (NH), 3110, 2939, 2907 (aromatic St.), 1693 (C=O), 
1630 (C=O) cm'; ?.max (DCM) 318 (e = 10658 dm 3mol'cm') 248 (15360) nm; OH. 
(250 MHz, CDC13), 10.86 (d, NH), 9.37 (NH), 8.20 (m, 1H, C=C), 7.24-7.10 (m, IIH, 
aromatic), 6.89-6.78 (m, 1H, aromatic), 4.03-3.98 (q, 2H, 3J = 7.14 Hz, COCH2CH3), 
3.00-2.90 (m, 1H, CH), 1.07-1.02 (t, 3H, 3J = 7.13 Hz, COCHH3), 0.93-0.72 (m, 
411, CH2CH2) ppm; OC (50 MHz, CDC13), 187 (C0), 185 (C=O), 167 (CO2Et), 160 
(C=CH), 159 (C=CH), 156, 1152, 148, 144 (quaternary aromatic C's), 127 (C=C), 
115 
117 (aromatic CH), 104 (aromatic CH), 59 (COCH2CH3), 30 (CH), 13 (COCH2CH3), 
5.9 (CH2CH2) ppm. oF (235 MHz, CDCI3), -116 (m, aromatic F), -132 (m, aromatic 
F), -143 (m, aromatic F) ppm. m/z (El); 313(M+), 267, 238; HRMS (El), found 
313.09316, C15H14F3NO3 requires 313.09258. 
Ethyl 3-cyclopropylamino-2-(2,3,4,5-tetrafluorobenzoyl)acrylate, (102). 
The mobile oil, ethyl (2-ethoxymetylene)-2,3,4,5-tetrafluorobenzoylacetate (1. 11 g, 
3.5 mmol), was suspended in DCM (20 ml) and cyclopropylamine (0.413 g, 7.25 
mmol) added. The solution was stirred at 25°C for 3 hours, under an atmosphere of 
nitrogen. After evaporation in vacuo the residue was dried to yield a pale orange 
coloured solid, (0.95 g, 86 %); m.p. 59-61 °C; TLC, Rf (B) 0.58, Rf (D) 0.71; 
C,H,N, found: C, 53.93; H, 3.99; N, 4.15; C15H13NF403 requires C, 54.28; H, 3.92; 
N, 4.23%; Vr,,a1 (CHBr3  mull), 3225 (NH), 3169 (NH), 3110, 2939, (aromatic st.), 
1695 (C=O), 1632 (C=O) cm'; A.max (DCM) 314 (c = 16544 dni3mol'cm 1) nm; OH 
(250 MHz, CDCI3), 10.90 (d, NH), 9.54 (NH), 8.23 (m, IH, C=C), 6.99-6.86 (m, 1H, 
aromatic), 4.08-3.92 (q, 2H, 3J = 7.13 Hz, COCH2CH3), 3.00-2.90 (m, 1H, CH), 
1.11-1.07 (t, 3H, 3J = 7.11 Hz, COCH2CH3), 1.03-0.70 (m, 4H, CH2CH2) ppm; OC 
(50 MHz, CDC13), 187 (C=O), 167 (CO2Et), 160 (C=CH), 149, 146, 144, 141, 138 
(quaternary aromatic C's), 124 (C=C), 109 (aromatic CH), 59 (OCH2CH3), 30 (CH), 
13 (OCHH3), 6 (CH2CH2) ppm; OF (235 MHz, CDCI3), -139 (m, aromatic F), -141 
(m, aromatic F), -155 (m, aromatic F), -159 (m, aromatic F) ppm; m/z (El); 331 
(M+), 285, 177; HRMS (El), found 331.08253, C15H13F4NO3 requires 331.08316. 
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Ethyl 3-cyclopropylamino-2-(2,4,5-trifluorobenzoyl)acrylate, (103). 
A solution of 2,4,5-trifluorobenzoylacetic acid ethyl ester (0.50 g, 2.0 mmol) and 
dimethylfOrmamide dimethyl acetal (0.3 ml, 2.2 mmol) in dry THF (13 ml) was stirred 
overnight, at 25°C, under an atmosphere of nitrogen. Cyclopropylamine (0.3 ml, 4.3 
mmol) was added dropwise, and stirring at 25°C was continued for a further 72 
hours. After 3 days, the solution was evaporated in vacuo and dried to yield a damp 
orange solid as the title compound, (0.53 g, 85 %); TLC, Rf (B) 0.58, Rf (D) 0.74; 
Vmax (CHBr3 mull); 3279 (NH), 3232 (NH), 3019 (aromatic st.), 1693 (C=O), 1630 
cm'; 6H (250 MHz, CDCI3), 10.80 (d, NH), 9.30 (s, NH), 8.13 (m, 1H, C=CH), 
7.26-7.06 (m, . 1H, aromatic), 6.82-6.71 (m, 1H, aromatic), 4.09-3.89 (q, 2H, 3J = 
7.13 Hz, COCH2CH3), 2.91-2.82 (m, 1H, CH), 1.13-1.10 (t, 3H, 3J = 7.10 Hz, 
COCH2CH3), 1.05-0.86 (m, 4H, CH2CH2) ppm; oF (235 MFIz, CDCI3), -116 (m, 
aromatic F), -132 (m, aromatic F), -143 (m, aromatic F) ppm; m/z (El), 314 (M+), 
267, 159; HRMS (El), found 3 13.09229, C15H14F3NO3 requires 313.09258. 
Ethyl 	l-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylate, 
(104). 
Ethyl 3-cyclopropylamino-2-(2,4,5'trifluorobenzoyl)acry1ate (0.100 g, 0.32 mmol) 
was dissolved in DCM (20 ml). TMG (0.86 ml, 6.4 mmol) was added and the solution 
heated to reflux under nitrogen. After 20 hours, the solution was cooled and water 
(20 ml) added. The aqueous layer was separated and the organic layer washed with 
2M HCI (2 x 20 ml), water (2 x 20 ml) and brine (2 x 30 ml). After drying over 
MgSO4 the solution was evaporated in vacuo to give the title compound as a white 
solid, (0.75 g, 80 %); m.p. 202-205°C; TLC, Rf (B) 0.40, Rf (D) 0.63; C,H,N, found 
C, 61.29; H, 4.84; N, 4.28; C15H13F2NO3 requires C, 61.43; H, 4.44; N, 4.78 %; Vm 
(CHBr3 mull); 3010 (aromatic st.), 1729 (C=O), 1691 (C=O), 1623 cm'. max (DCM) 
330 (c = 12682 dm 3mol'cm'), 316 (11707), 256 (16585), 248 (13658), 239 (11219) 
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nni; oH (250 MIHIz, CDC13), 8.5 (s, 1H, C=C), 8.26-8.18 (m, 1H, aromatic), 7.74-7.67 
(m, 1H, aromatic), 4.4-4.3 (q, 2H, 3J = 7.13 Hz, COCH2CH3), 3.4 (s, 1H, CH), 1.41-
1.30 (t, 3H, 3J = 7.08 Hz, COCH2CH3), 1.17-1.10 (m, 4H, CH2CH2) ppm; OC (50 
MiFlz, CDC13), 171 (C0), 164 (C0), 150 (C=CH), 146, 141, 139, 127, 124 
(quaternary aromatic C's), 117 (aromatic CH), 108 (aromatic CH), 60 (COCH2CH3), 
38 (CH), 14 COCH2CH3), 8.8 (CH2CH2) ppm; OF (235 MHz, CDC13) -127 (aromatic 
F), -139 (aromatic F) ppm. m/z (El), 293 (M+), 248, 221; HR.MS (El), found 
293.08834, C151113172NO3 requires 293.08635 
Ethyl 1-cyclopropyl-6,7,8-trifluoro- 1 ,4-dihydro-4-oxo-quinoline-3-carboxylate, 
(105). 
Ethyl 3 -cyclopropylamino-2-(2, 3,4, 5-tetrafluorobenzoyl)acrylate (0.15 g, 0.45 mmol) 
was dissolved in DCM (25 ml). TMG (1.21 ml, 9.0 mmol) was added and the solution 
heated to reflux under nitrogen. After 20 hours, the solution was cooled and water 
(20 ml) added. The aqueous layer was separated and the organic layer washed with 
2M HC1 (2 x 20 ml), water (2 x 20 ml) and brine (2 x 30 ml). After drying over 
MgSO4 the solution was evaporated in vacuo to give the title compound as a pale 
yellow solid, (0.118 g, 76 %); m.p. 166-169°C; TLC, Rf (B) 0.48, Rf (D) 0.67; 
C,H,N, found C, 58.05; H, 4.10; N, 4.35; C151112F3NO3 requires C, 57.88; H, 3.85; N, 
4.50 %, Vmaj (CHBr3 mull); 3019 (aromatic St.), 1729 (C=O), 1693 (C=O), 1623 cm 
Amax (DCM) 328 (c = 11333 dm 3mol 1cm 1), 316 (12888), 256 (11111), 248 
(13333), 240 (12444) nm; OH (250 MHz, CDC13), 8.5 (s, 1H, C=C), 8.00-7.99 (m, 
1H, aromatic), 4.38-4.29 (q, 2H, 3J = 7.13 Hz, COCH2CH3), 3.87 (s, 1H, CH), 1.39-
1.33 (t, 3H, 3J = 7.08 Hz, COCH2CH3), 1.27-1.15 (m, 4H, CH2CH2) ppm; OC (50 
MHz, CDC13), 171 (C0), 164 (C0), 150 (C=CH), 146, 145, 141, 139, 127, 124 
(quaternary aromatic C's), 108 (aromatic CH), 60 (COCH2CH3), 38 (CH), 14 
COCHH3), 8.8 (CH2CH2) ppm; OF (235 MHz, CDC13)  -135 (aromatic F), -139 
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(aromatic F), -150 (aromatic F) ppm. m/z (El), 311 (M+), 266; FIRMS (El), found 
311.07771, C15H12F3NO3 requires 311.07693. 
Ethyl 3-(4-fluoroanilino)-2-(2,3,4,5-tetrafluorobenzoyl)acrylate, (106). 
The mobile oil, ethyl (2-ethyoxymethylene)-2,3,4,5-tetrafluorobenzoylacetate (0.20 g, 
0.63 mmol), was suspended in DCM (10 ml) and 4-fluoroaniline (0.145 g, 1.31 mmol) 
added. The solution was stirred at 25°C for 3 hours, under an atmosphere of nitrogen. 
After evaporation in vacuo the residue was dried to yield a pale cream coloured solid, 
(0.21 g, 82 %); m.p. 88-90 °C; .TLC, Rf (A) 0.18, Rf (B) 0.61; C,H,N, found: C, 
55.92; H, 3.57; N, 3.80; C18H12F5NO3 requires C, 56.10; H, 3.12; N, 3.63 %; Vma1  
(CHBr3 mull), 3071, 2987, (aromatic St.), 1698 (C=O), 1631 (C=O) cm'; Am 
(DCM) 348 (e = 19789 drn 3mor1cm'), 240 (9243) nm; oH (250 MHz, CDC13), ,12.5 
(d, NH), 11.1 (NH), 8.47 (m, 1H, C=C), 7.24-6.97 (m, 5H, aromatic), 4.12-4.03 (m, 
2H, J=7.08 Hz, COCH2CH3), 1.11-1.07 (m, 3H, J=7.04 Hz, COCHH3), ppm; OC 
(50 MI-Iz, CDC13), 171 (C=O), 165 (CO), 153 (C=CH), 162, 158, 148, 145, 143, 126 
(quaternary aromatic C's), 134 (C=C), 119, 116, 109 (aromatic CH's), 103 
(quaternary aromatic C), 59 (OCH2CH3), 13 (OCHH3) ppm; OF (235 MHz, 
CDC13), -115 (s, aromatic F), -139 (m, aromatic F), -140 (m, aromatic F), -153 (m, 
aromatic F), -156(m, aromatic F), ppm; m/z (El); 385 (M), 311, HRMS (El), found 
385.7348, C18H12F5NO3 requires 385.07373. 
Ethyl 	1-(4-fluorophenyl)-6,7,8-trifluoro- 1 ,4-dihydro-4-oxo-quinoline-3- 
carboxylate, (107). 
Ethyl 3-(4-fluoroanilino)-2-(2,3,4,5-tetrafluorobenzoyl)acrylate (0.100 g, 0.26 mmol) 
was dissolved in DCM (15 ml). TMG (0.70 ml, 5.2 mmol) was added and the solution 
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heated to reflux under nitrogen. After 20 hours, the solution was cooled and water 
(20 ml) added. The-aqueous layer was separated and the organic layer washed with 
2M HCI (2 x 20 ml), water (2 x 20 ml) and brine (2 x 30 ml). After drying over 
MgSO4 the solution was evaporated in vacuo to give the title compound as a bright 
orange solid, (0.82 g, 86 %); m.p. 216-218°C; TLC, Rf (B) 0.40, Rf (D) 0.63; 
C,H,N, found C, 58.98; H, 3.35; N, 3.78; C18H11F4NO3 requires C, 59.17; H, 3.01 
3.83 N, %, Vm (CHBr3 mull); 3077, 2932 (aromatic St.), 1729 (C0), 1698 (C=O), 
1623 cm-1. A.max (DCM) 330 (c = 12682 dm 3moF'cm 1), 314 (16794), 295 (12778), 
248 (11938), rim; oH (250 MHz, CDCI3), 8.32 (s, 1H, C=C), 8.16-8.08 (m, 1H, 
aromatic), 7.750-7.45 (m, 2H, aromatic), 7.28-7.21 (m, 2H, aromatic), 4.4-4.3 (q, 
2H, J=7.04 Hz, COCH2CH3), 1.46-1.24 (t, 311, J=7.05 Hz, COCHH3) ppm; OC (60 
MHz, CDCI3), 171 (C0)3 165 (C=O), 150 (C=CH), 164, 160, 146, 143, 141, 124 
(quaternary aromatic C's), 138 (C=C), 127, 117, 109 (aromatic CH's), 61 
(COH2CH3), 14 COCHH3) ppm; OF (235 MHz, CDCI3) -110 (s, aromatic F), - 
134 (m, aromatic F), -138 (m, aromatic F), -150 (m, aromatic F) ppm. m/z (El), 365 
(M), 293 HRMS (El), found 365.06638, C18H11F4NO3 requires 365.0975 1. 
Ethyl 	1-cyclopropyl-6-fluoro-1 ,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3- 
carboxylate, (108). 
Ethyl 1 -cyclopropyl-6,7-difluoro- 1 ,4-dihydro-4-oxo-quinoline-3 -carboxylate (0.100 g, 
0.34 mmol) was dissolved in NIvIP (15 ml). Piperazine (0.246 g, 2.86 mmol) was 
added and the reaction mixture was heated to 110°C under an atmosphere of 
nitrogen. After 4 hours, the solution was cooled and evaporated in vacuo to yield a 
pale yellow/orange solid. The crude product was washed with water (20 ml) and 
extracted with chloroform ( 2 x 20 ml). Finally the chloroform extracts were dried 
over MgSO4 and evaporated in vacuo to yield the title compound as a yellow solid. 
(0.107 g, 89 %); m.p. 176-178°C; TLC, Rf (D) 0.21, Rf (F) 0.57; C,H,N, found C, 
62.32; H, 5.94; N, 10.12; C19H22FN303 requires C, 63.50; H, 6.12; N, 11.69. Vmax 
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(CHBr3  mull), 3397 (NH st), 3018, 2965 (aromatic St.), 1720 (C=O), 1675 (CO), 
1620 (aromatic) cm-1; Amax (DCM), 335 (6 = 10538 dm 3mor'cm'), 322 (9417), 280 
(28699) nm; oH (250 MHz, CDC13), 8.48 (s, 1H, C=CH), 8.0-7.94 (d, 1H, aromatic), 
7.22 (s, 1H, aromatic), 4.39-4.30 (q, 2H, 3J = 7.13 Hz, COcH2CH3), 3.42 (m, 1Ff, 
CH), 339-308  (m, 8H, CH2's), 2.39 (b, 1H, NH), 1.40-1.25 (t, 3H, 3J = 7.08 Hz, 
COCHH3), 1.19-1.12 (m, 4H, CH2CH2) PPM). 8C (50 MHz, CDC13), 173 (C=O), 
165 (CO2Et), 150 (C=CH), 155, 147, 144, 137, 122 (quaternary C's), 113, 109 
(aromatic CH), 60 (COCH2CH3), 50, 45 (CH2's), 34 (CH), 14 (COCHH3), 7.9 
(CH2CH2) ppm. OF (235 MHz, CDC13), -123 (s, aromatic F) ppm; m/z (El), 359 
(M+), 317, 287; HRMS (El), found 359.16499, C19H22FN303 requires 359.16452. 
Copoly(styrene-1 %-divinylbenzene)p-benzyloxybenzyl 2-(2,4,5-trifluorobenzoyl) 
-3-cyclopropylacrylate, (109), route (B). 
Copoly(styrene- I %-divinylbenzene)p-benzyloxybenzyl 2,4, 5-trifiuorobenzoylacetate 
(0.40 g, 0.96 mmol / g) was suspended in dry THF (20 ml). Dimethylformamide 
dimethyl acetal, (2.55 ml, 19.2 mmol) was added and the mixture was stirred under an 
atmosphere of nitrogen at 25°C, overnight. After 18 hours, cyclopropylamine (2.60 
ml, 38.4 mmol) was added and the mixture was stirred for a further 72-80 hours at 
25°C. The resin was then filtered and washed with copious amounts of the following 
solvents; DMF (x 2), methanol, water, THF, DMF and chloroform. The title 
compound was obtained as an orange coloured product (0.37g). OC (60 MHz, 
CDC13), 145, 133-125 (polystyrene), 118 (aromatic CH), 114, (polystyrene), 105 
(aromatic CH), 69 (p-benzyloxy CH2), 65 (benzyl CH2), 30 (CH), 6 (CH2CH2) PPM- 
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Copoly(styrene-1 %-divinylbenzene)p-benzyloxybenzyl 	6,7-difluoro-4-oxo- 1- 
cyclopropyl-quinoline-3-carboxylate, (110). 
Copoly(styrene- 1 %-divinylbenzene)p-benzyloxybeniyl 2-(2,4, 5 -trifiuorobenzoyl)-3 - 
cyclopropylacrylate (0.20 g, 0.96 mmol / g) was suspended in DCM (20 ml). TMG 
(4.81 ml, 38.2 mmol) was added and the reaction mixture was heated to reflux, under 
an atmosphere of nitrogen, overnight. After 18 hours, the resin was cooled and 
filtered off, then washed with copious amounts of DMF (x 2), methanol, water, THF, 
DMF and chloroform. The title compound was dried in vacuo to yield a pale 
brown/orange product, (0.20 g). ÔC (60 MHz, CDCI3), 145, 133-125 (polystyrene), 
118 (aromatic CH), 114 (polystyrene), 105 (aromatic CH), 69 (p-benzyl CH2), 66 
(benzyl CH2), 34 (CH), 7 (CH2CH2) PPM- 
1 -Cydo pro pyl-6,7-difluoro- 1,4-d ihyd ro-4-oxo-q  uinoline-3-carboxylic 	acid, 
(111). 
Copoly(styrene- 1 %-divinylbenzene)p-ben.zyloxyben.zyl 	6, 7-difiuoro-4-oxo- I -cyclo- 
propyl-quinoline-3-carboxylate (0.20 g, 0.96 mmol / g) was suspended in a solution of 
TFAIDCM (4:6, v/v, 10 ml) and stirred under an atmosphere of nitrogen at 25°C. 
After 1 hour, the resin was filtered off and washed with TFA followed by DCM. The 
filtrate was evaporated in vacuo to yield a pale yellow/brown oil. The residue was 
purified by short column chromatography on silica gel with CIICI3 / MeOH / AcOH; 
90 : 8 : 2. The collected fractions were evaporated to give a pale brown oil as the title 
compound, (16.5 mg, 56 %). oR (250 MHz, TFA-d), 9.12 (s, III, C=CH), 8.17-8.11 
(m, 2II, aromatic), 8.05 (s, 1II, aromatic), 3.81 (s, IH, CH), 1.38-1.13 (m, 4H, 
CH2CII2) ppm. m/z (El); 265 (M), 221; HRMS (El), found 265.05682, C13II19F2NO2 
requires 265.05505. 
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Copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl 6-fluoro-7-piperazinyl-4-
oxo-1-cyclopropyl-quinoline-3-carboxylate, (112). 
Copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl 6, 7-difluoro-4-oxo- 1 -cyclo 
propyl-quinoline-3-carboxylate (0.20 g, 0.96 mmol / g) was suspended in NIMP (20 
ml). Piperazine (2.00 g, 23.2 mmol) was added and the reaction mixture was heated 
to refiux under an atmosphere of nitrogen. After 4 hours, the resin was cooled, 
filtered off and washed with copious amounts of DMF (x 2), methanol, water, THF 
and chloroform. The yellow/orange coloured resin was dried in vacuo to yield the title 
compound (0.190 g). öC (60 MHz, CDC13), 145, 133-125 (polystyrene), 118 
(aromatic CH), 114 (polystyrene), 106 (aromatic CH), 69 (p-benzyloxy CH2), 64 
(benzyl CH2), 54, 50 (CH2's), 35 (CH), 7.8 (CH2CH2) ppm. 
1-Cyclopropyl-6-fluoro-1 ,4-dihydro-4-oxo-7-(1 -piperazinyl)-quinoline-3-
carboxylic acid, Ciprofloxacin®, (113). 
Copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl 6-fiuoro-7-piperazinyl-4-oxo-
1-cyclopropyl-quinoline-3-carboxylate (0.10 g, 0.96 mmol / g) was suspended in a 
solution of TFA / DCM (4:6, v/v, 10 ml) and stirred under an atmosphere of nitrogen 
at 25°C. After 1 hour, the resin was filtered off and washed with TFA followed by 
DCM. The filtrate was evaporated in vacuo to yield a pale yellow/brown oil. The 
residue was purified by short column chromatography on silica gel (varian mega bond 
elute Si) with CH3CN / H20 / tBuNH2; 18 : 2 : 1. The collected fractions were 
evaporated in vacuo to yield a pale orange solid as the title compound, 
Ciprofioxacin®, (0.017 g, 61 %). oH (400 MHz, TFA-d), 9.4 (s, 1H, C=CH), 8.28 (d, 
1H, aromatic), 8.05 (s, 1H, aromatic), 4.20 (s, 1H, CH), 4.09-3.80 (m, 8H, CH2's), 
1.31-1.04 (m, 4H, CH2CH2) PPM- 
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Copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl 6-fluoro-7-(1-piperazinyl) 
-4-oxo-1 -(4-fluoroanilino)-quinoline-3-carboxylate, (114). 
Copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl 2,4, 5-trifluorobenzoylacetate 
(0.20 g, 0.96 mmol / g) was suspended in dry THF (15 ml). Dimethylformamide 
dimethyl acetal (1.27 ml, 19.2 mmol) was added and the mixture was stirred under an 
atmosphere of dry nitrogen, at 25°C, overnight. After 18 hours, 4-fluoroaniline (ml, 
38.4 mmol) was added and the mixture was stirred for a further 72-80 hours, at 25°C. 
The resin was then filtered and washed with copious amounts of the following 
solvents; DMF (x 2), methanol, water, THF, DMF and chloroform. The resulting 
resin-bound enamide was suspended in a solution of TMG (4.81 ml, 38.2 mmol), in 
DCM (20 ml). To affect cyclization, the mixture was heated to reflux, under an 
atmosphere of nitrogen, overnight. After 18 hours, the resin was cooled and filtered 
off, then washed with copious amounts of DMF (x 2), methanol, water, THF, DMF 
and chloroform. The resin-bound quinolone was then suspended in NIvIP (20 ml) and 
pipera.zine (2.00 g, 23.2 mmol) added. The mixture was heated to 110°C, under an 
atmosphere of nitrogen, for 4 hours. On cooling, the resin was filtered off and washed 
with copious amounts of DMF (x 2), methanol, water, THF and chloroform. The title 
compound was dried in vacuo to yield a brown/orange product, (0.19 g). öC (250 
MHz, CDCI3), 145, 133-125 (polystyrene), 118 (aromatic CH), 114 (polystyrene), 
105 (aromatic CH), 69 (p-benzyl CH2), 66 (ben.zyl CH2), 54, 50 (w, CH2's) ppm. 
Copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl 	6,8-difluoro-7-(1 - 
piperazinyl)-4-oxo-1-(4-fluoroanhlino)-quinoline_3-carboxylate, (115). 
Copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl 	2,3,4, 5-tetrafiuorobenzoyl 
acetate (0.20 g, 0.96 mmol / g) was suspended in dry THF (15 ml). 
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Dimethylformamide dimethyl acetal (1.27 ml, 19.2 mmol) was added and the mixture 
was stirred under an atmosphere of dry nitrogen, at 25°C, overnight. After 18 hours, 
4-fluoroaniline (ml, 38.4 mmol) was added and the mixture was stirred for a further 
72-80 hours, at 25°C. The resin was then filtered and washed with copious amounts 
of the following solvents; DMF (x 2), methanol, water, THF, DIvIIF and chloroform. 
The resulting resin-bound enamide was suspended in a solution of TMG (4.81 ml, 
38.2 mmol), in DCM (20 ml). To affect cyclization, the mixture was heated to refiux, 
under an atmosphere of nitrogen, overnight. After 18 hours, the resin was cooled and 
filtered off, then washed with copious amounts of DMF (x 2), methanol, water, THF, 
DMF and chloroform. The resin-bound quinolone was then suspended in NW (20 
ml) and piperazine (2.00 g, 23.2 mmol) added. The mixture was heated to 110°C, 
under an atmosphere of nitrogen, for 4 hours. On cooling, the resin was filtered off 
and washed with copious amounts of DMF (x 2), methanol, water, THF and 
chloroform. The title compound was dried in vacuo to yield a brown/orange product, 
(0.19 g). öC (250 MHz, CDC13), 145, 133-125 (polystyrene), 118 (aromatic CH), 114 
(polystyrene), 69 (p-benzyl CH2), 66 (benzyl CH2), 54, 50 (CH2's) ppm. 
Copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl 	6-fluoro-7-(2,6-di- 
methyl)piperazinyl-4-oxo- 1-cyclopropyl-quinoline-3-carboxylate, (116). 
Copoly(styrene- I %-divinylbenzene)p-benzyloxyben.zyl-6, 7-difiuoro-4-oxo- 1 -cyclo-
propyl-3-quinoline carboxylate (0.20 g, 0.96 mmol / g) was suspended in NIVIP (20 
ml). 2,6-Dimethylpipera.zine (2.64 g, 23.2 mmol) was added and the reaction mixture 
was heated to refiux, under an atmosphere of nitrogen. After 4 hours, the resin was 
cooled, filtered off and washed with copious amounts of DMF (x 2), methanol, water, 
THF and chloroform. The orange coloured resin was dried in vacuo to yield the title 
compound (0.20 g). 6C (60 MHz, CDCI3), 145, 133-125 (polystyrene), 118 (aromatic 
CH), 114 (polystyrene), 109 (aromatic CH), 69 (p-benzyl CH2), 66 (benzyl CH2), 55, 
52 (w,CH2's), 36 (w, CH), 18 (CH3's), 7 (CH2CH2) ppm. 
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l-Cyclopropyl-1,4-dihydro-6-fluoro-7-(2,6-dimethyl)piperazinyl-quinolrne-3-
carboxylic acid, (116a). 
Copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl-6-fluoro-7-[2, 6-dimethyl]-
pipera.zinyl-4-oxo-1-cyclopropyl-3-quinoline carboxylate (0.20 g, 0.96 mmol / g) was 
suspended in a solution of TFA / DCM (4:6, v/v, 10 ml) and stirred under an 
atmosphere of nitrogen at 25°C. After 1 hour, the resin was filtered off and washed 
with TFA followed by DCM. The filtrate was evaporated in vacuo to yield a pale 
yellow/brown oil. The residue was purified by short column chromatography on silica 
gel with TFA / DCM. The collected fractions were evaporated in vacuo to yield a 
pale orange solid as the title compound, (0.020 g, %). 8H (250 MHz, TFA-d), 9.29 
(s, 1H, C=CH), 8.23 (b, 2H, aromatic), 4.18-3.90 (m, 7H, CH2's), 3.51-3.20 (b, 1H, 
NH), 1.76-1.25 (m, 7H) ppm. 
Copoly(styrene-1 %-divinylbenzene)p-benzyloxybenzyl 	2-(2,3,4,5-tetrafluoro- 
benzoyl)-3-tert butylaminoacrylate, (117). 
Copoly(styrene- I %-divinylbenzene)p-benzyloxybenzyl-2,3 ,4, 5 -tetrafiuorobenzoyl 
acetate (0.20 g, 0.96 mmol / g) was suspended in THF (20 ml). Dimethylformamide 
dimethyl acetal (1.27 ml, 19.2 mmol) was added and the mixture was stirred under an 
atmosphere of nitrogen, at 25°C, overnight. After 18 hours, tert.butylamine (4.0 ml, 
38.4 mmol) was added and the mixture was stirred for a further 72-80 hours, at 25°C. 
The resin was then filtered off and washed with copious amounts of the following 
solvents; DMF (x 2), methanol, water, THF, DMF and chloroform. The title 
compound was obtained as an orange coloured product (0.20 g). öC (60 MHz, 
CDCI3), 145, 133-125 (polystyrene), 118 (aromatic CH), 114 (polystyrene), 69 (p-
ben.zyl CH2), 66 (benzyl CH2), 29 (CH3's) PPM- 
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Copoly(styrene-1 %-divinylbenzene)p-benzyloxybenzyl 6,7,8-trifluoro-4-oxo-1-
tert. butyl-quinoline-3-carboxylate, (118). 
Copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl 2-(2, 3,4,5 -tetrafiuorobenzoyl)-
3-tert.butylaminoacrylate (0.20 g, 0.96 mmol / g) was suspended in DCM (20 ml). 
TMG (4.81 ml, 38.2 mmol) was added and the reaction mixture was heated to reflux, 
under an atmosphere of nitrogen, overnight. After 18 hours, the resin was cooled, 
filtered off, then washed with copious amonts of DMF (x 2), methanol, water, TIE, 
DMF and chloroform. The title compound was dried in vacuo to yield a pale 
brown/orange product (0.20 g). 6C (60 MHz, CDC13), 145, 133-125 (polystyrene), 
118 (aromatic CH), 114 (polystyrene), 69 (p-benzyl CH2), 66 (benzyl CH2), 31 
(CH3's) PPM- 
(4 x 1) Array- transesterification. 
Copoly(styrene-1%-divinylbenzene)p-benzyloxybenzyl alcohol resin (0.10 g, 0.80 
mmol / g) was measured manually into 4 seperate PINS (A1-A4). Each resin was 
suspended in toluene (4 ml). A catalytic amount of 4-DMAP was added to each PIN 
and the apparatus sonicated at room temperature for 30 minutes. After this time each 
of the following esters was added to the PINS (A1-A4) respectively; di-t-butyl 
malonate (0.34 g, 2.0 mmol), diethyl malonate (0.33 g, 2.0 mmol), 2,4,5-
trifluorobenzoylacetic acid ethyl ester (0.19 g, 0.8 mmol), and 2,3,4,5-
tetrafluorobenzoylacetic acid ethyl ester (0.21 g, 0.8 mmol). The apparatus was 
heated to reflux, for 3 days, under an atmosphere of chilled nitrogen. After 72 hours, 
each PIN was washed with copious amounts of toluene, ME, dioxane:water, ether, 
and finally DCM. The PINS containing the resin samples were dried, in vacuo, 
overnight to yield the following products, (0.10 g))- ; 
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Copoly(styrene- 1 %-divinylbenzene)p-benzyloxyben.zyl t-butyl acetate; Vmax  (KBr 
disc); 1751 (C=O), 1736 (C=O), cm-1; 6C (60MHz, CDCI3), 145, 133-125 
(polystyrene), 114 (polystyrene), 69 (p-benzyloxy CH2), 65 (benzyl CH2), 42 
(COCH2CO), 27 (COC(CH3)3) ppm. 
Copoly(styrene- 1 %-divinylbenzene)p-benzyloxybenzyl ethyl acetate; Vmax  (KBr disc) 
1750 (C=O), 1736 (C=O), cm; öC (60MHz, CDC13), 168 (C=O), 145, 133-125 
(polystyrene), 114 (polystyrene), 69 (p-ben.zyloxy CH2), 65 (benzyl CH2), 61 
(COcH2CH3), 41 (COCH2CO), 14 (COCHH3) ppm. 
Copoly(styrene- 1 %-divinylbenzene)p-ben.zyloxybenzyl 2,4, 5-trifiuorobenzoylacetate; 
Vmax. (KBr disc) 1751 (C=O), 1735 (C=O), cm-1; 6C (60 MHz, CDC13), 145, 133- 
125, (polystyrene), 119 (aromatic CH), 114 (polystyrene), 107 (aromatic CH), 70 (p-
benzyl CH2), 64 (benzyl CH2), 49 (COCH2CO) ppm. 
Copoly(styrene- 1 %-divinylbenzene)p-ben.zyloxybenzyl 2,3,4, 5-tetrafiuorobenzoyl-
acetate; Vmax (KBr disc) 1751 (C=O), 1734 (C=O), cm-1; 6C (60MHz, CDCI3), 
145, 133-125 (polystyrene), 117 (aromatic CH), 114 (polystyrene), 69 (p-benzyloxy 
CH2), 65 (benzyl CH2), 48 (COCH2CO) ppm. 
Loading of resin to DIVERSOMERTM Apparatus. 
p-Benzyloxybenzyl alcohol resin (1.0 g, 0.84 mmol / g) was suspended in chloroform 
(50 ml), while an additional lot ofp-ben.zyloxybenzyl alcohol resin (3.5 g, 0.93 mmol / 
g) was suspended in chloroform (100 ml). Using the TecanTm Robotic Sample 
Processor, (RSP), 5 ml (5 x 1 in]) of the first resin slurry was dispensed into each of 
the PINS, (A1-C4), and 5 ml (5 x 1 ml) of the second resin was dispensed into each of 
the PINS, (D1-J4). The holder block containing the 40 PINS, (A144) was drained by 
gravity. The resins in the PINS were then extensively rinsed with toluene (3 x 2 ml) 
using the TecanTm RSP. 
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40 Unit Quinolone array-R1S1 (transesterilication). 
A solution of 4-DMAP (1.02 g, 8.36 mmol) in toluene (135 ml) was prepared. 2,4,5-
Trifluorobenzoylacetic acid ethyl ester, X (1.82 g, 7.4 mmol) and 2,3,4,5-
tetrafluorobenzoylacetic acid ethyl ester, Y (5.88 g, 22.19 mmol) were dissolved in 
toluene (30 & 70 ml respectively). The 4-DMAP solution was dispensed (1 x 3 ml) 
into each of the 40 reaction wells, (A144) using the TecanTm RSP. The -keto esters, 
X & Y were dispensed, (1 x 2 ml) into the reaction wells (A1-C4) and (D144) 
respectively using the TecanTm RSP. To form the resin bound 13-ketoesters, the PINS 
containing the resins were submerged in the corresponding reaction wells. The 
manifold was attached and the apparatus was agitated in an ultrasound bath, at 110°C, 
for 18 hours, while an atmosphere of chilled nitrogen was maintained. After 18 hours, 
the ultrasound bath and apparatus were cooled to 25°C. The PINS were drained and 
washed repeatedly by dispensing fresh solvent directly to the resins in the PINS 
robotically; DMF (4 x 2 ml), methanol (4 x 2 ml), water (4 x2 ml), THF (4 x 2 ml), 
and DCM (6 x 2 ml). After each wash, the PINS were allowed to drain by gravity. 
The filtrates were collected in a common reservoir and monitored by TLC. The holder 
block and PINS containing the resin-bound products were dried in vacuo overnight. 
40 Unit Quinolone array-R2S1 (DMFA-activation). 
DMIFA (25.87 g, 217 mmol) was suspended in dry THF (200 ml). Using the TecanTM  
RSP, the dimethylformamide dimethyl acetal solution was dispensed, (1 x 4 ml) into 
clean reaction wells (A144). The PINS containing the resin-bound -keto esters (Al-
J4) were submerged in the reaction wells, the manifold was attached and the 
apparatus was agitated by ultrasound, for 18 hours, at 25°C, under an atmosphere of 
nitrogen. 
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40 Unit Quinolone array-R2S2 (amine displacement) 
After 18 hours, each of the following amines were dissolved in dry THF and 
dispensed, (1 x 1 ml) directly into the appropriate PINS using the Tecantm' RSP; 
while maintaining an anhydrous environment at the Tecan' workstation with Argon: 
cyclopropyl amine (6.32 g, 110 mmol) to PINS (Al-Ji), 4-fluoroaniline (12.16 g, 110 
mmol) to PINS (A242), 2,4-difluoroaniline (14.13 g, 110 mmol) to PINS (A343) 
and tert.butylamine (8.00 g, 110 mmol) to PINS (A444). The apparatus was agitated 
by ultrasound, at 25°C, under an atmosphere of nitrogen. After 72 hours, the PINS 
were drained and washed repeatedly by dispensing fresh solvent directly to the resins 
in the PINS robotically; DMF (4 x 2 ml), methanol (4 x 2 ml), water (4 x 2 ml), THF 
(4 x 2 ml), and DCM (6 x 2 ml). After each wash, the PINS were allowed to drain by 
gravity. The filtrates were collected in a common reservoir and monitored by TLC. 
The holder block and PINS containing the resin-bound products were dried in vacuo 
for 5 hours. 
40 Unit Quinolone array-R3S1 (cyclisation). 
A solution of 1MG (101 g, 878 mmol) in DCE (50 ml) and DCM (100 ml) was 
robotically dispensed, (1 x 5 ml) into 40 reaction wells (A144). To affect cyclization 
of the resin-bound enamides, the PINS were submerged in the reaction wells, the 
manifold was attached and the apparatus was agitated by ultrasound, at 55°C, under 
an atmosphere of chilled nitrogen. After 18 hours, the ultrasound bath and apparatus 
were cooled to 25°C. The PINS were drained and washed repeatedly by dispensing 
fresh solvent directly to the resins in the PINS robotically; ME (4 x 2 ml), methanol 
(4 x 2 ml), water (4 x 2 ml), THF (4 x 2 ml), and DCM (6 x 2 ml). After each wash, 
the PINS were allowed to drain by gravity. The filtrates were collected in a common 
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reservoir and monitored by TLC. The holder block and PINS containing the resin-
bound products were dried in vacuo for 2-3 hours. 
40 Unit Quinolone array-R4S1 (arylation). 
Solutions of piperazinyl derivatives were prepared in NMP and dispensed into the 
appropriate reaction wells using the Tecan RSP; piperazine (7.83 g, 91 mmol) to 
wells (A1-A4) and (D1-D4), 2,6-dimethylpiperazine (10.39 g, 91 mmol) to wells (Bi-
B4) and (E1-E4), 1-ethylpiperazine (11.85 g, 91 mmol) to wells (C1-C4) and (Fl-
F4), 1-methylpiperazine (6.34 g, 55 mmol) to wells (G1-G4), 2-methylpipera.zine 
(5.46 g, 55 mmol) to wells (H1-H4), 1-isopropylpiperazine (1.50 g, 12 mmol) to wells 
(11-14), and piperidine (4.64 g, 55 mmol) to wells (J144). The PINS, containing the 
resin-bound quinolones were submerged in the reaction wells. The manifold was 
attached and the apparatus agitated by ultrasound, at 110°C, for 4 hours, under an 
atmosphere of chilled nitrogen, for 4 hours. On cooling, the PINS were drained and 
washed repeatedly by dispensing fresh solvent directly to the resins in the PINS 
robotically; DMF (4 x 2 ml), methanol (4 x 2 ml), water (4 x 2 ml), THF (4 x 2 ml), 
and DCM (6 x 2 ml). After each wash, the PINS were allowed to drain by gravity. 
The filtrates were collected in a common reservoir and monitored by TLC. The holder 
block and PINS containing the resin-bound products were dried in vacuo overnight. 
40 Unit Quinolone array-R5S1 (acid cleavage). 
To effect cleavage the quinolones from the solid support, the PINS were submerged 
in the reaction wells containing a solution of TFA/DCM (4:6, v/v, 5 ml aliquots). The 
apparatus was assembled and agitated by ultrasound, at 25°C, for 1 hour. The PINS 
were removed from the reaction wells and drained by gravity into the corresponding 
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wells containing the dissolved products. Repetitive washing of the solid support to 
thoroughly extract the products was carried out The PINS were submerged in 
reaction wells containing TFAIDCM (4:6, v/v) and DCM (5 ml aliquots) sequentially, 
agitated by ultrasound, at 25'C, for 15 minutes and drained by gravity between each 
extraction cycle. All the filtrate extracts were robotically combined and analysed by 
TLC, Rf (D) 0.27. Concentration of the crude final product solutions was achieved by 
a positive nitrogen flow through a 40-channel manifold. 
40 Unit Quinolone array-Purification. 
Following concentration, the crude products were manually weighed. The 40 
quinolones (A1-J4) were purified by gravity chromatography on silica gel utilizing 
SPE cartridges, (Varian Mega bond elute Si). Intially, a holder rack containing 40 
SPE cartridges was placed on the TecanTm workstation. The cartridges were 
preconditioned with CH3CN / H20 / tBuNH2; 18:2:1 with the TecanTm RSP. The 
products were dissolved in the minimum amount of TFA and preloaded (0.5 ml) on 
the cartridges. The products were eluted robotically with CH3CN / H20/ IBuNH2: 
18:2:1. In total, ten racks were collected and using theTecanTm RSP each of the 
filtrates from the ten elutes were analysed by TLC. Appropriate fractions, racks D, E 
& F were combined robotically and transferred to Speedvac tared vials. Concentration 
of the final product solutions was achieved by applying vacuum in a speedvac at low 
temperature, overnight. The pure products were obtained as damp pale brown solids, 
weighing between 3.6-27.1 mg, corresponding to 8-90 % yield. 
Bis-(phenanthren-9-yI)methanol, (121). 
A solution of 9-bromophenanthrene (100 g, 39.0 mmol) in dry THF (100 ml) was 
slowly added to magnesium turnings (9.36 g, 39.0 mmol) under an atmosphere of 
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nitrogen. A crystal of iodine was added to initiate the exothermic reaction. After 2 
hours stirring, a thick green jelly formed and a solution of methyl formate (12 ml, 19.0 
mmol) in dry THF (25 ml) was added over a period of 20 minutes. After 2 hours 
under refiux, iced 2M HCI (100 ml) was added and a white solid precipitated. The 
precipitate was filtered and washed with water (2 x 50 ml) and ether (2 x 50 ml) to 
give a white solid (60 g, 80 %) as the title compound. m.p. 237-240°C, (Lit.217 238-
239°C); TLC, Rf (A) 0.13, Rf (B) 0.67; C,H, found C, 90.77; H, 5.29; C29H200 
requires C, 90.02, H, 5.20; Vmax (CHBr3 mull) 3408 (OH), 3100 (aromatic st.), 
1628, 1610, 1500 (aromatic C=C) cm; oH (200 MHz, CD3SOCD3), 8.86-8.74 (d, 
2H, 3J = 8.4 Hz, aromatic), 8.79-8.76 (d, 2H, 3J = 8.2 Hz, aromatic), 8.17-8.15 (d, 
2H, 3J= 8.05 Hz, aromatic), 7.80-7.51 (m, 12H, aromatic), 7.20 (d, 1H, 3J = 6.1 Hz, 
CH), 2.5 (s, 1H, OH) ppm. OC (50 MHz, CD3SOCD3), 13 7.8, 13 0.9, 13 0.2, 130.1, 
129.7 (quaternary aromatic C's), 128.7, 126.8, 126.4, 125.6, 124.6, 123.3 122.6, 
(aromatic CH), 68.1 (CHOH) ppm; m/z (FAB) 384 (M+), 367, 205; FIRMS (FAB), 
found 384.15146, C29H200 requires 384.15141. 
8bH-Tetrabenzo [a,c,g,ifluorene, (122). 
Bis-(phenanthren-9-yl)methanol (59 g, 15.0 mmol) was suspended in DCM (200 ml) 
and trifluoroacetic acid (75 ml) added. The reaction was monitored by the brief 
appearance of a blue colour. After stirring for 30 minutes the yellow material was 
evaporated to dryness. TFA was removed by successive evaporation of freshly added 
DCM (5 x 100 ml). The resulting residue was suspended in ether and filtered to yield 
a yellow solid, (44 g, 89 %). m.p. 279-280°C (Lit217 280-282°C); TLC, Rf (A) 0.65, 
Rf  (B) 0.77; CM, found C, 95.43; H, 4.96; C29H18 requires C, 95.34, H, 4.66; Vmax 
(CHBr3 mull) 1638, 1606 (aromatic) cm'. 	(DCM) 375 (c = 11105 dm 3mor'cm 
, 326 (4644), 253 (58575) nm; OH (200 MHz, CDCI3), 8.82-8.68 (m, 2H, aromatic), 
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8.22-7.07 (m, 15H, aromatic), 5.40 (s, 2H, CH) ppm. m/z (FAB) 365 (M); HRMS 
(FAB), 365.13303, C29H18 requires 365.13356. 
1-(17'-Tetrabenzo(a,c,g,ijfluorenyl)prop-2-ene, (124). 
To a suspension of 8bH-tetrabenzo[a,c,g,i]fluorene, (43 g, 12.0 mmol) in dry TI-IF 
(200 ml) at -78°C, n-butyllithium (1.6M in hexane, 80 ml, 13.0 mmol, 1.1equiv) was 
added and the orange solution stirred for 1 hour, under an atmosphere of nitrogen. 
Then allyl bromide (14.4 g, 12.0 mmol, lequiv) was added dropwise and the solution 
stirred for a further 1 hour at -78°C. On warming to room temperature, the solution 
was left stirring for a further 2 hours after which a saturated solution of ammonium 
chloride (200 ml) was added followed by DCM (2 x 200 ml). The organic layer was 
separated, dried over magnesium sulphate and evaporated in vacuo to give a dark 
yellow solid (33.8 g, 70%). m.p. 114-116°C, (Lit.  217 118-120°C); TLC, Rf (A) 0.62; 
C,H, found C, 91.46; H, 5.13; C32H22 requires C, 94.58, H, 5.41; Vmax  (CHBr3 
mull), 3070 (aromatic st.), 2980, 2900, 2850 (alkyl st.), 1638 (C=C), 1609, 1500 
(aromatic) cm-1; Amax 380 (DCM) (c = 22315 dm3mol 1cm 1), 364 (23119), 301 
(51286), 295 (31222), 253 (80386) nm; oil (200 MHz, CDC13), 8.80-8.66 (m, 6H, 
aromatic), 8.21-8.19 (m, 2H, aromatic), 7.72-7.57 (m, 8H, aromatic), 4.95 (s, 1H, 
TbfCH), 4.80-4.71 (m, 1H, CH), 4.43-4.24 (m, 2H, CH2 3-propene), 3.32-3.29 (dd, 
2H, CH2 1-propene) ppm; OC (50 MHz, CDC13), 143.5, 136.7, 131.2, 130.3, 128.5, 
127.6 (quaternary aromatic C's), 131.9, 127.6, 125.7, 125.5, 124.8, 124.3, 124.1, 
123.4, (aromatic CH's), 116 (=CH2), 46.7 (C-17), 37.6 (CH2) ppm; m/z (FAB) 406 
(M), 365; FIRMS (FAB), found 406.17214, C32H22 requires 406.17215. 
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3-(1 7'-Tetrabenzo [a, cg, i] flu orenyl)propanol, (125). 
A solution of 1-(17-tetrabenzo[a,c,g,i]fluorenyl)prop-2-ene, (10 g, 24.6 mmol) in dry 
THF (66 ml) was cooled to <20°C under nitrogen. 9-BBN (59 ml, 0.5M in THF, 1.2 
equiv) was added and the solution stirred for 3 hours. After 3 hours, aqueous sodium 
hydroxide (1.67 g in 17 ml water) was added followed by hydrogen peroxide (3.3 ml, 
30% in water, 1.2 equiv) and the temperature rose to ca. 45°C. The reaction mixture 
was stirred, at 60°C, for 1 hour and then cooled to room temperature. Fresh hydrogen 
peroxide (1 equiv) was added and the solution left to stir overnight. The product was 
extracted with DCM / methanol (9:1, 200 ml), washed with water, aqueous sodium 
hydrogen carbonate and dried over magnesium sulphate. After evaporation of the 
solvents, the residue was recrystallised from THF / CHCI3 to give a white solid (4.01 
g, 40 %). m.p. 187-189°C, (Lit.217 188-189°C); TLC, R f (A) 0.14; C,H, found C, 
82.00; H, 5.30; C32H240 requires C, 90.56, H, 5.66 Vmax  (CHBr3 mull) 3317 (OH), 
3010 (aromatic st.), 2950, 2860 (alkyl st.), 1604, 1500 (aromatic) cm; ?max  380 
(DCM) (E = 20400dm3mo1 1cm 1), 365 (20900), 295 (26600), 254 (36280) nm; 5H 
(200 MHz, CDCI3), 8.95-8.91 (m, 4H, aromatic), 8.57-8.54 (d, 2H, 3J = 7.9 Hz, 
aromatic), 8.35-8.33 (d, 2H, 3J = 7.9 Hz, aromatic), 7.78-7.65 (m, 8H, aromatic), 
5.31 (s, 1H, TbfCH), 3.98 (t, 1H, 3J = 5.1 Hz, OH), 2.84-2.79 (m, 2H, CH2), 2.58-
2.50 (m, 2H, CH2), 0.32-0.28 (m, 2H, CH2) ppm; öC (50 MHz, CDCI3), 144.4, 
135.6, 130.7, 129.7, 128.0 (quaternary aromtic C's), 158.3, 127.8, 127.1, 126.5, 
126.3, 125.9, 125.3, 124.5, 123.9, 123.6 (aromatic CH's), 60.4 (cH20H), 46.1 (C- 
17), 29.9, 25.6 (CH2) ppm; m/z (FAB) 424 (M), 407, 365; HRMS (FAB), found 
424.18273, C32H240 requires 424.18270. 
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3-(1 7'-Tetrabenzola,c,g,ilfluorenyl)propyl 2,4,5-trifluorobenzoylacetate, (126). 
3-(17'-Tetrabenzo[a,c,g,i]fluorenyl)propanol (0.120 g, 0.28 mmol) was dissolved in 
toluene (20 ml) and a catalytic amount of 4-13MAP added. To this solution 2,4,5-
trifluorobenzoylacetic acid ethyl ester (0.20 g, 0.84 mmol, 3 equiv.) was added and 
the mixture refluxed, under an atmosphere of nitrogen. After 72 hours the mixture 
was cooled in an ice/water bath and quenched with a saturated solution of ammonium 
chloride (10 ml). The product was extracted with toluene (4 x 50 ml), dried over 
MgSO4 and concentrated in vacuo to give a pale brown oil. The product was purified 
by dry flash chromatography (9:1, MeOH / CHC13) to yield the title compound as a 
pale brown solid (0.049 g, 56 %). m.p. 152-153°C; TLC, Rf (C) 0.20, Rf (B) 
0.69;.C,H, found: C, 75.18, H, 6.12; C41H2717303 requires C, 78.84, H, 4.32 %; 
vmax(CHBr3 mull) 2950, 2890 (CH St.), 1735 (C0), 1691 (C0), 1625, 1511 
(aromatic) cm'. max  (DCM) 380 (c = 16375 dm3mol 1cm 1), 364 (17187), 301 
(51250), 288 (43750) rim; oH (250 MHz, CDC13), 8.81-8.64 (m, 6H, aromatic), 
8.25-8.20 (m, 2H, aromatic), 7.73-757 (m, 9H, aromatic), 6.95-6.74 (m, 1H, 
aromatic), 5.07 (t, 11-1, TbfCH), [12.35 (s), 5.36 (s), 3.54 (d, 3J = 3.87 Hz)] 2H, 3.61 
(t, 2H, CH2), 2.76-2.65 (m, 2H, CH2), 0.75-0.61 (m, 2H, CH2) ppm; OC (50 MHz, 
CDCI3), 187.4 (C=O), 166.0 (C=O), 143.2, 136.9, 131.2, 130.3, 128.4, 127.8, 
(quaternary C's), 127.3, 126.8, 125.9, 125.7, 125.0, 124.1, 123.4, (aromatic CH's), 
118.2 (aromatic CH), 106 (aromatic), 65.7 (CH20), 49.0 (COCH2CO), 46.3 (C-17), 
29.6 (CH2), 21.5 (CH2) ppm; m/z (FAB) 624 (M), 424, 365; HRMS (FAB), found 
624.19130, C41H2717303 requires 624.19121. 
Ethyl 4-(10-bromodecyloxy)benzoate, (128). 
Ethyl 4-hydroxybenzoate (5 g, 30 mmol) was dissolved in dry DMF (100 ml) and 
sodium hydride (2.0 g, 80 mmol) slowly added. After 2 hours stirring, at room 
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temperature, a white solid precipitated and a solution of 1, 1 0-dibromodecane (30.0 g, 
100 mmol) in dry DMIF (50 ml) was added. After heating to 100°C the reaction was 
stirred for another 12 hours. On cooling, the product was extracted with ether (3 x 
150 ml), washed with water (3 x 150 ml), dried over magnesium sulphate and 
evaporated to dryness to give an off white solid. The crude product was purified by 
dry flash chromatography (20 % DCM in heptane - 100 % DCM) to yield a white 
solid (6.2 g, 54 %) as the title compound. m.p. 35-37°C; C,H, found: C 58.90; H, 
7.92 C19H29BrO3 requires C, 59.22; H, 7.53 %; TLC, RF (A) 0.77; Vm  (CHBr3 mull) 
2930, 2854 (CH st), 1707 (C=O), 1605, 1508 (aromatic) cm-1; ?max  (DCM) 256 (c 
4817 dm3mol 1cm 1) nrn; oH (200 MHz, CDC13), 7.96 (m, 2H, aromatic), 6.87 
(m, 2H, aromatic), 4.32 (q, 2H, 3J = 7.14 Hz, CO2CH2CH3), 3.97 (t, 2H, 3J = 6.49 
Hz, 2 x H-1,alkyl), 3.38 (t, 2H, 3J = 6.83, alkyl), 1.90-1.66 (m, 4H, alkyl), 1.39-1.29 
(m, 15H, alkyl) ppm; OC (50 MHz, CDC13), 166.2 (C=O), 162.7, 131.5, 122.5, 113.8 
(aromatic), 67.9 (alkyl), 60.45 (CO2CH2CH3), 33.9 - 25.82 (alkyl), 14.26 
(CO2CH2CH3) ppm; m/z (FAB) 388 (M+2), 386 (M+), 166; HRMS (FAB), found 
385.13607, C19H290313r requires 385.13783. 
Ethyl 4-(1 O-(1 7'-Tetrabenzo [a, c,g,ijfluorenyl)decyloxy)benzoate, (129). 
17-Tetrabenzo[a,c,g,i]fluorene (5.0 g, 14.0 mmol) was suspended in a degassed 
solution of dioxane (100 ml). The reaction mixture was heated to reflux, under an 
atmosphere of nitrogen and a solution of tetrabutylammonium hydroxide (10 ml) in 
degassed dioxane (30 ml) added whereby a yellow precipitate formed. The solid was 
separated by filtration under nitrogen, washed with warm dioxane (2 x 50 ml) and 
ether (2 x 50 ml). The resulting bright yellow solid was resuspended in dioxane (250 
ml) and ethyl 4-(10-bromodecyloxy)benzoate (4.76 g, 12.0 mmol) added. The mixture 
was refluxed under an atmosphere of nitrogen for 2.5 hours until the precipitate 
dissolved. After removal of all volatiles in vacuo, a dark green oil was formed and the 
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product extracted with ether, (2 x 100 ml). The crude brown solid was then purified 
by dry flash chromatography (5 % ether in hexane - 100 % DCM) to yield a beige 
solid (5.70 g, 63 %) as the title compound. m.p. 61-63°C; C,H,. found C, 84.61, H, 
8.18, C43H4603 requires C, 85.97, H, 6.86 %; TLC Rf (B) 0.60; Vmax  (CHBr3 mull) 
3067 (aromatic st), 2930, 2851 (CH st), 1701 (C=O), 1605, 1507 (aromatic); Xmax 
(DCM) 380 (e = 19287 dm3mol 1cm 1), 370 (20126), 301 (46961), 288 (38575), 
255 (101469) nm; oH (200 MHz, CDC13), 8.81-8.76 (m, 4H, aromatic), 8.70-7.67 
(m, 2H, aromatic), 8.01-7.95 (m, 2H, aromatic), 7.72-7.58 (m, 8H, aromatic), 6.87-
6.82 (m, 2H, aromatic), 5.00 (t, 1H, 3J = 4.39 Hz, TV H), 4.40-4.31 (q, 2H, 3J = 
7.12 Hz, CO2CH2CH3), 3.85 (t, 2H, 3J = 6.57 Hz, alkyl), 2.63-2.55 (m, 2H, alkyl), 
1.67-1.56 (m, 2H, alkyl, 1.39 (t, 3H, 3J = 7.12 Hz, CO2CH2CH3), 1.28-0.72 (m, 
14H, alkyl) ppm. OC (50 MIHz, CDCI3), 166.2 (CO), 162.9 (aromatic CH), 131.3 
(aromatic CH), 144.2, 136.6, 131.2, 130.2, 128.9, 127.9 (quaternary aromatic C's), 
126.0, 125.72, 125.5, 124.8, 124.3, 123.3, 122.4 (aromatic CH's), 113.4 (aromatic 
CH), 67.9 (CO2CH2CH3), 47.07 (C-17), 33.36-25.67 (alkyl) ppm; m/z (FAB) 670 
(M), 365; HRMS(FAB), found 670.34480, C4817 4603 requires 670.34470. 
4-(1 0-(1 7'-Tetrabenzo [a, c,g,iJ fluorenyl)decloxy)benzyl alcohol, (130). 
Ethyl 4-(10-(17'-tetrabenzo[a,c,g,i]fluorenyl)decyloxy)beoate (1.0 g, 1.5 mmol)) 
was dissolved in dry THF (20 ml) and diisobutylaluminium hydride (4 ml, 4.0 mmol, 
1.OM in DCM) was added. After 2.5 hours at room temperature the solution was 
poured into 2M HCI (30 ml). The product was extracted with ethyl acetate (2 x 50 
ml), washed with aqueous sodium hydrogen carbonate (20 ml), water (2 x 50 ml) and 
dried over magnesium sulphate. Evaporation in vacuo give a pale yellow solid (0.73 
g, 77 %) as the title compound. m.p. 69-71°C; TLC Rf (B) 0.44; C,H, found: C, 
88.40; H, 7.64; C46H02 requires C, 87.89; H, 7.00 %, Vmax (CHBr3 mull) 3593, 
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3433 (OH St.), 2927, 2852 (alkyl St.), 1609, 1511 (aromatic) cm- '; Xmax  (DCM) 380 
(e = 17088 dm3mol 1cm 1), 364 (17722), 301 (40506), 289 (35443), 252 (62658) 
nm; 5H (250 MHz, CDC13), 8.82-8.67 (m, 6H, aromatic), 8.26-8.21 (m, 2H, 
aromatic), 7.82-7.53 (m, 8H, aromatic), 7.28-7.21 (m, 2H, aromatic), 6.90-6.8 (m, 
2H, aromatic), 5.01 (t, 1H, 3J = 4.33 Hz, C-17), 4.60 (s, 2H, CH20H), 3.96-3.82 (t, 
2H, 3J = 6.55 Hz, alkyl), 2.64-2.55 (m, 2H, alkyl), 2.39 (b, 1H, OH), 1.66-1.52 
(m,,2H, alkyl), 1.28-0.35 (m, 14H, alkyl) ppm; 6C (50 MHz, CDC13), 158.6 
(quaternary aromatic C), 144.2, 136.6, 132.5, 131.1, 130.2, 127.9 (quaternary 
aromatic C's), 128.6, 128.4, 127.3, 126.6, 125.7, 125.4, 124.8, 124.3 (aromatic 
CH's), 123.3, 114.3 (aromatic CH's), 67.8 (cH20H), 64.9 (CH20), 47.0 (C-17), 
33.3-22.0 (alkyl CH's) ppm; m/z (FAB) 629 (M+1), 522, 365; HRMS (FAB), found 
628.33580 C46H4402 requires 628.33413. 
4-(1 O-(1 7'-Tetrabenzo Ia,c,g, ijfluorenyl)decyloxy)benzyl 	2,4,5-trifluorobenzoyl 
acetate, (131). 
4-(10-(1 7-Tetrabenzo[a,c,g,i]fluorenyl)clecyloxy)benzyl alcohol (0.60 g, 1 mmol) was 
dissolved in toluene (15 ml) and a catalytic amount of DMAP added. 2,4,5-
Trifluorobenzoyl acetic acid ethyl ester (0.70 g, 3 mmol, 3 equiv.) was added and the 
reaction mixture refluxed, under an atmosphere of nitrogen. After 72 hours, the 
mixture was cooled in an ice/water bath and quenched with a saturated solution of 
ammonium chloride (20 ml). The product was extracted with toluene (4 x 70 ml), 
dried over magnesium sulphate and concentrated in vacuo to give a pale brown oil. 
The product was purified by dry flash chromatography (MeOH / CHC13, 9:1) to yield 
the title compound as a dark brown solid. (0.21 g, 26 %); m.p. 63-65°C; TLC, Rf (A) 
0.39, Rf (B) 0.71; C,H, found C, 77.36, H, 6.48, C55H47F304 requires C, 79.71; H, 
5.67 %; Vmax (CHBr3 mull) 2927, 2854 (CH st. alkyl), 1733 (C=O), 1688 (C=O), 
1622, 1511 (aromatic) cm-1; ?max  (DCM) 380 (c = 17355 dm3mol 1cm 1), 364 
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(18181), 300 (45454), 289 (42148), 263 (76859), 247 (66942) nni. 611 (250 MHz, 
CDC13), 8.83-8.66 (m, 6H, aromatic), 8.29-8.25 (m, 2H, aromatic), 7.77-7.58 (m, 
9H, aromatic), 7.31-7.19 (m, 2H, aromatic), 6.98-6.78 (m, 3H, aromatic), 5.07 (t, 
1H, 3J = 4.41 Hz, C-17), [12.6 (s), 5.84 (s), 3.94 (d, 3J = 3.8 Hz)] 2H, 3.88 (m, 2H, 
alkyl), 2.64-2.58 (m, 2H, alkyl), 1.67-1.56 (m, 2H, alkyl), 1.28-0.74 (m, 12H, alkyl), 
0.39-0.36 (m, 2H, alkyl) ppm. 6C (50 MHz, CDC13), 185.0 (CO), 167.1 (CO), 
159.2, 144.2, 136.6, 131.1, 128.7, 128.4 (quaternary aromatic C's), 130.2, 130.0, 
127.9, 127.3, 126.6, 125.7, 125.5, 124.9, 123.3 (aromatic CH's), 118.7, 114.3, 106.1 
(aromatic CH's), 67.8 (CH20), 64.9 (CH2, alkyl), 49.4 (COCH2CO), 47.1 (C-17), 
33.4 (CH, alkyl), 29.2 (CH2, alkyl), 28.9 (CH2, alkyl), 25.6 (CH2, alkyl), 22.0 
(CH2, alkyl) ppm; m/z (FAB) 829 (M + 1), 722, 364; 1-IRMS (FAB), found 
828.34400, C55H47F304 requires 828.34265. 
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